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Preface 
 
November 26th, 1901.  Dr. Alzheimer was informed about a patient showing 
unusual clinical symptoms.  Auguste D., 51 years old, who had never been ill prior 
to that time, began to suffer from delusions, having trouble remembering things, 
and making serious mistakes in her daily activities a few months before.  Dr. 
Alzheimer analyzed the mental condition of Auguste D., who maintained 
confusing and illogical conversations.  The patient showed alterations in memory, 
language, thought, and behavior.  All symptoms worsened progressively, month by 
month, until 8th April, 1906, when she finally died.  Her illness had lasted just over 
five years and Alzheimer was convinced that this was an extraordinary case.  
Shortly after her death, the brain was analyzed with silver impregnation staining 
techniques and the findings were truly surprising.  Alzheimer and his co-workers, 
Perusini and Bonfiglio, observed lesions similar to those found in the brains of 
patients 70 and 80 years old suffering from dementia, but much more marked.  All 
three firmly believed that this was an unusual case, which had never been 
described.  Dr. Alzheimer would probably never understand the impact of his 
discovery.  However, since then, and especially in the last decades, Alzheimer’s 
disease (AD) has been the focus of intensive research, to establish the abnormal 
molecular mechanisms that lead to the onset of the disease and to develop novel 
therapeutic strategies.  Although considered the major cause of dementia, with 
prevalence increasing every year, AD is still not completely understood. 
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It is now established that AD can be triggered by toxic extra and intracellular 
aggregates formed from amyloid β and tau, respectively, but the nature of these 
peptides was not definitively discovered until mid 1980’s.  It is becoming clear that 
these aggregates accumulate in selectively vulnerable regions of the brain, 
compromising the function and viability of neurons and glia.  In the absence of the 
proper conditions to survive, neurons massively die, compromising the cognitive 
function of a brain affected by AD.  A specific type of cell death, apoptosis, has 
brought much attention in the last few years. 
The first observations of dying neurons was made in the 19th-century by a 
German naturalist, Carl Vogt, when studying the nervous system of toad embryos.  
However, it was not until 1951 when Ernst and Glucksmann discovered that cell 
death was an integral part of normal embryonic development.  During the 1960s, 
much was learned about cell death at the ultrastructural level using electron 
microscopy.  Finally, in 1972, John Kerry and co-authors described for the first 
time a specific process of cell death, when observing characteristic features of 
hepatocyte development.  The process was termed apoptosis, from the Greek word 
αποπτοσισ, whose prefix “apo” (απο) generally means “separation”, and the 
suffix “ptosis” (πτοσισ) the “act of falling off”.  The complete word can be 
translated as the falling of leaves from trees in the autumn and refers to the 
fragmentation of dying cells into characteristic small bodies.  Decades of 
investigation have shown that apoptosis is an intrinsic suicide program that 
determines the fate of a cell.  It is a common process in many types of cells and 
tissues.  Apoptosis is not only an important event in embryonic development, but 
also in tissue homeostasis during adult life.  In addition, its deregulation can also 
account for several pathological conditions, ranging from cancer to 
neurodegenerative disorders.  In fact, recent studies suggest a critical role for 
apoptosis and cell death mediators in AD, even before the reduction in neuronal 
number. 
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It has become clear in recent years that prevention of cell death in disorders 
associated with abnormally increased levels of apoptosis may positively affect the 
patient outcome.  Interestingly, an endogenous bile acid, ursodeoxycholic acid 
(UDCA) has been described as an inhibitor of apoptosis, not only in liver diseases, 
but also in other pathological conditions, including neurological disorders.  UDCA 
is a major constituent of black bear bile and has been used for centuries in 
traditional Chinese medicine for the treatment of liver diseases.  However, the 
mechanisms of action of the bile acid have been characterized only recently.  
UDCA administration can induce the protection of cholangiocytes against 
cytotoxicity of hydrophobic bile acids and stimulate the hepatobiliary secretion.  
Importantly, in 1998, Rodrigues and co-authors showed that UDCA can also have 
beneficial effects by inhibiting mitochondrial membrane perturbations associated 
with bile acid-induced apoptosis.  UDCA has blossomed as a potent modulator of 
apoptosis, acting in a tissue-independent manner.  Its effects have been tested in 
many pathological conditions, underscoring its potential and promising therapeutic 
use. 
 
When I started the Ph.D. program in the laboratory of Professor Cecília M. 
P. Rodrigues, I focused on investigating the apoptotic mechanisms triggered by 
neurons exposed to toxic stimuli, in the specific context of AD.  My first questions 
as a student who has just entered a new and exciting area of research, gave rise to 
additional new questions, which have made my last four years challenging, but 
rewarding.  The present work provides insight into the modulation of apoptosis 
associated with AD, and more importantly uncovers intriguing connections and 
links that warrant further investigations. 
The purpose of my work was to identify and characterize molecular targets 
for the use of taurourosodeoxycholic acid (TUDCA) as a modulator of apoptosis in 
AD, using in vitro and in vivo models.  As a conjugated form of UDCA with 
 
xi 
taurine, already in use for the treatment of primary biliary cirrhosis, TUDCA 
proved to be a potent tool in preventing apoptosis in non-hepatic diseases, such as 
Huntington’s and Parkinson’s disease.  The use of TUDCA in AD came as a 
natural extension of this work.  Chapter 1 provides a general, up-to-date review on 
the process of apoptosis.  In addition, the role of bile acids as modulators of 
apoptosis is discussed.  We also focus on describing AD and the role of apoptosis 
in this neurodegenerative disorder.  In Chapter 2, we characterize the mechanisms 
of neuronal protection by TUDCA in in vitro AD.  The role of cell cycle and 
apoptosis-related proteins in the effects of TUDCA is also presented and discussed.  
In Chapter 3, the role of p53, a cell cycle-related protein, in TUDCA 
neuroprotection is further examined, using an in vitro model of familial AD.  In 
Chapter 4, we investigate the role of apoptosis in neurodegeneration using a 
transgenic mouse model of tauopathy.  Apoptosis is presented as an early 
mechanism that contributes to increased toxicity, and eventually leads to 
characteristic neurological deficits of AD.  Further, we confirmed the existence of 
a link between amyloid β and tau, via activation of apoptosis-related proteins, and 
its inhibition by TUDCA.  Finally, Chapter 5 integrates our overall findings and 
discusses specific future perspectives. 
The exact mechanism(s) that triggers AD is still obscure.  Although more 
than 100 years have passed since its first description, and despite the efforts of a 
growing scientific community, an effective treatment is still not available.  
Nevertheless, in recent years, many mysteries of the disease have been unveiled, 
including the role of apoptosis as an important event in AD.  With this thesis, we 
hope to contribute to a better understanding of the mechanisms of apoptosis in AD 
and provide evidences for the neuroprotective role of TUDCA.  Ultimately, an 
increased knowledge of the disease and its potential modulation by bile acids may 
result in development of more efficient therapeutic interventions. 
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Summary 
 
Ursodeoxycholic (UDCA) and its taurine-conjugated form, 
tauroursodeoxycholic acid (TUDCA), are endogenous bile acids used in the 
treatment of cholestatic liver disorders.  Their cytoprotective effects result, in part, 
from their ability to modulate hepatocyte apoptosis.  Interestingly, UDCA and 
TUDCA play a unique role in modulating the apoptotic threshold in other cell 
types, including neuronal cells, by interfering with classic mitochondrial pathways.  
In these studies, we investigated the role of apoptosis using in vitro and in vivo 
models of Alzheimer’s disease (AD) and determined its potential modulation by 
TUDCA.  A hallmark pathologic feature of AD is the formation of amyloid 
plaques composed by aggregated amyloid β (Aβ).  Our results showed that 
TUDCA reduced Aβ-induced apoptosis in PC12 neuronal cells, through 
modulation of apoptosis- and cell cycle-related proteins.  In fact, TUDCA 
treatment resulted in inhibition of E2F-1 induction, p53 stabilization and Bax 
expression.  Further, TUDCA protected PC12 cells against p53- and Bax-
dependent apoptosis induced by E2F-1 and p53 overexpression, respectively.  The 
role of p53 in TUDCA effects was further confirmed using an in vitro model of 
familial AD.  In neuroblastoma cells expressing the amyloid precursor protein 
(APP) with the Swedish mutation (APPswe), or double-mutated human APP and 
PS1 (APPswe/∆E9), TUDCA modulated p53 activity, and Bcl-2 family changes.  
Moreover, overexpression of p53 was sufficient to induce apoptosis, which in turn 
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was reduced by TUDCA.  Another pathologic feature of AD is the intracellular 
aggregation of tau into neurofibrillary tangles.  Using the rTg4510 transgenic 
mouse model of tauopathy, expressing a mutated form of human tau, we confirmed 
the role of apoptosis in neurodegeneration.  Increased levels of DNA fragmentation 
and caspase-3 activation were observed in the hippocampus and frontal cortex of 
young mice.  These changes were associated with cleavage of tau into smaller 
intermediate fragments, which were often colocalized with active caspase-3.  In 
vitro, fibrillar Aβ resulted in nuclear fragmentation, caspase activation, and 
caspase-3-induced cleavage of tau.  Notably, incubation with TUDCA abrogated 
apoptosis-mediated cleavage of tau in rat cortical neurons.  The results suggest that 
caspase-3-cleaved intermediate tau species precede cell loss in rTg54510 brains 
and Aβ-exposed cultured neurons.  In conclusion, the work presented here 
underscores the role of apoptosis in neurodegeneration of AD and expands the 
antiapoptotic function of TUDCA.  Furthermore, the results demonstrate that 
TUDCA regulates specific transcriptional and posttranscriptional events that 
impact on mitochondrial function of neurons. 
 
 
Keywords: Amyloid β – Alzheimer’s disease - Apoptosis – Bcl-2 family – Bile 
acids – Caspases – E2F-1 – p53 – Tau 
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Sumário 
 
O ácido ursodesoxicólico (UDCA) e a sua forma conjugada com a taurina, o 
ácido tauro-ursodesoxicólico (TUDCA), são ácidos biliares endógenos, largamente 
utilizados no tratamento de doenças crónicas do fígado, como a cirrose biliar 
primária.  No entanto, só recentemente começaram a ser conhecidos e descritos os 
mecanismos de acção destes ácidos biliares.  Actualmente, sabe-se que o efeito 
citoprotector do UDCA e do TUDCA se deve, maioritariamente, à capacidade 
destas moléculas modularem a morte celular programada ou apoptose dos 
hepatocitos, fenómeno que se encontra desregulado em inúmeras patologias 
hepáticas.  De facto, através de estudos prévios, foi possível demonstrar que o 
UDCA e o TUDCA desempenham este papel anti-apoptótico, em parte, através da 
estabilização da membrana mitocondrial, prevenindo a sua despolarização e a 
consequente libertação de citocromo c e activação de caspases, responsáveis pela 
execução do processo apoptótico.  Porém, desconhece-se, ainda, a maior parte dos 
mecanismos de sinalização iniciados por estes ácidos biliares.  Uma vez que os 
vários produtos do metabolismo lipídico, incluíndo os ácidos biliares, possuem 
propriedades sinalizadoras, pensa-se que a regulação da apoptose exercida pelo 
UDCA e TUDCA poderá passar pela modulação a nível da transcrição génica ou 
mesmo a nível pós-transcricional.   
Curiosamente, o papel protector do UDCA parece estender-se a outros tipos 
celulares e em resposta a vários agentes tóxicos.  Por outro lado, após a conjugação 
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com a taurina e quando administrado sistemicamente, em sobredosagem, o UDCA 
pode ser distribuído por outros tecidos, incluíndo o cérebro, o que permite a sua 
aplicação em doenças não hepáticas, como é o caso de várias desordens 
neurológicas.  De facto, os efeitos protectores do TUDCA foram já testados, in 
vitro e in vivo, para as doenças de Hungtington e Parkinson, assim como em 
modelos de acidente vascular cerebral, do tipo isquémico e hemorrágico.  Muitas 
outras patologias associadas à desregulação da apoptose poderão, também, 
beneficiar desta estratégia terapêutica. 
A doença de Alzheimer (AD) é uma doença neurodegenerativa progressiva, 
à qual estão associadas graves perdas de memória e um acentuado défice cognitivo.  
O cérebro de um doente de Alzheimer caracteriza-se pela presença de placas 
amilóides, cujo principal componente é a proteína β amilóide (Aβ), e de tranças 
neurofibrilhares (NFT), compostas por agregados intracelulares da proteína tau.  
Como resultado da formação destes agregados tóxicos, os neurónios sofrem 
profundas alterações, tornam-se disfuncionais e acabam por morrer em grande 
escala.  A apoptose parece desempenhar um papel importante, como mecanismo 
essencial de morte celular associada à AD. 
No presente estudo, investigou-se o envolvimento da apoptose na 
neurodegenerescência associada à AD e a possível regulação dos mecanismos 
apoptóticos pelo TUDCA.  Foi também explorada a função de proteínas específicas 
da apoptose e do ciclo celular no papel anti-apoptótico do TUDCA. 
Numa primeira parte do trabalho, os resultados obtidos demonstraram que, 
apesar do aumento da expressão da proteína anti-apoptótica Bcl-2, incubações com 
Aβ induzem níveis significativos de apoptose em células neuronais PC12, o que foi 
eficazmente inibido em pré-tratamentos com TUDCA.  A inibição da apoptose 
induzida por Aβ parece ser feita através da via E2F-1/p53/Bax, mais 
especificamente pela inibição da indução do factor de transcrição E2F-1, da 
estabilização da proteína p53 e da expressão da Bax.  De facto, o TUDCA foi 
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capaz de proteger as células da apoptose dependente da expressão de p53 e de Bax, 
após sobre-expressão de E2F-1 e p53, respectivamente.  
De seguida, o papel das proteínas do ciclo celular, e mais especificamente da 
p53, na modulação, pelo TUDCA, da apoptose induzida por Aβ, foi confirmado 
num modelo das formas familiares da AD.  Apesar de se manifestar numa pequena 
percentagem da população mundial, a AD na sua forma familiar, associada a 
mutações na proteína precursora da Aβ (APP) ou nas presenilinas 1 e 2, possui 
características muito semelhantes à forma esporádica, embora o início da doença 
ocorra geralmente em idades mais precoces.  Utilizando células de neuroblastoma 
que expressam APP com a mutação Swedish (APPswe) ou duplamente mutadas na 
APP e na presinilina 1 (APPswe/ΔE9), observou-se um aumento dos níveis de 
apoptose, em consequência da produção endógena e agregação de Aβ.  De facto, 
detectou-se fragmentação nuclear e activação das caspases -2, -6 e -8 em células 
APPswe e APPswe/ΔE9.  Por outro lado, observou-se também um aumento da 
expressão de p53 e de Bax e uma diminuição da expressão de Bcl-2.  Em 
contrapartida, a pré-incubação com o TUDCA reduziu eficazmente os níveis 
apoptóticos e de activação das caspases -2 e -6, restabelecendo a expressão de p53 
e de proteínas da família Bcl-2.  A sobre-expressão de p53 induziu, por si só, a 
apoptose nas células de neuroblastoma, o que, por sua vez, foi reduzido pelo 
TUDCA.  No entanto, a inibição da via de sobrevivência fosfatidilinositol 3’-
cinase reduziu a capacidade do TUDCA para proteger a apoptose induzida pela 
p53.  Em conclusão, estes estudos demonstram que as mutações associadas às 
formas familiares da AD activam mecanismos apoptóticos muito semelhantes às 
formas esporádicas.  Por outro lado, o TUDCA é capaz de reduzir a apoptose, 
através da inibição da p53 e da consequente modulação dos níveis de expressão das 
proteínas da família Bcl-2. 
Por fim, numa terceira parte do trabalho, o papel da apoptose foi avaliado 
num modelo de tauopatia.  Na AD, assim como nas tauopatias, a proteína tau deixa 
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de induzir a estabilização dos microtúbulos a nível do axónio, é fosforilada de uma 
forma anómala e agrega em NFT no corpo celular dos neurónios.  Como resultado, 
os neurónios deixam de ser funcionais e, eventualmente, acabam por morrer.  Em 
estudos anteriores, o modelo transgénico rTg4510, que expressa uma forma mutada 
de tau humana, apresentou níveis elevados de morte neuronal, em estruturas 
corticais e límbicas associadas à AD, atrofia cerebral e défices cognitivos.  Nos 
nossos estudos, observou-se um aumento dos níveis de fragmentação nuclear e 
activação de caspase-3, especialmente em animais mais jovens, de 2,5 meses, e nas 
áreas do córtex frontal e do hipocampo.  De facto, a apoptose aparenta ser um 
evento precoce nestes animais transgénicos e a activação de caspase-3 parece estar 
associada à clivagem de tau na sua zona C-terminal, uma vez que se observou a co-
localização da caspase-3 activa e de tau clivada no cortex frontal e hipocampo de 
animais com 2,5 meses.  A clivagem de tau pela caspase-3 foi já descrita, por 
alguns autores, como sendo um acontecimento essencial à sua agregação em NFT, 
o que vem confirmar o papel da apoptose nesta patologia.  Apesar das tauopatias 
estarem associadas a mutações na proteína tau, não existem quaisquer mutações 
descritas na AD, sendo a Aβ apontada como principal responsável pelas alterações 
conformacionais da tau.  Em estudos in vitro, por nós realizados, fibrilhas de Aβ1-42 
induziram a fragmentação nuclear, a activação de caspases e clivagem de tau pela 
caspase-3, estabelecendo uma ligação entre as duas entidades patológicas da AD.  
Por outro lado, a pré-incubação com TUDCA inibiu, de forma significativa, a 
clivagem de tau induzida pela apoptose em neurónios corticais de rato.  Deste 
modo, os resultados sugerem que formas intermediárias de tau, clivadas pela 
caspase-3, precedem a morte neuronal nos cérebros dos ratos rTg4510 e em 
neurónios expostos a Aβ1-42 fibrilhar. 
Em suma, o presente trabalho demonstra a importância da apoptose na AD, 
não só como mecanismo de morte neuronal, mas também como mediadora de 
efeitos tóxicos.  Por outro lado, estes estudos revelam o potencial papel protector 
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do TUDCA em modelos de AD, actuando a montante dos eventos mitocondriais, 
nomeadamente através da regulação transcricional da expressão de proteínas do 
eixo apoptótico E2F-1/p53/Bax.  Ilustrou-se, ainda, a capacidade do TUDCA para 
inibir mecanismos tóxicos a jusante da mitocôndria, que culminam na clivagem de 
tau em fragmentos indutores da sua agregação. 
A caracterização do ácido biliar TUDCA como modulador transcricional e 
pós-transcricional da apoptose na AD, consolida o papel desta molécula como uma 
opção terapêutica no tratamento de doenças neurodegenerativas, expandindo o seu 
papel protector para além das doenças hepáticas. 
 
Palavras chave: Ácidos Biliares – Apoptose – β amilóide – Caspases – Doença de 
Alzheimer – E2F-1 – Família Bcl-2 – p53 – Tau   
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PS1 presenilin 1 
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VDCA voltage-dependent anion channel 
 
xxiii
  
 
 
 
 
 
 
 1   
 
 
 
General Introduction 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                  General Introduction 
_________________________________________________________________________ 
 
 
1. Apoptosis 
 
Apoptosis (from the Greek “falling off”) was originally described in 1972 by Kerr 
et al. as a common type of programmed cell death, repeatedly observed in various 
tissues and cell types (Kerr et al. 1972).  Apoptosis is one of the most frequent 
phenomena occurring in multicellular organisms and is fundamental to their health.  
In fact, as a physiological mechanism, apoptosis has an important role in 
embryogenesis, synaptogenesis, immune response and tissue homeostasis.  
Surprisingly, per day, the human body destroys ~ 60 x 109 cells through an 
apoptotic process, in response to physiological, pathogenic, or cytotoxic stimuli, 
underscoring the relevance of this orchestrated form of cellular suicide (Reed 
2002). 
In contrast to necrosis, apoptosis is an active energy-dependent process, 
defined by a series of biochemical and morphological modifications, including 
condensation of chromatin, shrinking of cytoplasm and nuclear compartments, 
degradation of DNA into oligonucleosome-length fragments and 
compartmentalization of nuclear material into vesicular apoptotic bodies (Kerr et 
al. 1972).  These are rapidly eliminated by resident phagocytic and neighboring 
cells, preventing the release of cellular components into the extracellular space, 
and consequent inflammatory response.  Defects in physiological pathways of 
apoptosis contribute to the development of numerous medical illnesses for which 
adequate therapy or prevention is lacking.  In fact, insufficient levels of apoptosis 
are implicated in cancer, autoimmune diseases and persistent infections, while 
excessive apoptosis can lead to neurodegenerative disorders and hepatocellular 
degeneration. 
The highly conserved molecular basis of apoptosis was originally described 
in the nematode Caernorhabditis elegans (C. elegans) (Ellis and Horvitz 1986).  
Interestingly, 113 of the 1090 embryonic somatic cell undergo apoptosis during the 
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development of C. elegans.  In a coordinated process, apoptosis is regulated by 
three important genes: ced-3, ced-4, that induce cell death, and ced-9, which has an 
antiapoptotic role (Metzstein et al. 1998). 
Apoptosis may occur by several molecular pathways.  The best characterized 
and most prominent, however, are the extrinsic death receptor and intrinsic 
mitochondrial pathways (Fig.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.  Schematic overview of extrinsic and intrinsic apoptotic pathways.  In the death 
receptor pathway, after interacting with their ligands, the death receptors recruit adaptor 
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proteins such as FADD and activate caspases-8 and -10.  These initiator caspases then 
cleave effector caspases-3, -6, and -7, which activate key downstream targets and execute 
the apoptotic process.  In the mitochondrial pathway, death stimuli target mitochondria 
either directly or through transduction by proapoptotic Bax and Bak.  Mitochondria release 
cytochrome c, Smac/DIABLO, Omi/Htr2 and other apoptogenic factors.  Cytochrome c 
induces oligomerization of Apaf-1 that recruits and activates procaspase-9.  Caspase-9 then 
activates effector caspases.  The crosstalk between both pathways is mediated by Bid, 
which is truncated and activated by caspases-8.  See text for more complete description. 
 
 
Both pathways are characterized by an initiation phase, when a signal 
triggers the apoptotic process; integration/decision phase, which involves the 
activation of several apoptotic mechanisms; and final execution/degradation phase 
that culminates in cell death.  Although apparently independent, the two apoptotic 
pathways often interact in many cell types to accomplish cell death signaling. 
 
1.1. Mitochondrial pathway 
 
As the primary generators of energy and important regulators of intracellular 
calcium, mitochondria are essential organelles for cell survival.  By coupling 
electron transport to the generation of proton gradients for oxidative 
phosphorylation, mitochondria produce ATP that is used in the metabolic activities 
of the cell.  Thus, highly metabolic tissues such as the brain are particularly 
dependent on mitochondria.  In the past decades, mitochondria have also emerged 
as critical players in cell death.  In fact, all the energy that is used for maintaining 
life in healthy cells is completely redirected to serve a mortal purpose, under 
pathological conditions.  After an apoptotic stimulus, such as oxidative stress, 
DNA damage, or protein misfolding, the levels of calcium are increased, the 
mitochondrial membrane is permeabilized, releasing apoptogenic factors from the 
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intermembrane space to the cytoplasm and disrupting the mitochondrial membrane 
potential, which culminates in cell death (Ricci et al. 2003). 
 
1.1.1. Structural modifications of mitochondria during apoptosis 
Under physiological conditions, mitochondrial inner membrane (IM) is nearly 
impermeable to all ions including protons.  This results in an electrochemical 
gradient, the inner mitochondrial transmembrane potential, that is essential for 
cellular bioenergetics (Mitchell and Moyle 1965a, b).  The permeability of the 
mitochondrial outer membrane (OM) is also well regulated, mainly by the presence 
of voltage-dependent anion channels (VDAC) (De Pinto and Palmieri 1992).  After 
an apoptotic stimulus, mitochondria undergo several modifications leading to 
mitochondrial membrane permeabilization (MMP), often considered as the “point 
of no return” (Green and Kroemer 2004).  The permeability of the OM increases, 
allowing the release of soluble proteins that are usually retained in the 
intermembrane space.  The IM looses its selectivity and becomes permeabilized, 
which results in permanent dissipation of the transmembrane potential (Marchetti 
et al. 1996).  Far from an accidental process, the MMP is a tightly regulated 
phenomenon, with the involvement of dynamic pore structures and interaction of 
different proteins.  One of the first events is the opening of the high conductance 
mitochondrial permeability transition (MPT) pore.  In fact, excessive calcium 
accumulation by mitochondria during apoptosis leads to opening of the MPT pore 
and massive mitochondrial swelling (Bernardi 1999).  Despite the uncertainty 
about the molecular composition, it has been suggested that the MPT pore spans 
the IM and the OM and is composed of proteins from membranes and matrix.  The 
adenine nucleotide translocator (ANT), located in the IM (Brustovetsky and 
Klingenberg 1996), the VDAC (De Pinto and Palmieri 1992), and the cyclophilin 
D, from the matrix (Crompton et al. 1998), were proposed to be part of the MPT 
pore complex.  In addition, proapoptotic proteins from the Bcl-2 family, namely 
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Bax and Bak, can also engage in a close molecular cooperation with some 
components of the MPT complex, such as the VDAC and/or the ANT (Tsujimoto 
and Shimizu 2002), or form themselves pores, further enhancing mitochondrial 
permeabilization (Wolter et al. 1997; Kuwana et al. 2002).  
 
1.1.2. Release of apoptogenic factors from mitochondria 
As a consequence of the MMP, several apoptogenic factors are released into the 
cytosol, activating a family of death-inducing cysteine proteases, the caspases.  
Cytochrome c, a peripheral protein of the IM that functions as an electron shuttle 
between complexes III and IV of the respiratory chain, is a crucial factor in 
mediating mitochondria-dependent apoptosis (Li et al. 1997).  Recent studies have 
identified an additional mitochondrial compartment, the intracristae space, that is 
formed by lamellar and tubular structures resulting from the convoluted folds of 
the IM cristae (Frey and Mannella 2000).  Most of the cytochrome c yield (~ 85%) 
is contained in this compartment, which suggests that an additional step for 
cytochrome c release may occur.  In fact, during apoptosis, cristae are remodeled, 
which results in the widening of junctions that delineate the intercristae space.  
This phenomenon facilitates the diffusion of cytochrome c to the intermembrane 
space and, consequently, to the cytosol through pores formed in the OM (Scorrano 
et al. 2002).  Although not completely understood, the reorganization of cristae 
may require several proteins involved in mitochondrial fusion and fission 
processes, such as the Drp1 (Germain et al. 2005). 
Once in the cytosol, cytochrome c binds and induces conformational changes 
to the apoptotic protease-activating factor-1 (Apaf-1), a CED-4 homolog, in the 
presence of ATP/dATP, recruiting procaspase-9, and forming the apoptosome.  
Caspase-9 then acquires the ability to trigger processing and activation of 
downstream caspases, finalizing the apoptotic process (Zou et al. 1999). 
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Similar to its murine homolog direct inhibitor of apoptosis proteins (IAP) 
binding protein with low pI (DIABLO), the second mitochondria-derived activator 
of caspases (Smac), is another apoptogenic factor released during MMP.  
Smac/DIABLO is a mitochondrial protein encoded by the nuclear genome, and is 
proteolytically processed within the intermembrane space to yield a mature 
polypeptide of 23 kDa with an IAP biding motif (Du et al. 2000).  Following 
MMP, Smac/DIABLO is released into the cytosol, neutralizing IAPs and thus 
promoting caspase activation.  Similar to Smac/DIABLO, the Omi/Htr2 protein is 
also processed in the intermembrane space into a mature form of 37 kDa (Martins 
2002).  Once in the cytosol, it promotes cell death either by antagonizing IAPs 
(caspase-dependent pathway), or via its proteolytic activity (caspase-independent 
pathway). 
The apoptosis inducing factor (AIF) also plays an important role in the 
apoptotic process.  In healthy cells, AIF is required for optimal detoxification of 
reactive oxygen species (ROS), and for the assembly or maintenance of the 
respiratory chain complex I (Vahsen et al. 2004).  However, once released from the 
intermembrane space, after OM permeabilization and proteolytic maturation, AIF 
translocates from the cytosol to the nucleus, promoting chromatin condensation 
and large-scale DNA fragmentation (Susin et al. 1999).  A similar role is played by 
endonuclease G (EndoG), a mitochondria-specific enzyme that also translocates to 
the nucleus during apoptosis.  However, the mechanism by which EndoG cleaves 
DNA into nucleosomal fragments (Li et al. 2001) is not entirely known. 
In addition to the above-described, many other factors are released from 
mitochondria during MMP.  However, their precise role, if any in cell death has 
not yet been elucidated.  Thus, further investigation is needed for the complete 
characterization of the mitochondrial pathway of apoptosis. 
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1.2. Death receptor pathway 
 
Many toxic and pathological situations are associated with changes in expression 
and/or functioning of death receptors and their ligands, leading to caspase 
activation and apoptosis (Fig. 1).  The tumor necrosis factor (TNF) death receptor 
superfamily is a group of cytokines with important functions not only in apoptosis, 
but also in immunity and inflammation, control of cell proliferation and 
differentiation (Baud and Karin 2001).  Nineteen different proteins have been 
identified within this family, including the TNF-α and the Fas/Apo-1/CD95 
receptors that are activated by binding of TNF-α and Fas ligand (FasL), 
respectively (Brunner et al. 1995).  The members of TNF receptor family are 
structurally similar membrane proteins of type I.  They consist of extracellular (N-
terminal), transmembrane, and intracellular (C-terminal) components.  Ligand-
binding domains of the extracellular compenent of death receptors are 
characterized by the presence of 2 to 6 repeats of about 40 amino acids enriched in 
cysteine (Banner et al. 1993).  After ligand binding, adaptor proteins such as the 
Fas-associated death domain (FADD) are recruited (Blagosklonny 2000), forming 
the death-inducing signaling complex (DISC) (Kischkel et al. 1995).  Once 
activated, death receptors induce the cleavage and activation of procaspase-8, and -
10.  In fact, FADD was shown to contain two death effector domains (DEDs) 
capable of recruiting caspase-8, and -10 (Krueger et al. 2001).  Depending on cell 
type, caspase-8, and -10 can directly activate downstream caspases, such as 
caspase-3 or -7 (Peter and Krammer 2003), or transmit the death signal to 
mitochondria, in a cross-talk between both apoptotic pathways (Li et al. 2002) 
(Fig. 1).  In this case, caspase-8 cleaves the inactive cytoplasmic Bid, a 
proapoptotic protein of the Bcl-2 family, exposing an active truncated fragment 
(tBid) (Scaffidi et al. 1998).  Once activated, tBid translocates to mitochondria, 
inducing conformational changes in proapoptotic proteins, such as Bax and Bak 
9 
 
 
 
 
 
 
 
Chapter 1 
_________________________________________________________________________ 
 
and, consequently, the MMP (Eskes et al. 2000).  Moreover, tBid can also inhibit 
antiapoptotic proteins, such as Bcl-2, (Kim et al. 2000), or even directly 
permeabilize the mitochondrial OM (Goonesinghe et al. 2005), ultimately inducing 
caspase-3 activation and perpetuating the apoptotic process. 
Finally, in the presence of ROS, TNF-R1 can also induce apoptosis via 
mitogen-activated protein kinase (MAPK) signaling, activating the c-Jun NH2-
terminal kinase (JNK) pathway (Shen and Pervaiz 2006).  Interestingly, TNF-R1 is 
capable of triggering survival signals, including the activation nuclear factor κB 
(NF-κB) (Barnhart and Peter 2003), underscoring the relevance and complexity of 
death receptors. 
 
1.3. Other molecular intervenients in the apoptotic process 
 
To execute apoptosis, many proteins, enzymes, and different factors are involved.  
In fact, to integrate death signals and perform the multiple reactions that culminate 
in cell death, several components, interactions, and biochemical processes are 
necessary, in a complex organization that defines the efficiency of apoptosis. 
 
1.3.1. Bcl-2 family 
Modulation of apoptosis is performed by the Bcl-2 family, a group of proteins that 
work in regulated protein-protein interactions.  This family gives its name to the 
first identified member, over 20 years ago, at the chromosomal breakpoint of 
t(14;18)(q32;q21) lymphomas, B-cell lymphoma-2 (Bcl-2).  Bcl-2 is an homolog 
of CED-9 (Tsujimoto et al. 1985).  Curiously, Bcl-2 was found to inhibit cell death, 
rather than promote proliferation, and since then many relatives of this family have 
been described.  In mammals, the Bcl-2 family consists of at least 20 members, 
including proteins that promote apoptosis, or proapoptotic proteins, and others than 
inhibit it, forming a complex balancing network that determines cell fate. 
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Bcl-2 members can be subdivided in three groups, according to their 
structure and function.  The antiapoptotic proteins, such as Bcl-2, Bcl-xL and Mcl-
1, among others, share 3 to 4 conserved Bcl-2 homology domains (BH1-4), 
forming group I.  Bcl-2 and its homologues potently inhibit apoptosis in response 
to many cytotoxic insults.  The proapoptotic proteins, such as Bax and Bak, share 3 
conserved domains (BH1-3), forming group II.  Group III contains a subgroup of 
proapoptotic proteins that only have the BH3, such as Bid, Bad, Noxa and Puma, 
among others (Cory et al. 2003).  Both types of proapoptotic proteins are required 
to initiate apoptosis; the BH3-only proteins usually act as damage sensors and 
direct antagonists of the antiapoptotic proteins, while proteins of group II act 
further downstream, mainly in mitochondria disruption. 
Under physiological conditions, Bcl-2 binds to the cytoplasmic face of 
mitochondrial OM, endoplasmic reticulum (ER) and nuclear envelope, promoting 
the integrity of membranes, by interacting and neutralizing proapoptotic proteins 
(Gottlieb 2001).  Bcl-2 overexpression decreases the amount of calcium mobilized 
from the ER to the mitochondria, inhibiting the opening of the PT pore (Baffy et al. 
1993).  In addition, some studies indicate that Bcl-2 and Bcl-XL can also interact 
with ANT and VDAC, inhibiting the formation of the MPT pore (Marzo et al. 
1998; Shimizu et al. 2000). 
Proapoptotic Bax, under normal circumstances, resides as a monomer in the 
cytoplasm (Hsu et al. 1997), while Bak is attached to the mitochondrial OM as an 
integral membrane protein (Griffiths et al. 1999).  Following induction, an 
increased expression of proapoptotic proteins occurs, changing the balance 
between anti- and proapoptotic factors.  Consequently, Bax undergoes 
conformational changes, translocates to the mitochondria, oligomerizes and inserts 
into the OM (Wolter et al. 1997).  Once attached to mitochondria, it is thought that 
Bax, alone or associated with Bak, can provoke or contribute to permeabilization 
of the OM, allowing the release of cytochrome c (Kuwana et al. 2002).  The 
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mechanism by which proapoptotic proteins permeabilize the OM, however, is still 
controversial and not entirely understood.  Some studies suggest that Bax and Bak 
can themselves form hydrophobic pores in the membrane (Wolter et al. 1997; 
Kuwana et al. 2002), or simply destabilize membrane lipid bilayers (Basanez et al. 
2002).  Alternatively, Bax might interact with proteins of the MPT pore, such as 
VDAC and ANT, inducing the MMP (Tsujimoto and Shimizu 2002).  Further, Bax 
and Bak can enhance the loading of the ER calcium store, boosting the calcium 
load to mitochondria (Scorrano et al. 2003). 
Finally, BH3-only proteins act as sentinels that when activated trigger 
apoptosis in response to developmental cues or intracellular damage.  These 
proapoptotic proteins exert their action by two different mechanisms.  In fact, they 
can interact with antiapoptotic proteins, dissociating them from other BH-3-only or 
from BH1-3 proteins, and promoting MMP (e.g. Bad), or they can directly activate 
the BH1-3 proteins to initiate MMP, either by stimulating the translocation of Bax 
to mitochondrial OM or by local effects on Bak (e.g. tBid) (Letai et al. 2002). 
 
1.3.2. Caspases 
Caspases are a family of cysteine proteases that play an important role in the 
execution of apoptosis, cleaving a restricted set of target substrates after an 
aspartate residue in their primary sequence (Thornberry and Lazebnik 1998).  In 
1993, the gene ced-3 was discovered in C. elegans, showing great similarities with 
caspase-3; a connection between caspases and apoptosis was established for the 
first time (Yuan et al. 1993).  Since then, many other caspases have been described 
in mammalian and non-mammalian species. 
Caspases share similarities in amino acid sequence, structure, and substrate 
specificity.  In healthy cells, they are present in the cytosol as inactive precursors, 
called zymogens.  Caspases contain three domains, including a N-terminal 
prodomain, a large subunit with the active cysteine, and a C-terminal small unit 
 
12 
 
 
 
 
 
                                                                                  General Introduction 
_________________________________________________________________________ 
 
 
(Thornberry and Lazebnik 1998).  After an apoptotic signal, the zymogen is 
exposed to two cleavage events.  The first proteolytic cleavage divides the chain 
into large and small caspase subunits, and a second cleavage removes the N-
terminal prodomain (Wolf and Green 1999).  The cleavage of the zymogen is not 
always an obligatory requirement for caspase activation.  However, all activated 
caspases can be detected as cleaved fragments in apoptotic cells (Degterev et al. 
2003). 
According to their function, caspases are grouped as upstream proteases 
termed initiator caspases (caspases-2, -8, -9 and -10), and their downstream targets 
known as effector or executioner caspases (caspase-3, -6 and -7) (Thornberry and 
Lazebnik 1998).  The initiator caspases function as signal integrators for apoptotic 
or proinflammatory stimuli.  They contain larger prodomains and specific sequence 
motifs, such as the caspase recruitment domain (CARD), for caspase-2 and -9, or a 
pair of DEDs, for caspase-8 and -10 (Hofmann et al. 1997; Ashkenazi and Dixit 
1998).  These domains mediate the recruitment of zymogen to death signaling 
complexes, leading to its auto-catalytic activation.  Moreover, the 
homodimerization of zymogens appears to be a crucial step for the activation of 
initiator caspases in contrast to executioner caspases. 
Caspase-9 is a key component of the mitochondrial pathway and its 
activation occurs after cytochrome c release and formation of the apopotosome.  
The zymogen is recruited to the complex through CARD-CARD interactions, and 
rapidly processed into active caspase-9, which in turn is responsible for the 
activation of downstream caspases, such as caspase-3 (Thornberry and Lazebnik 
1998).  On the other hand, caspase-8 has a key role in the death receptor pathway 
and is activated in the presence of external death signals.  In response to the 
activation of receptors of the TNF family, the zymogen is recruited to the DISC via 
binding to FADD, resulting in caspase-8 activation and subsequent activation of 
downstream caspases (Boldin et al. 1996; Varfolomeev et al. 1998). 
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Caspase-10 is structurally very similar to caspase-8, but its function in 
apoptosis is not entirely known (Degterev et al. 2003).  In fact, some studies 
suggest that caspase-10 may have a function that overlaps with caspase-8 in Fas 
ligand-mediated apoptosis.  Caspase-10 might be recruited to the Fas DISC, cleave 
Bid, and activate the mitochondrial pathway. 
Finally, caspase-2 was one of the first caspases discovered, but its 
physiological function and activation remain obscure.  Recent results suggest that 
caspase-2 can be activated by dimerization (Butt et al. 1998) or by recruitment of a 
large complex similar to the apoptosome, named the PIDDosome (Tinel and 
Tschopp 2004).  It is often localized in the cytosol, the nucleus (Colussi et al. 
1998), and the Golgi (Mancini et al. 2000), although its protein targets in these 
compartments remain largely unclear.  Nevertheless, it was demonstrated that in 
some cells caspase-2 is responsible for the mitochondrial OM permeabilization and 
the release of apoptogenic factors in response to DNA damage (Zhivotovsky and 
Orrenius 2005).  It can also associate with the Fas DISC, but apparently it is not 
required for Fas-induced cell death (Lavrik et al. 2006).  Interestingly, caspase-2 
can also function independently of its protease activity, such as by activation of 
MAPK and NF-κB signaling pathways (Lamkanfi et al. 2005). 
Once activated, initiators caspases cleave effector caspases, which lack the 
long prodomain and the ability to self-activate.  Effector caspases are responsible 
for cleaving most of the cellular substrates, finalizing the apoptotic process.  
Caspase-3 is the main downstream effector caspase, which can be activated via the 
death receptor pathway, following activation by caspase-8, and through the 
mitochondrial pathway, by caspase-9 (Porter and Janicke 1999).  It is responsible 
for cleavage of many substrates, including nuclear lamins and cytoskeletal 
proteins, such as fodrin and gelsolin that are associated with morphological 
changes in apoptotic cells (Kothakota et al. 1997).  In addition, caspase-3 cleaves 
the inhibitor of caspase-activated DNAse (ICAD), promoting the activation of the 
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endonuclease CAD, which induces the characteristic nucleosomal DNA 
fragmentation (Sakahira et al. 1998).  Caspase-3 is also responsible for the 
cleavage of poly(ADP-ribose) polymerase (PARP), inhibiting its capacity to repair 
DNA (Rosen and Casciola-Rosen 1997).   
Caspase-7 is highly homologous to caspase-3, with similar substrate 
specificity and redundant functions in the majority of general apoptotic events.  It 
can be activated by caspase-8 (Hirata et al. 1998) and caspase-9 (Li et al. 1997), 
and has also a specific role in the ER-stress response pathway (Rao et al. 2001).  
Caspase-6, although structurally similar to caspase-3 and -7 has different substrate 
specificities.  Its function and activation are still not entirely understood.  However, 
some caspase-6 substrates have been already described and include lamin A 
(Takahashi et al. 1996).   
Even with apparently similar functions, effector caspase-3, -6 and -7 have 
different relevance to the apoptotic process.  In fact, depletion of caspase-3 in a 
cell-free apoptotic system inhibited most of the downstream events, including 
DNA fragmentation and chromatin condensation, while elimination of caspase-6 
and -7 did not produce the same effects (Slee et al. 2001).  Thus, caspase-3 appears 
to be the primary effector caspase, with more specialized functions.  Nevertheless, 
if caspase-3 is missing or not functioning, the other effector caspases can 
compensate the catalytic mechanisms, creating alternative and novel networks 
(Zheng et al. 2000). 
Other caspases play important roles in the inflammation process, such as 
caspase-1, -5 and -11.  In fact, caspase-1 is involved in proinflammatory cytokine 
maturation (Ghayur et al. 1997), while caspase-5 is associated with the formation 
of the inflammasome.  This protein complex is responsible for the activation of 
inflammatory caspases (Martinon et al. 2002).  Caspase-11 was proposed to be the 
murine functional orthologue of human caspase-5 (Lin et al. 2000).  Finally, 
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caspase-12 also appears to have a distinct role in ER-stress mediated pathway, 
which is correlated with disruption of calcium homeostasis (Lamkanfi et al. 2004). 
Overall, caspases are the key executioners of apoptosis, with different 
functions, integrating and terminating the mechanisms that lead to cell dysfunction 
and death.  Their expression and activation are spatially and temporally regulated, 
depending on cell type and development stage, underscoring versatility and wide 
spread function.  Giving their importance and power to destroy cells, caspases are 
tightly regulated in normal cell function.  The IAPs are the primary inhibitors of 
caspase activation, whose homologues have been subsequently described in all 
eukaryotes, from yeast to humans (Crook et al. 1993).  The p53 protein (Clem et al. 
1991) and CmrA (a cytokine response modifier gene) (Ray et al. 1992) can also 
regulate the activation of caspases.  In the last years, several peptide and non-
peptide inhibitors have been developed, providing novel therapeutic tools in 
prevention of apoptosis associated with pathogenic situations, such as 
neurodegenerative and infectious diseases, and ischemia-reperfusion disorders.  
However, most studies did not result in less cell death, since the use of caspase 
inhibitors often sensitizes cells to necrosis and/or autophagy (Vandenabeele et al. 
2006).  Moreover, cells can also undergo apoptosis in caspase-independent 
pathways, involving several other proteases such as cathepsins, calpains and 
granzymes.  This compromises the expected regulation and inhibition by 
therapeutic drugs, challenging science to discover and develop better solutions. 
 
1.3.3. Cell cycle-related proteins 
The balance between cell death and proliferation may be the most important 
phenomenon in tissues homeostasis.  Typically, eukaryotic cells replicate with a 
complexity of events involving a large number of proteins.  However, after stress 
stimuli or DNA-damaging events, cells undergo several modifications to induce 
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either cell cycle arrest and DNA repair, or apoptosis when injury compromises 
survival (Fig. 2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.  Schematic representation of modulation of apoptosis by cell cycle-related proteins.  
Under normal conditions, the transcription factor E2F-1 and p53 are downregulated by pRb 
and Mdm-2, respectively.  Following an apoptotic stimulus, E2F-1 is released and either 
activates or represses its target genes, including those encoding for p73 and p14ARF, and 
NF-κB.  Consequently, p14ARF inhibits Mdm-2 and indirectly stabilizes p53.  p53 regulates 
the expression of proapoptotic Bax, Noxa, Puma, among others.  In addition, it can 
transcriptionally repress Bcl-2 and induce Apaf-1 expression, further enhancing the 
apoptotic response.  p53 also regulates the mitochondrial death pathway, in a transcription-
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independent manner, by inhibiting Bcl-2 and Bcl-xL, and activating Bax and Bak.  See text 
for more complete description. 
 
 
A central player in protecting the integrity of the genome is the tumor 
suppressor p53, a transcription factor that regulates the expression of a large 
number of target genes.  The protein p53 is present at low levels under 
physiological conditions but becomes rapidly stabilized and activated in response 
to a variety of stimuli.  The p53 network is activated through at least three 
independent pathways.  These include DNA damage via the protein kinase ataxia 
telangiectasia mutated (ATM) and Chk2; aberrant hyperphosphorylation and cell 
cycle re-entry triggered by oncogenes Ras or Myc and by p14ARF, and by cytotoxic 
stimuli such as chemotherapeutic agents, in a ATM, Chk2 or p14ARF-independent 
pathway (Vogelstein et al. 2000).  Once activated, p53 can either cause cell cycle 
arrest by transactivation of p21, or induce apoptosis by both transcription-
dependent and -independent mechanisms (Steele et al. 1998).   
The precise mechanisms by which p53 becomes stabilized are not entirely 
clear, but may involve post-translational modifications of p53 and its repressor 
Mdm-2.  Under unperturbed conditions, p53 is tightly regulated by Mdm-2, an E3 
ubiquitin ligase that binds to and poly-ubiquitinates p53, targeting it for 
degradation (Iwakuma and Lozano 2003).  Moreover, Mdm-2 is itself a 
transcriptional target of p53, in a negative feedback loop that maintains low 
physiological levels of p53 (Zauberman et al. 1993).  In addition, several proteins 
have recently been shown to cooperate with Mdm-2 in p53 regulation, such as the 
homolog MdmX protein  (Parant et al. 2001).  In toxic conditions that lead to 
activation and increased levels of p53, the Mdm-2/p53 interaction is affected by 
conformal changes and phosphorylation of p53 in specific residues (Lakin and 
Jackson 1999).  Once stabilized, p53 accumulates in the nucleus, regulating 
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expression of numerous proapoptotic genes, such as Bax (Miyashita and Reed 
1995), Noxa (Oda et al. 2000), and Puma (Nakano and Vousden 2001).  In 
addition, it can also transcriptionally repress Bcl-2 (Miyashita et al. 1994) and 
induce Apaf-1 expression (Robles et al. 2001), further enhancing the apoptotic 
response.  Moreover, p53 is capable of transactivating genes involved in the death 
receptor apoptotic pathway, such as FasL and Fas (Vogelstein et al. 2000).  Recent 
evidence also indicates that p53 regulates the mitochondrial death pathway, in a 
transcriptional-independent, non-nuclear mechanism.  In fact, the results suggest 
that p53 binds and inhibits Bcl-2 and Bcl-xL, and activates proapoptotic and multi-
domain Bax and Bak, inducing permeabilization of the mitochondrial OM (Schuler 
and Green 2005).  Thus, it is clear that p53 is more than a transcription factor, 
working in a varied and complex manner to promote efficient elimination of 
malfunctioning cells. 
E2F-1 is also a transcription factor, member of the E2F family that 
comprises six elements with the ability to regulate many target genes involved in 
the control of cell proliferation.  Regulation of E2F-1 is mediated primarily by 
interaction with unphosphorylated retinoblastoma protein (pRb) that masks and 
inhibits the transactivation domain of E2F-1.  Following phosphorylation of pRb 
by cyclin-cyclin dependent (CDK) complexes, E2F-1 is released and free to 
mediate activation of target genes (Dyson 1998).  Interestingly, E2F-1 can also 
regulate apoptosis by at least three different mechanisms.  In fact, E2F-1 stabilizes 
p53 by induction of p14ARF, a possible direct target of E2F-1, which binds to Mdm-
2 and prevents p53 degradation (Kamijo et al. 1998).  On the other hand, E2F-1 
transcriptionally upregulates p73, a homolog of p53 that shares the ability to 
induce apoptosis (Irwin et al. 2000).  E2F-1 can also inhibit antiapoptotic factors, 
such as NF-κB, thus promoting cell death (Phillips et al. 1999).  It is thought that 
different apoptotic pathways induced by E2F-1 occur simultaneously in 
cooperative actions that further enhance the death signal. 
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Thus, after a toxic stimulus and under appropriate conditions, cells have 
mechanisms to either arrest cell cycle and repair DNA, or trigger a complex and 
efficient mechanism that culminates in death. 
 
2. Role of bile acids in apoptosis 
 
Bile acids are produced in the liver and secreted into the intestine, where they play 
crucial biological roles such as the solubilization of lipids in the intestinal lumen, 
among many others.  However, certain hydrophobic bile acids are cytotoxic 
molecules that can increase cell proliferation in the intestinal tract (Bayerdorffer et 
al. 1993) and/or induce cell death by necrosis and apoptosis (Patel and Gores 
1995).  In contrast, more hydrophilic species can be cytoprotective (Heuman et al. 
1991). 
 
2.1. Bile acid biosynthesis and physiology 
 
Bile acids are the major components of bile, synthesized in the liver from neutral 
sterols by a complex series of chemical reactions (Russell and Setchell 1992).  
They are a class of acidic steroids with a cyclopentanoperhydrophenanthrene 
nucleus (ABCD-ring) containing 19 carbons, and most commonly a C5 side chain 
with a terminal carboxylic acid (Rodrigues et al. 2004).  In humans and most 
animal species, bile acids are produced primarily from the cholesterol metabolic 
pathway.  The complete synthesis of bile acids requires approximately seventeen 
enzymes.  The expression of these enzymes is tightly regulated by nuclear 
hormone receptors and other transcription factors, which ensure a steady supply of 
bile acids to a highly demanding metabolic environment.  Importantly, the initial 
and rate-limiting step for the major bile acid biosynthetic pathway is the 7α-
hydroxylation of cholesterol, catalyzed by the cytochrome P450 enzyme, 
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cholesterol 7α-hydroxylase (CYP7A1).  Different bile acid species have diverse 
degrees of hydrophobicity, as determined by their biochemical and 
physicochemical properties.  The amphipathic structure allows these water-soluble 
compounds to interact with proteins and insert into lipid bilayers.  These effects 
will have severe influences on cell function and structure, particularly when 
intracellular concentrations of bile acids exceed certain limits, as it is the case in 
cholestasis. 
Primary bile acids are synthesized in the liver, conjugated with the amino 
acids glycine or taurine, and then secreted via the bile ducts and gallbladder into 
the lumen of small intestine (Russell and Setchell 1992).  Bile acids act as 
detergents to emulsify dietary lipids and fat-soluble vitamins, but they can also 
solubilize bilirubin and other catabolites.  Furthermore, the expression of genes 
that synthesize cholesterol, fatty acids, and bile acids are regulated by 
intermediates and/or end-products of the bile acid pathway itself (Repa and 
Mangelsdorf 1999).  While emulsified nutrients are taken up by enterocytes in the 
proximal segments of the gut, bile acids re-enter the liver via the portal vein, and 
are transported back into the gallbladder for use in the next feeding cycle (Russell 
and Setchell 1992). 
The biliary bile acid pool also includes secondary bile acids, such as 
deoxycholic and lithocholic acids.  These bile acids are not formed in the liver, but 
rather result from the metabolism of primary bile acids by intestinal bacteria.  
Biotransformations of primary bile acids include also the formation of 
ursodeoxycholic acid (UDCA), by oxidation of chenodeoxycholic acid to 7-
oxolithocholic acid, followed by reduction yielding the 7β-isomer. 
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2.2. Bile acids and apoptosis 
 
2.2.1.  Bile acid-induced apoptosis 
Accumulation of toxic bile acids is a common feature of several chronic human 
liver diseases, resulting from interruption in bile flow.  This pathological condition, 
known as cholestasis, can promote liver cell death, leading to cirrhosis (Hofmann 
2002).  It was thought that hydrophobic bile acids, such as glycochenodeoxycholic 
and taurochenodeoxycholic acids could induce cytotoxicity by acting as detergents 
on cell membranes.  However, other evidence suggests that basic cellular 
mechanisms of hepatocyte injury might be primarily involved (Schmucker et al. 
1990), ultimately causing cell death by either necrosis or apoptosis.  Importantly, 
the presence of classic Councilman bodies and cell failure suggests that apoptosis 
may play a key role in cholestasis.  Bile acid-induced apoptosis has been shown in 
vivo as well as in primary rat hepatocytes and human hepatoma HuH-7 cells 
(Rodrigues and Steer 2000).  However, the predominant type of liver injury may 
depend upon several factors, such as the cell type, level of exposure, and metabolic 
status of the cell. 
The mechanisms by which bile acids induce apoptosis in hepatocytes are still 
not entirely known.  Several studies have shown that caspase activation, 
mitochondrial dysfunction, and cellular distribution of Bcl-2-related proteins 
determine the fate of hepatocytes in models of cholestasis (Maher 2004).  In 
addition, toxic bile acids can also induce ligand-dependent and -independent death 
receptor pathways, via Fas- and tumor necrosis factor-related apoptosis inducing 
ligand (TRAIL) receptors (Faubion et al. 1999; Higuchi et al. 2003).  
Subsequently, FADD is recruited and activates caspase-8 and Bid, which results in 
downstream activation of effector caspases and cathepsin B (Roberts et al. 1999; 
Sokol et al. 2001).  The activation of death receptors invariably signals the 
mitochondrial pathway of apoptosis in hepatocytes.  In fact, deoxycholic acid 
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(DCA) was shown to induce the MPT pore formation in isolated mitochondria 
(Rodrigues et al. 1998a), as well as mitochondrial depolarization, increased ROS 
production, translocation of Bax to mitochondria and cytochrome c release 
(Rodrigues et al. 1999; Rodrigues et al. 2003a).  Further, MPT was prevented by 
antioxidants and cyclosporine A, an inhibitor of the megapore channel (Botla et al. 
1995; Rodrigues et al. 1998b; Sokol et al. 2001). 
Curiously, the liver has the ability to limit apoptosis during cholestasis by 
triggering specific mechanisms.  Although it has been shown that Bcl-2, Bcl-xL, 
and Bax are expressed in the liver, only cholangiocytes and not hepatocytes 
normally express antiapoptotic Bcl-2.  However, induction of cholestasis by bile 
duct ligation leads to Bcl-2 expresion in hepatocytes, which may represent an 
adaptative phenomenon to protect hepatocytes (Kurosawa et al. 1997).  In addition, 
the activation of NF-κB and subsequent regulation of antiapoptotic genes 
(Schoemaker et al. 2003), as well as the cytoplasmic sequestration of p53 (Oh et al. 
2002) are complementary mechanisms triggered by the liver to inhibit or modulate 
apoptosis induced by toxic bile acids. 
 
2.2.2.  Inhibition of apoptosis by ursodeoxycholic acid 
In contrast to toxic hydrophobic bile acids, UDCA improves liver function in 
patients with hepatobiliary disorders (Lazaridis et al. 2001).  It is normally present 
in human bile in a low concentration, representing only 3% of total bile acids.  In 
black bears, however, UDCA is the major biliary bile acid.  Bear bile has been 
used for centuries in traditional Chinese medicine as a remedy for liver disorders 
(Hagey et al. 1993).  In the Western world, UDCA has been used for a few decades 
as a therapeutic agent for chronic cholestatic liver diseases.  At the present, it is the 
only drug approved by the United States Food and Drug Administration for the 
treatment of primary biliary cirrhosis (Lazaridis et al. 2001; Paumgartner and 
Beuers 2004). 
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Both unconjugated UDCA and its amidated conjugates, 
tauroursodeoxycholic acid (TUDCA) and glycoursodeoxycholic acid (GUDCA) 
are effective modulators of toxicity induced by more hydrophobic bile acids 
(Rodrigues and Steer 2000).  The mechanisms of action of UDCA in cholestasis 
may involve the protection of injured cholangiocytes, stimulation of impaired 
biliary secretion, detoxification of hydrophobic bile acids, and/or inhibition of 
hepatocyte apoptosis (Paumgartner and Beuers 2004).  It is not clear which of these 
mechanisms play a primary role for the beneficial therapeutic effects of UDCA.  
Most likely, UDCA acts in a coordinated process involving several effects, 
depending on the type and stage of the disease. 
The role of UDCA in preventing apoptosis in cholestasis has been intensely 
studied .  In fact, toxic bile acids fed to rats induced apoptosis in the liver, while 
UDCA inhibited this effect in vivo, in part by preventing translocation of 
proapoptotic Bax from the cytosol to the mitochondria (Rodrigues et al. 1998b) 
(Fig. 3).  These studies were subsequently extended to show that UDCA plays a 
unique role in modulating apoptosis in different cell types, in response to a variety 
of agents, acting through different apoptotic pathways (Rodrigues et al. 1998a).  
The antiapoptotic effect of UDCA appears to involve the mitochondrial membrane.  
In fact, UDCA and its conjugates prevent the release of cytochrome c, caspase 
activation, and PARP cleavage associated with mitochondrial depolarization and 
Bax channel formation induced by apoptotic stimuli (Rodrigues et al. 1999).  
Moreover, UDCA partially prevented apoptosis via the death receptor pathway in 
primary mouse hepatocytes co-cultured with fibroblasts expressing the Fas ligand, 
possibly by its direct effects at the mitochondrial membrane (Azzaroli et al. 2002)  
Additional mechanisms of action for UDCA may also be engaged, where the 
bile acid interferes with alternate molecular targets (Fig. 3).  In fact, DNA 
microarray analysis showed that UDCA can significantly modulate the expression 
of 96 different genes, most of them involved in apoptosis, but also in cell cycle 
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regulation and proliferation (Castro et al. 2005).  Apaf-1 was found to be 
downregulated in rat hepatocytes in response to UDCA incubations.  Importantly, 
UDCA can also interfere with molecular targets upstream of the mitochondria.  
UDCA inhibited TGF-β1-induced E2F-1 transcriptional activation, p53 
stabilization and p53-associated Bax expression, independently of its effect on the 
mitochondria and/or caspases (Solá et al. 2003b).  UDCA also inhibited the 
downregulation of Bcl-2 by TGF-β1, which is consistent with decreased p53 
stabilization and/or of NF-κB degradation.  Furthermore, recent evidence showed 
that both UDCA and TUDCA reduce transcriptional activation and expression of 
cyclin D1 in primary rat hepatocytes incubated with deoxycholic acid (Castro et al. 
2005; Castro et al. 2007).  The modulation of cyclin D1 expression appears to 
contribute to the antiapoptotic effects of the bile acid, in part through a p53-
dependent mechanism.  In fact, UDCA modulates the E2F-1/Mdm-2/p53 apoptotic 
pathway in hepatocytes via a nuclear steroid receptor (NSR)-dependent mechanism 
(Solá et al. 2004).  UDCA upregulated both glucocorticoid (GR) and 
mineralocorticoid (MR) receptor expression in hepatocytes during TGF-β1-
induced apoptosis.  Moreover, it was shown that UDCA promotes GR/hsp90 
dissociation, inducing subsequent NSR translocation (Solá et al. 2005).  The 
deletion of the C-terminal region of GR inhibited the capacity of UDCA to induce 
GR/hsp90 dissociation, GR translocation and modulation of apoptosis, indicating 
that the ligand binding domain of GR is required for the antiapoptotic function of 
UDCA.  These results strongly suggest that UDCA translocates to the nucleus, in a 
complex with GR, where it may modulate apoptosis-related genes.  In contrast, 
recent evidence suggests that the modulation of induced neuronal apoptosis by 
TUDCA requires an interaction with MR (Solá et al. 2006). 
TUDCA was also shown to regulate the ER stress-mediated pathway in 
HuH-7 cells, reducing the calcium efflux and the activation of caspases-12 (Xie et 
al. 2002) (Fig. 3).  Moreover, treatment of obese and diabetic mice with TUDCA 
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resulted in normalization of ER-induced hyperglycemia and restored systemic 
insulin response (Ozcan et al. 2006).  TUDCA was also responsible for resolution 
of fatty liver disease and enhancement of insulin action in liver, muscle, and 
adipose tissues, expanding its beneficial role to type 2 diabetes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.  Proposed mechanisms for the antiapoptotic actions of UDCA and TUDCA.  UDCA 
negatively modulates the mitochondrial pathway by inhibiting Bax translocation, ROS 
formation, cytochrome c release and caspases-3 activation.  UDCA can also interfere with 
the death receptor pathway, inhibiting caspase-3 activation.  Moreover, TUDCA inhibits 
apoptosis associated with ER stress, by modulating intracellular calcium levels, and 
inhibiting calpain and caspase-12 activation.  UDCA interacts with NSR, leading to 
NSR/hsp90 dissociation and nuclear translocation of NSR.  The nuclear trafficking of 
Fas L
Fas
Cytochrome c
E2F-1UDCA
?
Nucleus
hsp90
p53
p14ARF Mdm-2
NSR
UDCA
UDCA
NSR
NSR
hsp90
Endoplasmic
Reticulum
Caspase-3
UDCA
Bax
Bax
Bax
Bcl-2
UDCA
Ca2+Ca2+
Ca2+ Procaspase-12Calpain
Caspase-12
Mitochondria
TUDCA
APOPTOSIS
Cyclin 
D1
Apaf-1
 
26 
 
 
 
 
 
                                                                                  General Introduction 
_________________________________________________________________________ 
 
 
UDCA allows it to modulate the E2F-1/p53/Bax pathway, preventing apoptosis.  Finally, 
UDCA downregulates cyclin D1 and Apaf-1, further inhibiting the mitochondrial apoptotic 
cascade.  See text for more complete description. 
 
 
Finally, it is becoming increasingly evident that activation of survival 
pathways may represent an important additional mechanism by which UDCA 
inhibits apoptosis.  One possible survival pathway involves the activation of NF-
κB by several molecules, including the inflammatory cytokines TNF-α and 
interleukin-1β (Bradham et al. 1998).  In addition, TUDCA was shown to protect 
mitochondria-controlled apoptosis in primary rat hepatocytes by activating the 
phosphatidylinositol 3-kinase (PI3K) and MAPK pathways (Schoemaker et al. 
2004). 
 
2.3. Bile acids for the treatment of neurodegenerative disorders 
 
The therapeutic role of UDCA has been established in the treatment of certain liver 
diseases.  Importantly, UDCA has the ability to modulate apoptosis at several 
levels, suggesting a common mechanism of cell survival regulation that is 
independent of cell type.  Thus, the use of UDCA to non-liver diseases in which 
increased levels of apoptosis contribute to their pathogenesis is now a major 
consideration. 
Mitochondrial dysfunction and subsequent oxidative damage have been 
implicated in several neurobiological disorders, such as acute stroke and chronic 
neurodegenerative diseases.  Moreover, increasing evidence suggests that apoptosis 
plays a crucial role in the pathogenesis of such disorders (Mattson 2006).  
Interestingly, after conjugation with taurine, UDCA administrated in high doses 
can be delivered to other tissues, including the brain (Keene et al. 2001).  In vitro, 
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TUDCA inhibits apoptosis induced by several stimuli in neuronal cells (Rodrigues 
et al. 2000; Solá et al. 2003a).  Furthermore, the protective role of TUDCA has 
been extended to several models of neurological disorders, including 
Hungtington’s disease (HD), Parkinson’s disease (PD), and acute ischemic and 
hemorrhagic stroke. 
HD is a genetically dominant neurological disorder caused by abnormal 
expansion of the trinucleotide (CAG) repeat sequence in exon 1 for the gene Htt 
encoding the huntingtin protein (Walker 2007).  In HD, mitochondrial function is 
compromised, which is demonstrated by abnormal energy metabolite levels, 
impaired striatal mitochondrial respiratory chain complex II/III activity and 
increased stress-induced mitochondrial depolarization, ROS production, and 
associated oxidative damage.  A consequence of mitochondrial dysfunction may be 
the activation of certain apoptotic pathways, confirmed by activation of caspases 
and DNA fragmentation in HD brains.  Chronic administration of 3-nitropropionic 
acid (3-NP), an irreversible inhibitor of succinate dehydrogenase provides a 
relatively accurate animal model of HD, closely resembling the pathology and 
symptoms of the disease.  The systemic administration of TUDCA in the 3-NP rat 
model of HD was shown to reduce the associated morphologic striatal lesions 
(Keene et al. 2001).  Moreover, behavioral studies correlated with 
histopathological findings, since the significant neuroprotection resulted in almost 
complete prevention of hyperactive behavior associated with 3-NP administration, 
while maintaining neophobia characteristic of cognitively intact animals.  TUDCA 
also markedly reduced the mitochondrial perturbations associated with apoptosis 
induction in cultured neuronal cells incubated with 3-NP (Rodrigues et al. 2000).  
These data suggested that TUDCA could possibly act as a therapeutic agent for 
regulating cell survival in HD.  Thus, initial studies were extended to the R6/2 
transgenic mouse model of HD, which express exon 1 of the human huntingtin 
gene with ~ 150 CAG repeats and the human huntingtin promoter.  Administration 
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of TUDCA induced a marked reduction in striatal cell apoptosis and degeneration 
of R6/2 transgenics (Keene et al. 2002).  In addition, TUDCA prevented striatal 
atrophy, reduced the average size and number of individual characteristic 
intracellular inclusions of huntingtin and ubiquitin, and, consequently, improved 
the locomotor and sensorimotor abilities of R6/2 transgenic mice. 
Transplantation of human embryonic dopamine neurons in patients with PD 
is currently being evaluated in clinical trials.  Although transplantation of nigral 
tissue ameliorates deficiencies characteristic of PD, a major hurdle for successful 
neural grafting is the poor survival of dopaminergic neurons implanted into the 
brain of recipient patients.  There is strong evidence showing that the majority of 
cell death occurring in neuronal grafts results from apoptosis.  Thus, based on its 
antiapoptotic properties, TUDCA was added to cell suspensions prior to 
transplantation to improve cell survival of nigral grafts in a rat model of PD (Duan 
et al. 2002).  The results showed that TUDCA reduced the levels of cultured cells 
undergoing apoptosis, increasing the number tyrosine-hydroxylase-positive 
neurons.  In transplantation studies, where TUDCA treated-cell suspensions were 
injected into the striatum of 6-hydroxydopamine lesioned rats, there was a 
significant improvement of amphetamine-induced rotation scores, resulting from 
increased survival of dopamine positive cells.  More recently, TUDCA was shown 
to partially rescue a PD model of C. elegans from mitochondrial dysfunction (Ved 
et al. 2005). 
Prompted by these results, the antiapoptotic role of TUDCA was extended to 
acute conditions, particularly to a rat model of transient focal cerebral ischemia 
(Rodrigues et al. 2002).  Neuronal cell death resulting from acute stroke is a 
complex process and appears to involve a variety of different pathways.  Although 
originally thought to be mainly necrotic, cell death can also occur via apoptosis in 
both ischemic and hemorrhagic stroke (Friedlander et al. 1997; Matsushita et al. 
2000).  Intravenous administration of TUDCA resulted in improved neurologic 
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function and reduced infarct volumes by ~ 50%.  In addition, TUDCA significantly 
reduced the number of apoptotic cells, prevented mitochondrial swelling and 
membrane disruption, and partially inhibited downstream caspases activation and 
endogenous substrate cleavage associated with apoptosis.  TUDCA also reduced 
the levels of apoptosis, caspase-3-like activation and histological damage of the 
peri-hematoma region in a collagenase-induced hemorrhagic model of stroke 
(Rodrigues et al. 2003b).  In addition, TUDCA inhibited NF-κB activation, 
maintained elevated the levels of Bcl-2, and activated the PI3K survival pathway, 
consequently improving neurological functions. 
Cell death induced by glutamate may be involved in neuronal injury 
associated with chronic neurodegenerative disorders, including HD, and with acute 
conditions, such as hypoxia-reperfusion.  The mechanisms by which neurons die 
when exposed to glutamate can either be necrotic or apoptotic, depending on the 
severity of the insult (Bonfoco et al. 1995).  Interestingly, pretreatment with 
TUDCA also significantly reduced glutamate-induced apoptosis of rat cortical 
neurons (Castro et al. 2004).  TUDCA inhibited the release of cytochrome c from 
mitochondria as well as the activation of caspases-3.  In addition, TUDCA induced 
marked phosphorylation and translocation of Bad to cytosol, which was prevented 
after inhibition of the PI3K survival pathway.  These results suggested that 
TUDCA modulates glutamate-induced apoptosis in part by activating a PI3K-
dependent Bad signaling pathway. 
Taken together, these studies provide evidence for the antiapoptotic role of 
UDCA and TUDCA.  As a hydrophilic acid, TUDCA is readily water-soluble, can 
be administrated orally and intravenously, and is associated with minimal toxicity.  
These characteristics make TUDCA a potent therapeutic tool in several disorders 
associated with higher susceptibility to apoptotic cell death.  Thus, it would be 
relevant and interesting to further extend its clinical applications to other 
neurodegenerative diseases, such as Alzheimer’s disease (AD). 
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3. Alzheimer’s disease 
 
In 1906, the physician Alois Alzheimer gave a lecture at a congress of psychiatry 
in Tübingen, Germany.  For the first time, he described a disease that Kraepelin 
some years later named AD.  Over several years, Alzheimer had been observing a 
patient at the Frankfurt Asylum named Auguste D., who presented strange 
behavioral symptoms, including a decline in short-term memory, confusion and 
disorientation.  After her death, staining techniques revealed the presence of 
amyloid plaques and neurofibrillary tangles (NFT) in the brain, which are today 
recognized as hallmarks of the disease.  AD is the most common form of dementia.  
However, after 100 years of its discovery, the triggering mechanisms of AD are not 
entirely understood, and effective diagnosis and treatment are still lacking. 
 
3.1. Epidemiology and risk factors 
 
AD is a severe and common cause of dementia, accounting for 50-60% of all cases 
(Ferri et al. 2005).  This neurodegenerative disease targets specific brain regions 
early in its course, especially the cholinergic basal forebrain and medial temporal 
lobe structures, including the hippocampus, amygdale and entorhinal cortex.  With 
disease progression, the pathogenesis spreads to other regions, including the 
posterior cingulate, temporal and parietal isocortical regions (Braak and Braak 
1991).  AD is characterized by progressive memory loss, anomia, constructional 
apraxia, anasognosia, and variable degrees of personality changes (Katzman 1992).  
The prevalence of AD is less than 1% in individuals aged 60-64 years, but the 
probability of developing the disorder increases with age.  In Western countries, 
the prevalence reaches 24-33% in people aged 85 years or older.  In 2001, more 
than 24 million people in the world had dementia.  With life expectancy increasing, 
the numbers are predicted to double every 20 years, reaching up to 81 million in 
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2040 (Ferri et al. 2005).  In Portugal, there are ~ 60,000 patients with AD, although 
the numbers might be under estimated, given the difficulty of diagnosis. 
In the vast majority of cases, the cause of AD remains unclear.  Like most 
other chronic conditions, AD probably develops as a result of multiple factors, 
rather than a single cause.  Undoubtedly, the greatest risk factor is advancing age, 
but epidemiological studies have suggested several possible associations.  
Decreased reserve capacity of brain, including reduced brain size, low levels of 
education and occupation, low mental ability in early life, and reduced mental and 
physical activities during late life, can increase the susceptibility to develop AD 
(Mayeux 2003).  In addition, it has been suggested that head injury can also be 
linked to AD (Jellinger 2004).  Other risk factors are hypo- and hyperthyroidism, 
hypercholesterolemia, hyperthension, atherosclerosis, heart disease, smoking, 
obesity, and diabetes (Mayeux 2003). 
Although environmental influences might increase the susceptibility to 
sporadic AD, genetic factors have a significant impact in the development of the 
disease.  The genetic factor that accounts for more cases of late-onset sporadic AD 
is the apolipoprotein ε4 allele (APOE) located on chromosome 19.  APOE ε4 
increases the risk of developing AD 3-fold in heterozygotes and by 15-fold in 
homozygotes, and also influences the age of disease onset (Farrer et al. 1997; 
Meyer et al. 1998).  The mechanisms by which APOE ε4 triggers AD are not 
entirely understood, but may include enhanced rate of amyloid β (Aβ) deposition, 
as well as reduced protection against oxidative stress and efficacy of neuronal 
repair (Horsburgh et al. 2000).  The search for additional susceptibility genes for 
sporadic AD is still ongoing, but none has been verified with certainty. 
A small percentage of AD patients have a familial form of the disease, 
related to a specific hereditary mutation.  Familial AD is rare, with a prevalence 
below 0.1 % (Harvey et al. 2003).  It is an autosomal-dominant disorder with early 
onset, striking patients in their mid-thirties to mid-fifties.  To date, more than 100 
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mutations of 3 genes have been identified to cause this specific form of AD.  The 
first mutation related to familial AD was identified in the amyloid precursor 
protein (APP) gene on chromosome 21 (Goate et al. 1991).  Since then, several 
additional mutations have been described.  The largest number of mutations, 
however, is located in the presenilin 1 (PS1) gene, responsible for most cases of 
familial AD (Sherrington et al. 1995).  Finally, a small number of mutations have 
also been identified in the presenilin 2 (PS2) gene in chromosome 1 (Levy-Lahad 
et al. 1995).  All mutations result in elevated Aβ levels.  Although related to 
hereditary factors, familial AD patients develop the same histopathological features 
and cognitive deficits observed in sporadic cases. 
 
3.2. Pathogenesis 
 
Neurodegeneration in AD is estimated to begin 20-30 years before clinical onset 
(Davies et al. 1988).  During this preclinical phase and after diagnosis, several 
pathologic mechanisms occur in specific areas of the brain.  At the microscopic 
level, Aβ and tau deposit and aggregate into characteristic external amyloid 
plaques and internal NFT, respectively.  At the same time and/or consequently, 
other cellular abnormalities occur, such as neuronal dysfunction, cell cycle 
deregulation, ROS production, inflammation and mitochondrial failure.  
Ultimately, all these pathological mechanisms culminate in neuronal death and 
cognitive decline. 
 
3.2.1. Amyloid plaques 
The main constituent of amyloid plaques found in AD brains is the Aβ peptide 
(Glenner and Wong 1984).  Initially, Aβ was thought to be an abnormal protein.   
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Fig. 4.  Diagram of APP processing.  In the nonamyloidogenic pathway, APP is cleaved by 
β-, γ- and α-secretases, generating a soluble sAPPα fragment.  In contrast, the cleavage of 
APP by β- and γ-secretases produces Aβ, with high capacity to aggregate into amyloid 
plaques.  See text for more details. 
 
 
However, it is also constitutively produced during normal cell metabolism 
(Haass et al. 1992).  Aβ is generated by proteolytic cleavage of APP, mediated by 
the transmembrane proteins β- and γ-secretases (Vassar et al. 1999) (Fig. 4).  The 
β-site APP cleaving enzyme (BACE1), a member of the pepsin family of aspartyl 
proteases, cleaves the ectodomain of APP to generate a membrane bound C-
terminal fragment, which is subsequently, cleavage by γ-secretase.  Importantly, 
although not entirely understood, the metabolism of APP appears to be modulated 
both directly and indirectly by phosphorylation and phosphorylation-dependent 
events (da Cruz e Silva and da Cruz e Silva 2003).  Depending on the exact 
cleavage site, peptides with 38 to 43 amino acids may be generated.  Nevertheless, 
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the most common and toxic forms of Aβ contain 40 and 42 amino acids in length, 
and are termed Aβ1-40 and Aβ1-42, respectively.  These fragments of ~ 4 kDa 
account for the majority of Aβ found in AD brains.  Finally, APP can also be 
cleaved by a third protease, the α-secretase (Allinson et al. 2003).  α-secretase 
cleavage is nonamyloidogenic and precludes subsequent BACE1 cleavage, 
generating a soluble sAPPα fragment that appears to be neuroprotective (Meziane 
et al. 1998).  Under normal conditions, the brain also has the capacity to degrade 
Aβ by the peptidases insulin-degrading enzyme, neprilysin, and by endothelin-
converting enzyme (Carson and Turner 2002).  Moreover, Aβ is cleared from the 
brain in a process balanced by a system of efflux and influx that allows the peptide 
to cross the blood-brain barrier (Tanzi et al. 2004). 
The amyloid cascade hypothesis is considered the major cause of AD (Hardy 
and Selkoe 2002).  According to this, an imbalance between production and 
clearance of Aβ in the brain triggers neuronal degeneration and dementia, as the 
initial step of the process.  Support for this hypothesis includes the finding of 
mutations in APP, and in PS1 and PS2, implicated in familial AD.  Moreover, the 
discovery of a third APP gene in people with Down’s syndrome, who develop AD 
early in life, suggested that life-long APP overexpression triggers Aβ deposition.  
Following cleavage, soluble Aβ undergoes conformational changes in its β-sheet 
content.  Next, the peptide self-aggregates by a complex process starting with self-
dimerization, followed by oligomerization, protofibril formation, and eventual 
aggregation into large insoluble fibrillar structures (Urbanc et al. 2004).  
Importantly, increasing evidence suggest that the ratio Aβ1-42/Aβ1-40 is important in 
AD pathogenesis, rather than the total amount of Aβ produced.  In fact, due to its 
hydrophobic nature, Aβ1-42 has a higher tendency to aggregate and is believed to 
initiate amyloid plaques formation, by triggering the misfolding of other Aβ 
species (Jarrett et al. 1993; Iwatsubo et al. 1994).  
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Initially, only Aβ plaques were assumed to be neurotoxic.  However, there 
are several phenomena that can not be explained by fibrillar deposits alone.  
Indeed, affected neurons do not necessarily colocalize with amyloid plaques in the 
brain (Li et al. 1994).  Similarly, amyloid plaques do not correlate with cognitive 
decline, as it would be expected if plaques were the main toxic entity in AD 
(Naslund et al. 2000).  Thus, it has been suggested that intermediate soluble 
oligomers of Aβ may be toxic entities (McLean et al. 1999).  These protofibrils are 
present in AD brain, and represent a distinct form of low molecular weight Aβ, 
containing 9 to 50 molecules of the peptide.  Interestingly, exposure of neuronal 
cultures and mouse brains to soluble oligomers of Aβ resulted in higher levels of 
toxicity and neuronal dysfunction, compared to fibrillar species, but the results are 
still controversial (Dahlgren et al. 2002; Kirkitadze et al. 2002).  Moreover, the 
role of tau in AD pathogenesis can not be neglected and it possibly accounts for 
other dysfunctions not directly correlated with Aβ aggregation. 
 
3.2.2. Neurofibrillary tangles 
Neurobrillary tangles, in addition to amyloid plaques, are another pathological 
feature of AD, whose major component is the protein tau.  Tau is a family of 
microtubule associated proteins, abundant in the central nervous system and 
predominantly expressed in axons (Binder et al. 1985).  Through its microtubule-
binding domains, tau promotes microtubule assembly and stability.  In addition, it 
can also play a role in vesicular transport and axonal polarity.  In adult human 
brain, tau contains six different isoforms, ranging from 45 to 65 kDa, resulting 
from alternative splicing.  The isoforms differ by the presence of either three- (3R) 
or four-repeat domains (4R) in the C-terminal region, the binding domains, and the 
absence or presence of one or two inserts in the N-terminal region (Goedert et al. 
1989).  Each isoform is likely to have particular roles, since they are differentially 
expressed during development.  In fact, it has been demonstrated that adult tau 
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isoforms with 4R are more efficient at promoting microtubule assembly than the 
fetal isoform with 3R (Goedert and Jakes 1990). 
Tau is very hydrophilic, soluble, and natively unfolded.  The functions of tau 
are regulated by phosphorylation, which can occur in multiple sites.  For instance, 
it was demonstrated that tau is more efficient in promoting microtubule assembly 
when in a more dephosphorylated state.  Interestingly, the longest form of human 
tau contains 80 serine or threonine residues and five tyrosine residues, which 
represents almost 20% of the protein with potential for phosphorylation (Stoothoff 
and Johnson 2005).  Several kinases have been shown to phosphorylate tau.  The 
glycogen synthase kinase 3 (GSK3β) is the main kinase, responsible for 
phosphorylation of tau at numerous sites.  GSK3β may also play a role in 
regulating the degradation of tau, via the proteasome (David et al. 2002).  In 
addition to GSK3β, the cycline-dependent kinase 5 (CDK5), and the microtubule 
affinity-regulating kinase (MARK) are also known to regulate the physiological 
role of tau through phosphorylation.  In contrast, to counterbalance the action of 
kinases, tau is readily dephosphorylated by numerous phosphatases, including 
protein phosphatase 1 (PP1), 2A (PP2A), 2B (PP2B), and 5 (PP5) (Tian and Wang 
2002). 
The underlying mechanisms contributing to the pathological processing of 
tau in neurodegenerative conditions have not been entirely elucidated.  
Nevertheless, it is clear that tau becomes characteristically altered both 
functionally and structurally in AD and other tauopathies.  Supporting a central 
role for tau in dementia, genetic studies showed that missense mutations in the tau 
gene induce the development of neurodegenerative disorders such as the 
frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) 
(Hutton et al. 1998).  Interestingly, in FTDP-17 and other sporadic tauopathies, 
pronounced tau pathology was observed, without amyloid plaque formation.  
Moreover, the distribution and abundance of tau pathology in AD is well correlated 
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with neuronal degeneration and clinical symptoms, underscoring the relevance of 
tau (Braak and Braak 1991).  The majority of tau mutations are associated with 
either reduced ability of the protein to interact with microtubules, or increased 
capacity to aggregate (Hasegawa et al. 1998).  Nevertheless, there are no identified 
mutations associated with AD pathology. 
The abnormal phosphorylation of tau has been proposed as the primary 
modification of tau in AD brains.  For example, phosphorylation of Ser205, 
Ser396, Ser404, Thr205, and Thr212 enhance the polymerization of tau into 
filaments (Necula and Kuret 2005).  Proteolysis of tau is another posttranslational 
event that may influence the aggregation in NFT.  In fact, truncation at both the N- 
and C-terminal regions directly influences fibril formation of tau.  Cleavage of tau 
by caspase-3 at Asp421 in the C-terminal region has been detected in AD brains 
and was shown to promote tau assembly in vitro (Gamblin et al. 2003b).  This 
fragment apparently causes neuronal death, with a significant role in the 
nucleation-dependent filament formation (Rissman et al. 2004).  In contrast, the 
removal of the N-terminal region greatly inhibits the aggregation of tau, although 
this specific truncation occurs later in the NFT formation process (Gamblin et al. 
2003a).  Thus, aggregation of tau within neurons appears to involve an ordered 
series of events.  First, the microtubule binding function needs to be neutralized.  
Then, tau molecules must self-associate to promote oligomerization, which leads to 
conformational changes and increased insolubility of tau.  Finally, these oligomers 
induce nucleation and formation of NFT, which accumulate in neuron cell bodies. 
Amyloid plaques and NFT are often present in the same area of the brain, but 
the relationship between these two entities is not known.  It was recently 
demonstrated that Aβ-induced caspase-3 activation leads to tau cleavage, and 
aggregation in NFT (Rissman et al. 2004).  In addition, hyperphosphorylation of 
tau was detected in mature hippocampal neurons treated with Aβ (Ferreira et al. 
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1997).  Thus, NFT pathology may represent a downstream effect of Aβ 
accumulation probably triggered by apoptosis, among other toxic mechanisms. 
 
3.2.3. Neuronal dysfunction and degeneration 
In the AD brain, multiple mechanisms occur simultaneously and it is not always 
easy to distinguish changes that promote the disease from the consequences of the 
disease.  It is established, however, that amyloid plaques and NFT are extra- and 
intracellular aggregates that are toxic to neurons (Fig. 5). 
Several reports have suggested that Aβ activates microglia, inciting an 
inflammatory response and release of neurotoxic cytokines.  In fact, prominent 
activation of inflammatory processes and the innate immune response are observed 
in AD brains (Wyss-Coray and Mucke 2002).  Neuroinflammation would then 
occur in the early stages of the disease, driving the pathology.  However, other 
studies suggest that inflammation may even be beneficial and responsible for 
triggering survival pathways (Wyss-Coray 2006).  Thus, the exact role of 
inflammation in AD is still controversial. 
Aβ can also trigger excessive release of excitatory amino acids such as 
glutamate from glial cells, injuring nearby neurons and inducing the production of 
ROS.  Indeed, increasing evidence supports a role for oxidative stress in vulnerable 
brain regions of AD patients.  Oxidative damage begins early in the disease and 
can even be responsible for a decline in proteasome function (Cecarini et al. 2007).  
Moreover, Aβ may directly or indirectly injure mitochondria, thus decreasing the 
brain metabolism.  Aβ is involved in disruption of calcium homeostasis, via ER-
mediated stress, inducing mitochondrial dysfunction (Pereira et al. 2004).  In 
addition, Aβ blocks the respiratory complex I and the pyruvate dehydrogenase, 
inducing a decline in ATP and enhancing ROS production (Casley et al. 2002).  In 
fact, as regulators of both energy metabolism and apoptotic pathways, 
mitochondria and their consequent dysfunction have a key role in AD (Moreira et 
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al. 2006).  Moreover, because synaptic function has a high energy demand, 
mitochondrial failure is a major factor of synaptic failure in AD.  In addition, 
cholinergic transmission and synaptic density are considerably decreased in AD 
patients and probably contribute to memory loss and cognitive deficits.  Finally, 
Aβ and tau may be responsible for paralyzing axonal and dendritic transport.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5.  Proposed mechanism of citotoxicity induced by Aβ and tau.  Soluble and/or 
aggregated Aβ interacts with glial cells, inducing the release of glutamate and 
inflammatory cytokines.  Aβ triggers signal transduction cascades that culminate in 
increased production of ROS and disruption of calcium homeostasis.  Moreover, Aβ may 
directly or indirectly injure mitochondria, enhancing ROS production and inducing 
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proteasome failure.  Effector caspases are activated, which can be responsible for the 
cleavage of tau.  In addition, abnormal phosphorylation of tau might be enhanced by Aβ.  
Tau aggregates into NFT and redistributes in neuron cell bodies, paralyzing axonal and 
dendritic transport.  All together, these abnormal mechanisms in AD brains are thought to 
culminate in neuronal dysfunction and degeneration. 
 
 
In conclusion, mitochondrial dysfunction and consequent energy deficits 
contribute to impaired clearance of protein aggregates and neuronal dysfunction, 
affecting neurotransmission and neuronal transport in AD brains.  In this scenario, 
neurons no longer have the ability to survive and massively die in the affected 
brain regions.  However, the primary mechanism(s) by which neurons die is still 
not clear.  Nevertheless, apoptosis has been the focus of intense research in the last 
few years as a pivotal phenomenon in AD progression. 
 
3.2.4. The role of apoptosis and cell cycle proteins in AD 
First hints that apoptosis could be involved in AD came from studies performed in 
the mid-90’s, where cultured neurons were incubated with fibrillar Aβ (Loo et al. 
1993).  Since then, both in vitro and in vivo models have supported apoptosis as a 
general mechanism of cell death in AD.  Analysis of post-mortem brain tissue has 
also provided evidence for nuclear DNA fragmentation and activation of apoptotic 
mechanisms in humans.  Studies in the brain of AD patients showed an 
upregulation of 50-fold in the levels of apoptosis, as compared with age-matched 
controls (Colurso et al. 2003).  Nevertheless, evidence for frank cellular apoptosis 
in AD brains is controversial, since clear detection of apoptotic cells is difficult and 
problematic.  In this regard, apoptosis in the pathogenesis of AD is still an issue of 
debate, and it has even been suggested that it provides a protective role in 
removing damaged cells from the brain. 
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Studies of human AD tissue demonstrated that the expression of the 
antiapoptotic Bcl-2 and proapoptotic Bax proteins are regulated in brain areas 
showing increased apoptosis (Su et al. 1997).  In addition, c-Jun, a protein of the 
JNK-pathway and an immediate-early proapoptotic molecule was found to be 
colocalized in neurons with fragmented DNA (Anderson et al. 1996).  Moreover, 
recent evidence suggests that mitochondrial dysfunction and ER-induced stress 
have pivotal roles in the execution of apoptosis in AD (Takuma et al. 2005).  In 
fact, together with Aβ-induced toxicity, many other stimuli, such as oxidative 
stress, neurotrophic factor deprivation, low energy metabolism, and mitochondrial 
failure, known to induce apoptosis in cultured neurons, are also prominent in AD 
brains. 
Activation of caspases-3 in AD has been reported using specific antibodies 
to the activated form of the enzyme (Su et al. 2001).  Caspases-3 was detected in 
more than 50% of hippocampal neurons showing granulovascular degeneration and 
often colocalized with tau protein.  In addition, an increase in brain fodrin 
proteolysis in sprouting neurons was observed (Peterson et al. 1991).  Caspase-6 
was also found to be activated in AD brains (Guo et al. 2004).  The activation of 
caspase-6 occurs primarily in the frontal and temporal cortex, and is colocalized 
with pre-tangles, suggesting that it may be an early event in AD pathogenesis.  
Despite the clear activation of effector caspases, coincident morphologic evidence 
of apoptosis are not always easy to detect and levels of apoptosis can not per se 
explain the massive neuronal degeneration observed in AD brains.  Nevertheless, 
since AD is a chronic disease, and the apoptotic process short-lived, the detection 
of substantial apoptotic neurons in AD brains could be difficult.  Moreover, the 
apoptotic mechanisms may play an important role in disease pathogenesis, even in 
the absence of clear apoptosis.  In fact, caspases-3 can cleave APP and presenilins, 
and the product of APP cleavage, a C-terminal peptide called C31, is a potent 
inducer of cell death (Lu et al. 2000).  Importantly, caspases-3 appears to be 
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responsible for cleaving tau in its C-terminal region early in disease pathogenesis.  
In AD brains, caspases-3-cleaved tau colocalizes with both intracellular Aβ and 
activated caspases-3, mainly in tangle-bearing neurons (Rissman et al. 2004).  
Recent studies have suggested that caspases-6 is also capable of cleaving tau and 
promotes its aggregation in NFT (Guo et al. 2004).  While caspases-6-cleaved tau 
was found in amyloid plaques and NFT, caspases-6 was located primarily in 
neurites.  This suggests that apoptosis-like mechanisms can damage synapses, 
axons and dendrites without causing overt neuronal death. 
Expression of cell cycle markers in AD neurons suggests their potential 
involvement in the disease process.  In postmitotic neurons, which lack the 
required components to complete the cell cycle, the presence of mitotic markers 
indicates a breach of cell cycle check points.  This activated but uncoordinated cell 
cycle activity can induce deleterious effects and result in many pathological events 
in AD, including apoptosis.  For example, as a response to DNA damage and ROS 
production, cyclin D-CDK was found to be upregulated in AD (Park et al. 1998).  
In addition, phosphorylation and dysfunction of pRb resulting in E2F-1 release 
may occur in neuronal cells (Phillips and Vousden 2001). 
Evidence for a pivotal function of p53 in neuronal death has been provided 
by data from cell culture models documenting increased p53 levels in affected 
neurons (Morrison et al. 2003).  Coincidently, accumulation of both Aβ1-42 and p53 
was found in degenerating neurons in both transgenic mice and human AD brain.  
Intracellular Aβ1-42 may cause p53-dependent neuronal apoptosis through activation 
of the p53-promoter, thus demonstrating an alternative pathway of cell death in AD 
(Ohyagi et al. 2005).  The inhibition of p53 attenuates Aβ-induced apoptosis, 
associated with preserved mitochondrial function and reduced activation of 
caspases-3 (Culmsee et al. 2001).  These findings suggest that p53 is an important 
mediator of ROS-induced signaling upstream of the mitochondrial dysfunction.  
Moreover, upregulation of p53 is also associated with indirect induction of tau 
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abnormal phosphorylation in HEK293a cells, underscoring the relevance of p53 in 
AD pathology (Hooper et al. 2007). 
Several lines of evidence confirm the pivotal role of apoptosis in AD.  Either 
by inducing effective neuronal death or enhancing mechanisms that culminate in 
neuronal dysfunction, the importance of apoptosis in the pathogenesis of AD 
should not be ignored.  Indeed, therapeutic interventions targeting apoptosis and 
specific molecular intervenients, such as p53, are expected to play a role in AD 
treatment. 
 
3.3.  Clinical diagnosis and treatment of AD 
 
After the first symptoms appear, the diagnosis of AD is based on the medical 
history, together with clinical, neurological and psychiatric examinations.  Given 
the complexity of the disease and a possible overlapping of clinical and 
pathological features with other dementias, the diagnosis of AD is not always 
evident.  Absolute diagnosis requires microscopic examination of the cerebral 
cortex, and the identification of amyloid plaques and NFT (McKhann et al. 1984).  
Cortical biopsy can provide efficient results during patient’s life but is not 
routinely performed.  Thus, a definitive diagnosis of AD is typically obtained in 
post mortem analysis.  Neuroioimaging, including magnetic resonance imaging 
(MRI) and computed tomography (CT), is important to exclude alternative causes 
of dementia, such as brain tumor and subdural hematoma.  MRI and CT are 
valuable tools to detect cerebral atrophy, specifically in the hippocampus and 
entorhinal cortex.  Positron emission tomography imaging of glucose is a 
promising method and it can be used to differentiate with high sensitivity patients 
with AD from cognitively normal elderly people or with other dementias 
(Silverman et al. 2001).  Furthermore, the identification of cerebrospinal fluid 
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biological markers, such as total and hyperphosphorylated tau and Aβ1-42,  for the 
prediction of incipient AD shows great promise (Blennow and Hampel 2003).   
Unfortunately for the millions of patients that are diagnosed with AD, the 
efficacy of the available treatment is far from satisfactory.  Currently, approved 
drugs can only slow progression of disease, albeit with some improvement in 
quality of life.  They typically ameliorate the neurotransmitter disturbances that 
account for the characteristic memory decline and other cognitive symptoms.  
Acetylcholinesterase inhibitors, including donopezil, galantamine, and 
rivastigmine are designed to combat impairment of cholinergic neurons by slowing 
degradation of acetylcholine after its release at synapses.  Memantine is another 
drug that is currently used in AD treatment, which prevents overstimulation of the 
N-methyl-D-aspartate subtype of glutamate receptors.  To manage the behavioral 
signs, such as aggression, agitation and psychosis, many AD patients also receive 
antipsychotics and antidepressants. 
Over the last decade, many pathways have been identified that may 
contribute to the pathogenesis of AD.  Thus, substantial efforts are underway to 
translate this knowledge into novel therapeutic interventions that prevent or arrest 
the disease.  The major focus has been to inhibit Aβ production and aggregation, 
and to increase Aβ clearance from the brain.  Currently, inhibitors of β- and γ-
secretases to reduce brain Aβ concentrations are being tested in transgenic mice as 
well as phase I studies (Chang et al. 2004; Siemers et al. 2005).  In addition, α-
secretase stimulation is also being tested for APP processing into non-
amyloidogenic peptides production and consequent Aβ reduction (Etcheberrigaray 
et al. 2004).  On the other hand, Aβ immunotherapy is being studied and has been 
shown to markedly reduce AD pathology (Schenk et al. 2004).  A 
glycosaminoglycan mimetic and the metal chelator clioquinol have been shown to 
reduce Aβ fibrillization in vitro and in transgenic mice (Cherny et al. 2001; 
Sadowski et al. 2004).  Inhibitors of tau phosphorylation are under investigation 
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despite the involvement of multiple kinases and phosphatases.  Finally, different 
types of drugs and supplements, such as anti-inflammatory and cholesterol-
lowering drugs, estrogens, and antioxidants have been suggested as having a 
protective role on AD.  Nevertheless, the results are controversial and the 
beneficial effects have been difficult to prove.  
It will probably take several decades before a cure for AD is discovered.  
However, we now know that for an effective treatment, this devastating disease 
requires a complete therapeutic intervention that targets several cellular and 
molecular deregulated mechanisms.  Given the growing evidence that apoptosis 
contributes significantly to neuronal death and dysfunction in AD, a strategy of 
antiapoptotic therapy is expected to provide some beneficial results. 
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Objectives 
 
The research presented in this thesis was motivated by three major 
objectives.  First, our main goal was to characterize the role of apoptosis in AD.  
By using in vitro and in vivo models of sporadic and familial AD, we confirmed 
the relevance of apoptosis in a neurodegenerative disorder that affects millions of 
people every year.  Second, we investigated the potential antiapoptotic function of 
TUDCA in AD.  Given its efficacy at modulating several models of non-hepatic 
diseases, such as neurological disorders, the role of TUDCA as modulator of 
apoptosis was further expanded to AD models.  Finally, we intended to 
characterize the molecular pathways by which TUDCA inhibits apoptosis in AD.  
In this regard, the role of apoptosis and cell cycle-related proteins in TUDCA 
antiapoptotic effects has emerged as challenging targets for further therapeutic 
intervention.    
The specific questions addressed in this thesis are: 
1. Is apoptosis a relevant mechanism of cell death in AD and how can it 
contribute to the pathogenesis of the disease? 
2. Is TUDCA capable of reducing the levels of apoptosis in several models 
of AD? 
3. Does modulation of apoptosis and cell-cycle related proteins play a role 
during AD-associated apoptosis and can they be targeted for future 
therapeutic intervention?  
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Ultimately, our overarching goal is to achieve a better understanding of the 
pathologic function of apoptosis in AD and to characterize the antiapoptotic 
mechanisms of TUDCA.  The identification of specific targets and modulators of 
the bile acid will help design effective therapeutic strategies.  
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Abstract 
  
Amyloid β-peptide (Aβ)-induced cell death may involve activation of the E2F-1 
transcription factor and other cell cycle-related proteins.  In previous studies, we 
have shown that tauroursodeoxycholic acid (TUDCA), an endogenous bile acid, 
modulates Aβ-induced apoptosis by interfering with crucial events of the 
mitochondrial pathway.  In this study, we examined the role of E2F and p53 
activation in the induction of apoptosis by Aβ, and investigated novel molecular 
targets for TUDCA.  The results showed that despite Bcl-2 upregulation, PC12 
neuronal cells underwent significant apoptosis after incubation with the active 
fragment Aβ25−35, as assessed by DNA fragmentation, nuclear morphology and 
caspase-3-like activation.  In addition, transcription through the E2F-1 promoter 
was significantly induced and associated with loss of the retinoblastoma protein.  
In contrast, levels of E2F-1, p53 and Bax proteins were markedly increased.  
Overexpression of E2F-1 in PC12 cells was sufficient to induce p53 and Bax 
proteins, as well as nuclear fragmentation.  Notably, TUDCA modulated Aβ-
induced apoptosis, E2F-1 induction, p53 stabilization, and Bax expression.  
Further, TUDCA protected PC12 cells against p53- and Bax-dependent apoptosis 
induced by E2F-1 and p53 overexpression, respectively.  In conclusion, the results 
demonstrate that Aβ-induced apoptosis of PC12 cells proceeds through a E2F-
1/p53/Bax pathway, which in turn can be specifically inhibited by TUDCA, thus 
underscoring its potential therapeutic use. 
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Introduction 
 
Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by 
progressive memory loss and deficit of cognitive skills.  The pathological 
hallmarks of AD include selective damage of synapses and neurons, neurofibrillary 
tangles, activated glia, and presence of senile plaques (Selkoe 2001).  Amyloid β-
peptide (Aβ) is the major constituent of senile or amyloid plaques found in the 
brains of AD patients.  Aβ is derived from the processing of the amyloid precursor 
protein (Haas and Selkoe 1997), and is thought to play a critical role in the onset or 
progression of AD.  Previous studies have shown that Aβ-induced cytotoxicity 
involves oxidative stress, inflammation and perturbation of calcium homeostasis 
(Selkoe 2001).  In fact, both necrosis and apoptosis are thought to occur in primary 
neurons and neuronal cell lines after exposure to Aβ, as well as in brains of AD 
patients (Yankner et al. 1990; Loo et al. 1993; Behl et al. 1994; Su et al. 1994; 
Mark et al. 1995). 
Cell cycle-related molecules are upregulated in post-mitotic neurons within 
effected brain regions during AD (Mcshea et al. 1997; Vincent et al. 1997; Busser 
et al. 1998).  However, it is unclear whether deregulation of cell cycle events 
contributes to neurodegeneration in AD.  E2F-1 is the best-characterized member 
of the E2F family of transcription factors that regulates genes involved in cell 
cycle, proliferation and apoptosis (Phillips and Vousden 2001).  Under certain 
stress conditions and during the cell cycle, E2F-1 is released from the 
retinoblastoma protein (pRb) (Mittnacht 1998), thus transactivating its target 
genes.  Interestingly, E2F-1 expression is increased in Aβ-treated cells suggesting 
that this transcription factor may also promote neuronal apoptosis via E2F-1 
transcriptional activation (Giovanni et al. 1999; Giovanni et al. 2000; Hou et al. 
2000).  Activation of E2F-1 induces cells to undergo apoptosis that may occur 
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through stabilization of the tumor suppressor protein p53 via the transcription of 
p14ARF, transcriptional activation of the p53 homologue p73, and inhibition of the 
anti-apoptotic signaling of nuclear factor κB (Phillips and Vousden 2001).   
Although the role of p53 in suppressing cell cycle progression has been 
extensively described, less is known about the mechanism by which p53 induces 
apoptosis.  Nevertheless, both E2F-1 and p53 can upregulate apoptotic proteins 
such as Bax and the apoptosis protease-activating factor 1 (Apaf-1), resulting in 
caspase activation and death in several cell types, including neuronal cells 
(Miyashita et al. 1994; Moroni et al. 2001; O´Hare et al. 2000; Fortin et al. 2001).  
The involvement of p53 in Aβ-induced apoptosis was initially thought to be 
negligible (Blasko et al. 2000).  However, it has recently been demonstrated that 
p53 participates in apoptosis of primary human neurons triggered by Aβ peptide, 
probably through modulation of Bax expression (Zhang et al. 2002).  During 
apoptosis, cytosolic Bax is translocated to the mitochondrial membrane where it 
induces cytochrome c release.  Once in the cytosol, cytochrome c is a coactivator 
of Apaf-1 in the cleavage of procaspase-9 and execution of apoptosis through the 
mitochondrial pathway (Green 2000).  Exposure of cells to Aβ peptide has been 
shown to result in mitochondrial perturbation and subsequent caspase activation 
(Paradis et al. 1996; Selznick et al. 2000; Xu et al. 2001; Luo et al. 2002; Solá et al. 
2003).  In addition, we have reported that Aβ induces cytochrome c release via 
direct mitochondrial membrane permeabilization (Rodrigues et al. 2000a), which 
appears to be associated with profound changes on membrane lipid and protein 
structure (Rodrigues et al. 2001).   
Ursodeoxycholic acid (UDCA) and its taurine-conjugated derivative 
TUDCA are endogenous bile acids that increase the apoptotic threshold in several 
cell types (Rodrigues et al. 1998).  We have previously shown that TUDCA 
stabilizes the mitochondrial membrane and prevents Aβ-induced apoptosis in 
primary rat neurons (Solá et al. 2003).  TUDCA acts by inhibiting mitochondrial 
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membrane depolarization and channel formation, production of reactive oxygen 
species, release of cytochrome c, and caspase activation (Rodrigues et al. 2000b; 
Rodrigues et al. 2003a).  Interestingly, we have also demonstrated that TUDCA 
inhibits E2F-1-induced apoptosis, in part, through a caspase-independent 
mechanism (Solá et al. 2003).  Finally, TUDCA is neuroprotective in a transgenic 
mouse model of Huntington’s disease (Keene et al. 2002), and in rat models of 
ischemic and hemorrhagic stroke (Rodrigues et al. 2002; Rodrigues et al. 2003b).  
Here, we further characterized the anti-apoptotic effects of TUDCA in Aβ-induced 
death of PC12 neuronal cells.  Our results suggest that TUDCA specifically 
inhibits the activation of E2F-1, p53 and Bax triggered by Aβ peptide, thus 
modulating the apoptotic threshold. 
 
Material and methods 
 
Cell culture and induction of apoptosis 
PC12 cells were grown in RPMI-1640 medium (Sigma Chemical Co., St. Louis, 
MO, USA) supplemented with 10% heat-inactivated horse serum (Sigma Chemical 
Co.), 5% fetal bovine serum (Invitrogen Corp., Grand Island, NY, USA) and 1% 
penicillin/streptomycin, and maintained at 37ºC in a humidified atmosphere of 5% 
CO2.  Cells were plated at either 2 x 105 cells/cm2 for morphologic assessment of 
apoptosis and viability assays, or 4 x 105 cells/cm2 for transfection assays and 
protein extraction, and differentiated in the presence of nerve growth factor as 
described previously (Park et al. 1998).  PC12 neuronal cells were then incubated 
in medium supplemented with 100 μM TUDCA (Sigma Chemical Co.), or no 
addition (control) for 12 h, and exposed to 25 μM Aβ25-35 peptide active fragment 
(Bachem AG, Bubendorf, Switzerland) for 1, 8, 24, and 48 h.  Cells were fixed for 
microscopic assessment of apoptosis or processed for cell viability assays.  In 
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addition, total and cytosolic proteins were extracted for immunoblotting and 
caspase activity. 
 
Evaluation of apoptosis and caspase activation 
Viability of PC12 neuronal cells was analyzed by the metabolism of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium (MTT) bromide (Sigma Chemical 
Co.), and by trypan blue dye exclusion.  Hoechst labeling of cells was used to 
detect apoptotic nuclei.  In brief, cells were fixed in 4% paraformaldehyde in 
phosphate-buffered saline (PBS), pH 7.4, for 10 min at room temperature, 
incubated with Hoechst dye 33258 (Sigma Chemical Co.) at 5 mg/ml in PBS for 5 
min, and then washed with PBS and mounted using PBS:glycerol (3:1, v/v).  
Fluorescent nuclei were scored blindly by laboratory personnel and categorized 
according to the condensation and staining characteristics of chromatin.  Normal 
nuclei showed non-condensed chromatin dispersed over the entire nucleus.  
Apoptotic nuclei were identified by condensed chromatin, contiguous to the 
nuclear membrane, as well as nuclear fragmentation of condensed chromatin.  
Three random microscopic fields per sample of ~ 150 nuclei were counted and 
mean values expressed as the percentage of apoptotic nuclei.  In addition, for the 
terminal transferase-mediated dUTP-digoxigenin nick end-labeling (TUNEL) 
assay, cells were fixed in 4% paraformaldehyde in PBS, pH 7.4, for 10 min at 
room temperature, and post-fixed in precooled ethanol:acetic acid (2:1, v/v) for 5 
min at -20ºC.  Digoxigenin-nucleotide residues were added to 3’-OH ends of 
double or single-stranded DNA by the terminal deoxynucleotidyl transferase.  
Reactions were performed according to the manufacturer’s recommendations 
(Serologicals Corp., Norcross, GA, USA), and the specimens were then 
coverslipped with mounting medium before analysis by phase-contrast 
microscopy. 
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Finally, caspase activity was determined in cytosolic protein extracts after 
harvesting and homogenization of cells in isolation buffer, containing 10 mM Tris-
HCl buffer, pH 7.6, 5 mM MgCl2, 1.5 mM KAc, 2 mM DTT, and protease 
inhibitor cocktail tablets (CompleteTM; Roche Applied Science, Mannheim, 
Germany).  General caspase-3-like activity was determined by enzymatic cleavage 
of chromophore p-nitroanilide (pNA) from the substrate N-acetyl-Asp-Glu-Val-
Asp-pNA (DEVD-pNA; Sigma Chemical Co.).  The proteolytic reaction was 
carried out in isolation buffer containing 50 µg cytosolic protein and 50 µM 
DEVD-pNA.  The reaction mixtures were incubated at 37°C for 1 h, and the 
formation of pNA was measured at 405 nm using a 96-well plate reader. 
 
Transfections and CAT assays 
Transfections were performed using reporter constructs E2F-1CAT and 
4xE2FCAT, and four expression constructs, pCMVE2F-1, pCMVE2F-1Δ53, 
pCMVp53 and pCMVp53(143Ala).  E2F-1CAT consisted of the entire human 
E2F-1 promoter fused to the chloramphenicol acetyltransferase (CAT) gene 
(Johnson et al. 1993); and 4xE2FCAT was generated by insertion of a synthetic 
promoter containing four E2F consensus binding sites (Ohtani and Nevins 1994) 
upstream of the CAT reporter gene.  Overexpression plasmids were generated by 
cloning either wild type E2F-1 (pCMVE2F-1) and p53 (pCMVp53) or mutant 
E2F-1 (pCMVE2F-1Δ53) and p53 (pCMVp53(143Ala)), all under CMV 
enhancer/promoter control (Qin et al. 1992).  PC12 cells at 40% confluence were 
transfected with 4 and 8 μg of reporter and expression plasmids, respectively, 
using LipofectamineTM 2000 (Invitrogen Corp.).  To assess transfection efficiency, 
cells were cotransfected with the luciferase construct, PGL3-Control vector 
(Promega Corp., Madison, WI, USA).  Based on this reporter, transfection 
efficiencies were  ~ 70% and did not differ between wild-type and dominant 
negative plasmids.  Twelve hours after E2F-1CAT or 4xE2FCAT transfection, 
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vehicle or 100 μM of TUDCA was added to cells.  After an additional 12 h, 25 μM 
Aβ was included in the cultures.  The cells were incubated with Aβ for 24 h after 
which all cells were harvested for CAT ELISA (Roche Applied Science) and 
luciferase assays (Promega Corp.), according to the manufacturers’ instructions.  
Twelve hours prior to transfection with the expression plasmids, PC12 neuronal 
cells were treated with vehicle or 100 μM of TUDCA.  At 48 and 60 h post-
transfection, all cells were harvested, and total protein extracts analyzed for p53 or 
Bax expression, respectively.  In parallel experiments, cells were also fixed for 
morphologic detection of apoptosis. 
 
Immunoblotting 
Steady-state levels of E2F-1, pRb, Mdm-2, p53, Bcl-2, Bax, and Bcl-xL proteins 
were determined by Western blot analysis.  Briefly, 150 μg of total protein extracts 
were separated on 8 or 12% SDS-polyacrylamide electrophoresis gels.  Following 
electrophoretic transfer onto nitrocellulose membranes, immunoblots were 
incubated with 15% H2O2 for 15 min at room temperature.  After blocking with 5% 
milk solution, the blots were incubated overnight at 4ºC with primary mouse 
monoclonal antibodies reactive to E2F-1, Mdm-2, p53, Bax and Bcl-2, or primary 
rabbit polyclonal antibodies to pRb and Bcl-xS/L (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA); and finally with secondary antibodies conjugated with 
horseradish peroxidase (Bio-Rad Laboratories, Hercules, CA, USA) for 3 h at 
room temperature.  The membranes were processed for protein detection using 
Super SignalTM substrate (Pierce, Rockford, IL, USA).  β-actin was used as a 
loading control.  Protein concentrations were determined using the Bio-Rad protein 
assay kit according to the manufacturer’s specifications. 
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Densitometry and statistical analysis 
The relative intensities of protein bands were analyzed using the ImageMaster 1D 
Elite v4.00 densitometric analysis program (Amersham Biosciences, Piscataway, 
NJ, USA).  All data were expressed as mean ± SEM from at least three separate 
experiments.  Statistical analysis was performed using GraphPad InStat version 
3.00 for Windows 95 (GraphPad Software, San Diego, CA, USA) for the Student’s 
t test.  Values of p < 0.05 were considered significant. 
 
Results 
 
TUDCA inhibits Aβ-induced apoptosis in PC12 cells 
Numerous studies have shown that both Aβ1−40 or Aβ1−42 and its active fragment 
Aβ25−35 are highly toxic to primary neurons and a variety of neuronal cell lines.  In 
addition, TUDCA prevents cell death caused by apoptotic stimuli in a multiplicity 
of cell types (Solá et al. 2003; Rodrigues et al. 1998; Rodrigues et al. 2000b), 
suggesting that it could also modulate Aβ toxicity in a neuronal cell line.  We used 
an in vitro model of Aβ-induced death of neuronal PC12 cells which has provided 
potentially valuable insight into Aβ signaling events.  Apoptosis was assessed by 
changes in nuclear and DNA fragmentation, and by caspase-3-like activation (Fig. 
1).  Increased levels of apoptosis were observed in PC12 cells after incubation with 
active fragment Aβ25−35, with a maximum apoptotic response at 48 h (p < 0.01).  In 
contrast, the control reverse peptide Aβ35−25 was not toxic to PC12 cells (data not 
shown).  TUDCA prevented both nuclear fragmentation and caspase-3-like 
activation by 60-75% (p < 0.05).  A marked protection by TUDCA was also 
confirmed using cell viability assays (data not shown).  Taken together, these 
findings indicate that PC12 neuronal cells undergo apoptosis when exposed to Aβ, 
which in turn is markedly prevented by TUDCA. 
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Fig. 1.  TUDCA inhibits apoptosis 
induced by Aβ in PC12 neuronal cells.  
Cells were incubated with 25 μM 
Aβ25−35, or no addition (control), ± 100 
μM TUDCA for 1, 8, 24 and 48 h.  In 
coincubation experiments, TUDCA 
was added 12 h prior to incubation 
with Aβ.  Cells were fixed and stained 
for microscopic assessment of 
apoptosis, and cytosolic proteins were 
extracted for caspase activity as 
described in “Materials and Methods”.  
A: TUNEL staining in cells incubated 
with Aβ ± TUDCA for 24 h.  B: 
Fluorescence microscopy of Hoechst 
staining (top) and percentage of 
apoptosis in cells exposed to Aβ ± 
TUDCA at the indicated times 
(bottom).  C: DEVD-specific caspase 
activity in cytosolic fractions after 
incubation with Aβ ± TUDCA.  Cells 
pretreated with TUDCA showed less 
nuclear fragmentation and caspase 
activation compared to Aβ alone (p < 
0.05).  The results are expressed as 
mean ± SEM of at least 3 different 
experiments. *p < 0.01 from controls 
at the same time point. 
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E2F-1 expression and pRb loss are modulated by TUDCA 
The E2F-1 transcription factor controls cell cycle progression as well as induction 
of apoptosis.  It has been suggested that E2F-1 participates in Aβ-induced 
apoptosis of neuronal cells (Giovanni et al. 2000).  In addition, TUDCA inhibited 
Aβ-associated apoptosis in PC12 cells, indicating that E2F-1 could be an important 
regulatory factor targeted by TUDCA.  PC12 cells were transfected with CAT 
transcription reporter plasmids under the control of the E2F promoters, and 
incubated with Aβ for 48 h.  CAT activity assays showed that Aβ-induced 
apoptosis was associated with a mild increase in transcription by E2F-1 at 24 h (p 
< 0.01) (Fig. 2).  Pretreatment with TUDCA caused a significant decrease in Aβ-
driven transcriptional activation of E2F-1 (p < 0.05).  In contrast, CAT activity was 
unchanged with the 4xE2F promoter at 24 h, suggesting that Aβ specifically 
induces E2F-1 within the E2F family (data not shown).   
 
 
 
Fig. 2. TUDCA effect on E2F-1-mediated transcription in PC12 cells incubated with Aβ.  
Cells were cotransfected with a CAT transcription reporter plasmid under the E2F-1-
dependent promoter E2F-1CAT, and a luciferase control construct as described in 
“Materials and Methods.”  After 12 h, vehicle or 100 μM of TUDCA was added to cells.  
At 24 h, 25 μM Aβ was included in the cultures and cells harvested for the CAT ELISA 
and luciferase assays.  E2F-1-mediated transcription in cells exposed to Aβ for 1, 8, 24 and 
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48 h (left), or incubated with Aβ ± TUDCA for 24 h (right).  CAT activity (absorbance/mg 
protein) was normalized to control luciferase expression, and the results are expressed as 
mean ± SEM arbitrary units of at least 3 different experiments.  *p < 0.05 from control; †p 
< 0.05 from Aβ. 
 
 
Next, we evaluated E2F-1 protein levels by immunoblot analysis to assess 
whether transcriptional changes were associated with altered protein expression.  
PC12 cells exhibited a marked increase in E2F-1 protein levels, which was 
significant at 1 h (2.5-fold, p < 0.05) through 48 h (3.5-fold, p < 0.01) of 
incubation with Aβ peptide (Fig. 3A).  Notably, TUDCA reduced Aβ-induced 
E2F-1 upregulation by ~ 60% (p < 0.05) (Fig. 3B).  Thus, Aβ-induced apoptosis in 
PC12 neuronal cells appears to involve the E2F-1 transcription factor.  
Interestingly, it appears that E2F-1 is required for reactivation of the cell cycle, 
which is a prerequisite for Aβ-induced  neuronal death (Copani et al. 1999).   
The retinoblastoma protein regulates both the transactivation and function of 
the E2F family of transcription factors.  Thus, we determined whether Aβ induced 
E2F-1 activation by modulating pRb function.  Indeed, the results showed that Aβ 
caused a marked loss of pRb by 30-50% throughout the time course of 48 h (p < 
0.01) (Fig. 3A).  Further, the inhibition of E2F-1 expression by TUDCA was also 
dependent on changes in pRb expression.  TUDCA prevented Aβ-associated loss 
of pRb by ~ 65% at 24 h (p < 0.05) (Fig. 3B).  Therefore, these data suggest that 
TUDCA reduces E2F-1 activation induced by Aβ peptide not only by directly 
modulating E2F-1 levels, but also by inhibiting loss of pRb. 
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Fig. 3. Modulation of E2F-1 and pRb expression in PC12 cells.  Cells were incubated 
with 25 μM Aβ, or no addition (control), ± 100 μM TUDCA, which was added to the 
incubation media 12 h prior to incubation with Aβ.  Total proteins were extracted for 
Western blot analysis as described in “Materials and Methods”.  A: Protein levels of E2F-1 
and pRb in cells incubated with Aβ for 1, 8, 24 and 48 h.  B: Protein levels of E2F-1 and 
pRb in cells exposed to Aβ ± TUDCA for 24 h.  The results are normalized to endogenous 
β-actin production and expressed as mean ± SEM arbitrary units of at least 4 different 
experiments.  §p < 0.05 and *p < 0.01 from control; †p < 0.05 from Aβ. 
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TUDCA inhibits Aβ-induced p53 stabilization via the Mdm-2 protein 
Many cellular genes contain E2F sites that contribute to transcriptional regulation.  
The p53/Mdm-2 pathway is a potential target of the E2F-1 transcription factor, 
which activates p53 through inhibition of the Mdm-2 protein.  Immunoblot 
analysis of total protein extracts showed that Aβ induced a swift and stable 
increase in p53 levels up to 5-fold at 24 h (p < 0.01) (Fig. 4A).  This was 
accompanied by increased activation of p53, since its inhibitor Mdm-2 was also 
markedly diminished during Aβ exposure (~ 60% at 8 h, p < 0.01).  Incubation 
with TUDCA alone produced no significant changes in p53 and Mdm-2 protein 
levels (Fig. 4B).  However, coincubation with TUDCA reduced the observed Aβ 
increase in p53 by 60%, and almost completely inhibited the decrease in Mdm-2 (p 
< 0.05). 
 
TUDCA modulates Aβ-induced expression of Bcl-2 family proteins 
p53 has been shown to regulate the expression of Bcl-2 family proteins (Miyashita 
et al. 1994).  Our data also suggest that E2F-1-mediated p53 stabilization may 
modulate Bcl-2 family protein expression.  Exposure to Aβ led to a prompt 
increase in pro-apoptotic Bax levels which was maintained throughout the time 
course (Fig. 5A).  At 24 h of incubation, Bax protein production was enhanced by 
> 2-fold (p < 0.01).  Anti-apoptotic Bcl-2 was also increased after incubation of 
PC12 cells with Aβ (p < 0.05).  In contrast, the anti-apoptotic Bcl-xL protein 
remained relatively unchanged.  Coincubation with TUDCA reduced Aβ-
associated Bax increase by ~ 80% at 24 h (p < 0.05) (Fig. 5B).  Similarly, TUDCA 
prevented Bcl-2 protein changes.  These results suggest that TUDCA prevents Aβ-
induced changes in Bcl-2 family protein expression, restoring the equilibrium 
between pro- and anti-apoptotic members. 
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Fig. 4. Effects of TUDCA on Aβ-induced modulation of Mdm-2 and p53.  PC12 neuronal 
cells were incubated with 25 μM Aβ, or no addition (control), ± 100 μM TUDCA.  In 
coincubation experiments, TUDCA was added to cells 12 h prior to incubation with Aβ.  
Total proteins were extracted and subjected to Western blot analysis as described in 
“Materials and Methods”.  A: Protein levels of Mdm-2 and p53 in cells incubated with Aβ 
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for 1, 8, 24 and 48 h.  B: Protein levels of Mdm-2 and p53 in cells exposed to Aβ ± 
TUDCA for 24 h.  The results are normalized to endogenous β-actin production and 
expressed as mean ± SEM arbitrary units of at least 4 different experiments. §p < 0.05 and 
*p < 0.01 from control; †p < 0.05 from Aβ.   
 
 
 
 
Fig. 5. Modulation of Bcl-2 family members in PC12 neuronal cells.  Cells were 
incubated with 25 μM Aβ, or no addition (control), ± 100 μM TUDCA that was added to 
hepatocytes 12 h prior to incubation with Aβ.  Total proteins were extracted for Western 
blot analysis as described in “Materials and Methods”.  A: Representative immunoblots of 
Bax, Bcl-2, and Bcl-xL proteins in cells exposed to Aβ for 1, 8, 24 and 48 h.  B: 
Immunoblots of Bax, Bcl-2, and Bcl-xL proteins in cells incubated with Aβ, ± bile acids for 
24 h.  The blots were normalized to endogenous β-actin protein levels. 
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The E2F-1/p53/Bax pathway is modulated by TUDCA 
To further characterize the mechanism by which TUDCA modulates the p53-
regulated apoptosis pathway, we investigated its effects within the E2F-1/p53/Bax 
pathway.  PC12 cells were transfected with plasmids to overexpress either wild-
type or mutant E2F-1, or p53.  In the absence of Aβ, cells transfected with wild-
type E2F-1 and p53 showed ~ 40 and 65% of apoptosis, respectively, compared 
with only 10 and 19% of cells transfected with the corresponding mutant plasmids 
(p < 0.01) (Fig. 6A).  Interestingly, TUDCA markedly reduced apoptosis after 
transfection with wild-type plasmids to almost control levels (p < 0.01). 
Overexpression of E2F-1 led to an ~ 2-fold increase in p53 levels, when 
compared with cells expressing the E2F-1 mutant plasmid (p < 0.05) (Fig. 6B).  
Pretreatment with TUDCA completely prevented the increase in p53 induced by 
E2F-1 (p < 0.01), suggesting a direct effect at the level of E2F-1.  This action was 
supported by a mild transcriptional repression of E2F-1 by TUDCA (data not 
shown).  However, because overexpressed wild-type E2F-1 is regulated differently 
than native E2F-1, the protective effect of TUDCA could involve other 
mechanisms, such as pRb modulation.  Cells overexpressing wild-type p53 showed 
a 2-fold direct increase in target protein Bax relative to cells expressing mutant p53 
(p < 0.05).  p53 overexpression was also accompanied by an increase in its 
degradation, detected by several intense bands with a molecular weight < 53 kDa 
(data not shown), which may have been because p53 induces its specific inhibitor, 
Mdm-2.  Nevertheless, TUDCA completely prevented the p53-induced Bax 
expression (p < 0.01).  Thus, our results indicate that TUDCA controls p53 
function directly, and not only by interfering with upstream factors of the E2F-
1/p53/Bax pathway. 
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Fig. 6. TUDCA specifically inhibits the E2F-1/p53/Bax pathway.  Twelve hours after 
incubation with 100 μM TUDCA, PC12 cells were transfected with the constructs 
pCMVE2F-1 and pCMVE2F-1Δ53, or with pCMVp53 and pCMVp53(143Ala) plasmids.  
At 48 and 60 h post-transfection, cells were fixed and stained for morphological detection 
of apoptosis.  In addition, total proteins were extracted and subjected to Western blot 
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analysis of p53 and Bax as described in “Materials and Methods”.  A: Percentage of 
apoptosis in cells exposed to bile acids and transfected with the constructs pCMVE2F-1 
and pCMVE2F-1Δ53 (left), or with pCMVp53 and pCMVp53(143Ala) plasmids (right).  
The results are expressed as mean ± SEM of at least 4 different experiments.  B: p53 
expression in cells transfected with the constructs pCMVE2F-1 and pCMVE2F-1Δ53 (left) 
and Bax expression in cells tranfected with pCMVp53 and pCMVp53(143Ala) plasmids 
(right).  The results were normalized to luciferase expression and expressed as mean ± 
SEM arbitrary units relative to mutant E2F-1 or p53 of at least 3 different experiments.  §p 
< 0.05 and *p < 0.01 from respective mutant; ‡p < 0.01 from respective wild-type. 
 
 
Discussion 
 
The precise molecular mechanisms responsible for AD-associated 
neurodegeneration are not fully understood; however, it has been proposed that Aβ 
peptide plays a crucial role in the pathogenesis of the disease.  Aβ-induced toxicity 
is a multifactorial process that is thought to involve generation of reactive oxygen 
species, alteration of intracellular calcium homeostasis, mitochondrial perturbation, 
and caspase activation.  We have previously reported that TUDCA prevents Aβ-
induced apoptosis of cortical neurons by inhibiting the mitochondrial pathway of 
cell death (Solá et al. 2003).  The present study provides evidence that Aβ-induced 
apoptosis of PC12 neuronal cells involves activation of the E2F-1/p53/Bax 
pathway, which in turn is significantly altered by TUDCA.  Thus, our results 
suggest that TUDCA can interfere with alternate molecular targets. 
Previous studies have reported that a variety of cyclins, cyclin-dependent 
kinases, and pRb are activated in neurons following exposure to Aβ (Giovanni et 
al. 1999) and in the brains of AD patients (McShea et al. 1997; Vincent et al. 1997; 
Busser et al. 1998).  Thus, proteins that normally control cell cycle progression in 
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proliferating cells may also modulate neuronal death.  Further, neurons lacking 
E2F-1, a transcription factor regulated by pRb, are significantly protected from 
death due to Aβ peptide (Giovanni et al. 2000).  In the present study, we further 
investigated the role of E2F-1 in Aβ-induced neurotoxicity.  PC12 neuronal cells 
treated with active fragment Aβ (25−35) showed elevated levels of apoptosis, 
together with a significant increase in E2F-1 promoter-driven transcription and 
E2F-1 protein production.  The role of E2F-1 in apoptosis was also demonstrated 
in overexpression experiments, where a significant percentage of cells showed 
increased nuclear fragmentation.  In addition, pRb levels were markedly decreased 
after Aβ exposure, probably allowing release and activation of E2F-1.  This is 
consistent with previous findings where loss of pRb is associated with increased 
cell death (Liu and Kitsis 1996; Shan et al. 1996) and overexpression of pRb 
results in enhanced survival (Fan et al. 1996; Macleod et al. 1996; Berry et al. 
1996).  Finally, mice lacking pRb show massive neuronal loss during development 
(Jacks et al. 1992).   
Activation of E2F-1 may result in modulation of proteins involved in the 
apoptotic process such as p53, Bax, and Apaf-1, or in the G1/S transition of the cell 
cycle (Moroni et al. 2001; O´Hare et al. 2000; Phillips et al. 1997).  Interestingly, 
Aβ peptide appears to act as a proliferative signal for differentiated neurons, 
driving cells into the cell cycle (Copani et al. 1999).  It was suggested that neurons 
must cross the G1/S transition before Aβ induces apoptosis.  The mechanism by 
which Aβ promotes transcription of E2F-1 is still not clear.  Nevertheless, TUDCA 
efficiently prevented E2F-1 upregulation and pRb loss, thus modulating activity of 
the transcription factor.  This effect may be related to a recently described 
interaction between unconjugated UDCA and steroid nuclear receptors (Miura et 
al. 2001), linking cytoprotection to modulation of transcription and gene 
expression. 
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The tumor suppressor p53 appears to play an important role in E2F-1-
associated apoptosis.  Given its importance, p53 is a tightly regulated molecule, 
mainly at the level of protein stability.  In normal cells, p53 activity is restrained 
through a negative feedback loop in which the tumor suppressor induces its 
specific inhibitor, Mdm-2, which in turn binds to p53 and targets its proteosomal 
degradation (Haupt et al. 1997; Kubbutat et al. 1997).  However, in cells under 
stress, p53 is activated in part through inhibition of its degradation by Mdm-2 
(Ashcroft et al. 2000).  p53 stabilization can also be achieved through an E2F-1-
dependent mechanism, in which E2F-1 induces the tumor suppressor protein 
p14ARF (Bates et al. 1998) that binds to Mdm-2, thus preventing p53 degradation 
(Kamijo et al. 1998).  Interestingly, it has been recently shown that Aβ can 
promote p53 stability by activating the c-Jun N-terminal protein kinase 1 pathway, 
and increasing the levels of p53 independent of its affect on phosphorylation 
(Fogarty et al. 2003).  Our results indicate that Aβ markedly induced E2F-1 
activity, which then resulted in Mdm-2 degradation, p53 stabilization and 
apoptosis.  In contrast, TUDCA significantly suppressed the Aβ peptide effects on 
p53 and Mdm-2 proteins, thereby inhibiting the Aβ-activated E2F-1/p53 pathway.  
Further, TUDCA inhibited E2F-1-induced p53 activation and the marked levels of 
apoptosis with E2F-1 overexpression.  Our results suggest that TUDCA inhibition 
of Aβ-induced apoptosis likely involves pathways for both E2F-1 transcription 
factor and the tumor suppressor, pRb. 
Aβ peptide appears to also modulate protein levels of Bcl-2 family members 
in PC12 cells, resulting in upregulation of pro-apoptotic Bax and increased 
expression of anti-apoptotic Bcl-2.  This is not surprising since p53 is known to 
modulate Bcl-2 family gene expression (Miyashita et al. 1994).  p53 is highly 
expressed in cells after accumulation of Aβ and in the brains of AD patients 
(Zhang et al. 2002; LaFerla et al. 1996; Kitamura et al. 1997), and p53 inhibitors 
can prevent neuronal cell death induced by Aβ (Culmsee et al. 2001).  Further, Aβ 
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has been shown to either upregulate pro-apoptotic Bax expression or require Bax to 
mediate neurotoxicity (Paradis et al. 1996; Seznick et al. 2000; Culmsee et al. 
2001).  Although controversial, Bax protein levels have also been reported to 
increase in AD brain (MacGibbon et al. 1997; Nagy et al. 1997; Su et al. 1999).  
Finally, we have demonstrated that Bax protein increases in mitochondria during 
Aβ-induced apoptosis of neurons, thus providing a mechanism for cytochrome c 
release, and subsequent caspase-3 activation and nuclear fragmentation (Solá et al. 
2003).  In this study, the results of transgene overexpression suggest that 
upregulation of Bax was indeed a result of p53 activation.  TUDCA, by decreasing 
E2F-1 transcriptional activation, prevented the downstream events of Aβ-induced 
cell death associated with Bax production.  Further, TUDCA can specifically 
modulate the E2F-1/p53/Bax pathway, abrogating E2F-1-induced p53 and p53-
associated Bax expression.  Of note is that phosphorylated Bad was upregulated 
following Aβ incubation (data not shown), thereby possibly sequesting Bad from 
its mitochondrial targets, and increasing the availability of Bcl-2.  
In conclusion, this study suggests that TUDCA strongly abrogates Aβ-
induced apoptosis of PC12 neuronal cells.  The bile acid specifically inhibited the 
E2F-1/p53 apoptotic pathway, thus modulating the expression of Bcl-2 family 
elements.  The mechanism(s) by which TUDCA regulates the activation of E2F-1, 
or modulates sections of the E2F-1/p53/Bax pathway remains to be elucidated.  
Nevertheless, identification and validation of cellular targets that control life and 
death decisions may ultimately prove useful at developing new therapeutic 
interventions for diseases associated with deregulation of the apoptotic process. 
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Abstract 
  
Early onset familial Alzheimer’s disease (FAD) is linked to autosomal dominant 
mutations in amyloid precursor protein (APP) and presenilin 1 and 2 (PS1, PS2) 
genes.  These are critical mediators of total amyloid β-peptide (Aβ) production, 
inducing cell death through uncertain mechanisms.  Tauroursodeoxycholic acid 
(TUDCA) modulates exogenous Aβ-induced apoptosis by interfering with E2F-
1/p53/Bax.  Here, we used mouse neuroblastoma cells that express either wild-type 
APP, APP with the Swedish mutation (APPswe), or double-mutated human APP 
and PS1 (APPswe/∆E9), all exhibiting increased Aβ production and aggregation.  
Cell viability was decreased in APPswe and APPswe/∆E9, but partially reversed 
by z-VAD.fmk.  Nuclear fragmentation and caspase-2, -6, and -8 activation were 
also readily detected.  TUDCA reduced nuclear fragmentation as well as caspase-2 
and -6, but not caspase-8 activities.  p53 activity, and Bcl-2 and Bax changes were 
also modulated by TUDCA.  Overexpression of p53, but not mutant p53, in wild-
type and mutant neuroblastoma cells was sufficient to induce apoptosis, which in 
turn was reduced by TUDCA.  In addition, inhibition of the phosphatidylinositide 
3’-OH kinase pathway reduced TUDCA protection against p53-induced apoptosis.  
In conclusion, FAD mutations are associated with the activation of classical 
apoptotic pathways.  TUDCA reduces p53-induced apoptosis and modulates 
expression of Bcl-2 family. 
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Introduction 
 
Alzheimer’s disease (AD) is a neurodegenerative disorder usually classified into 
sporadic, more frequent form, and familial AD (FAD), with rare gene mutations.  
Both sporadic and familial AD, however, present the same histopathological 
hallmarks, including deposition of amyloid β-peptide (Aβ), formation of neuritic 
plaques and neurofibrillary tangles, and loss of synapses (Masters et al. 1985; 
Selkoe 1990; Selkoe 1997).  Aβ is derived from the processing of the amyloid 
precursor protein (APP), an integral membrane glycoprotein (Kang et al. 1997).  A 
variety of APP mutations have been linked to autosomal FAD.  In this regard, a 
double mutation at codons 670 and 671 (APPswe) has been identified in a Swedish 
family (Mullan et al. 1992).  The β-secretase cleavage site of APP is mutated, 
resulting in very strong β-secretase activity and, consequently, increased Aβ 
production.  The majority of early-onset FAD, however, is linked to mutations in 
presenilins genes, PS1 and PS2.  Since its discovery, more than 35 different 
mutations have been described in the PS1 gene and all appear to be associated with 
high levels of Aβ production and aggregation (Schellenberg et al. 1992). 
Previous studies have shown that Aβ-induced cytotoxicity involves oxidative 
stress, inflammation and perturbation of calcium homeostasis (Selkoe 2001).  Both 
necrosis and apoptosis are thought to occur in primary neurons and neuronal cell 
lines after exposure to exogenous Aβ, as well as in brains of AD patients (Loo et 
al. 1993; Behl et al. 1994; Su et al. 1994).  Further, cell cycle-related molecules are 
up-regulated in post-mitotic neurons within affected brain regions during AD 
(McShea et al. 1997; Vincent et al. 1997; Busser et al. 1998), but the specific role 
of these proteins in neurodegeneration is not clearly known.  In fact, the 
involvement of the tumor suppressor protein p53 in Aβ-induced apoptosis was 
initially thought to be negligible (Blasko et al. 2000).  It is now accepted that p53 
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can up-regulate apoptotic proteins such as Bax and the apoptosis protease-
activating factor 1 (Apaf-1), resulting in caspase activation and death in several 
cell types, including neuronal cells (Miyashita et al. 1994; Fortin et al. 2001).  In 
addition, we have demonstrated that p53 participates in Aβ-induced apoptosis of 
PC12 neuronal cells through modulation of Bax expression (Ramalho et al. 2004).  
Moreover, a recent study suggests a novel biological function of intracellular Aβ1-
42 as a transcription factor for the p53 promoter, enhancing p53-dependent neuronal 
apoptosis in AD (Ohyagi et al. 2005). 
Exposure of cells to Aβ has been shown to result in mitochondrial 
perturbation and subsequent caspase activation (Xu et al. 2001; Luo et al. 2002; 
Solá et al. 2003a).  On the other hand, recent studies in primary neurons suggest 
that activation of death receptors, such as the tumor necrosis factor type receptor 1 
(TNF-R1) and Fas play a crucial role in Aβ-induced apoptosis (Li et al. 2004; 
Ethell and Buhler 2005).  At least 7 different caspases (caspase-1, -2, -3, -6, -8, -9, 
and -12) have been implicated in regulating neuronal death in response to Aβ 
exposure in vitro, in animal models of neurodegenerative diseases, and in the 
human AD brain itself (Roth 2001).  Nevertheless, despite all the data implicating 
caspases and apoptosis as etiologic factors in AD, the direct involvement of 
caspase-dependent neuronal apoptosis in AD pathogenesis remains uncertain.  In 
essence, features of caspase-mediated neuronal apoptosis have been difficult to 
address in vivo, as well as extrapolating results from in vitro studies to animal 
models. 
Ursodeoxycholic acid (UDCA) and its taurine-conjugated derivative, 
TUDCA, are endogenous bile acids that increase the apoptotic threshold in several 
cell types (Rodrigues et al. 1998; Rodrigues et al. 2000; Rodrigues et al. 2003a).  
Further, TUDCA inhibits E2F-1-induced apoptosis, upstream of the mitochondrial 
commitment, in part through a caspase-independent mechanism (Solá et al. 2003b).  
We have previously shown that TUDCA modulates mitochondrial function and 
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prevents Aβ-induced apoptosis (Ramalho et al. 2004; Solá et al. 2001a).  
Importantly, TUDCA was neuroprotective in a transgenic mouse model of 
Huntington’s disease (Keene et al. 2002), reduced lesion volumes in rat models of 
ischemic and hemorrhagic stroke (Rodrigues et al. 2002; Rodrigues et al. 2003b), 
improved the survival and function of nigral transplants in a rat model of 
Parkinson's disease (Duan et al. 2002), and partially rescued a Parkinson’s disease 
model of C. elegans from mitochondrial dysfunction (Ved et al. 2005).  In 
addition, the subcutaneous administration of TUDCA every three days from 6 to 
12 weeks of age increased significantly the levels of bile acid in the brain of 
transgenic mice with Huntington’s disease (Keene et al. 2002). 
The incubation of cells with Aβ represents a relatively inaccurate model of 
AD.  In fact, the concentrations added to the culture medium are necessarily much 
higher than those found in the brains of AD patients.  Therefore, it is important to 
carry out studies of Aβ-induced neurotoxicity under more physiological conditions 
that mimick the natural process of AD.  Herein, we used a neuroblastoma cell 
model of AD, in which the cells were engineered to express wild-type APP, APP 
with the Swedish mutation, or the double-mutated human APP and PS1, thereby 
exhibiting endogenous Aβ aggregation at different levels (Thinakaran et al. 1996; 
Xu et al. 1997; Luo et al. 2002).  Our results suggest that FAD mutations are 
associated with the activation of classical apoptotic pathways.  In cell culture, 
TUDCA can interfere with the apoptotic mitochondrial pathway via p53 and 
inhibit the activation of caspase-2 and -6, thus modulating the apoptotic threshold. 
 
Material and methods 
 
Cell lines 
N2a neuroblastoma control cells or the N2a cell lines with stable expression of 
APP695 (APPwt), Swedish mutant APP (APPswe) or the exon-9 deletion mutant 
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PS1 (APPswe/∆E9) were grown in culture medium containing 45% Dulbecco’s 
modified Eagle’s medium (DMEM) and 50% OptiMEM (Invitrogen Corp., Grand 
Island, NY, USA), supplemented with 5% fetal bovine serum (Invitrogen Corp.), 
1% L-Glutamine 200 mM (Merck & Co. Inc., NJ, USA) and 1% 
penicillin/streptomycin (Invitrogen Corp.).  APPwt, APPswe and APPswe/∆E9 
medium was also supplemented with 0.2 µg/ml G418, and 0.4 µg/ml hygromycin 
for APPswe/∆E9 only.  Cells were plated at either 1 x 105 cells/cm2 for 
morphologic assessment of apoptosis and viability assays or 2 x 105 cells/cm2 for 
protein extraction.  Neuroblastoma cells were incubated in medium supplemented 
with 100 μM TUDCA (Sigma Chemical Co., St. Louis, MO, USA), or no addition 
for 12 h.  The expression of the transgenes was then induced by the addition of 1 
μM butyric acid (sodium salt) (Sigma Chemical Co.) for 12 h in 1% serum 
medium, considered as non-toxic conditions (Kurita-Ochiai et al. 2001).  In a 
subset of experiments, cells were incubated with 50 µM z-VAD.fmk (Sigma 
Chemical Co.), a general caspase inhibitor, for 1 h prior to transgene induction or 
with 250 µM H2O2 for 1 h after transgene induction.  Cells were fixed for 
microscopic assessment of apoptosis or processed for cell viability assays.  In 
addition, total and cytosolic proteins were extracted for immunoblotting and 
caspase activity assays, respectively. 
 
Evaluation of apoptosis 
Hoechst labeling of cells was used to detect apoptotic nuclei.  In brief, cells were 
fixed in 4% paraformaldehyde in phosphate buffer (PBS), pH 7.4, for 10 min at 
room temperature, incubated with Hoechst dye 33258 (Sigma Chemical Co.) at 5 
μg/ml in PBS for 5 min, and then washed with PBS and mounted using 
PBS:glycerol (3:1, v/v).  Fluorescent nuclei were scored and categorized according 
to the condensation and staining characteristics of chromatin.  Normal nuclei 
showed non-condensed chromatin dispersed over the entire nucleus.  Apoptotic 
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nuclei were identified by condensed chromatin, contiguous to the nuclear 
membrane, as well as nuclear fragmentation of condensed chromatin.  Three 
random microscopic fields per sample of ~ 150 nuclei were counted and mean 
values expressed as the percentage of apoptotic nuclei.  In addition, for the 
terminal tranferase-mediated dUTP-digoxigenin nick end-labeling (TUNEL) assay, 
cells were fixed in 4% paraformaldehyde in PBS, pH 7.4, for 10 min at room 
temperature, and post-fixed in pre-cooled ethanol:acetic acid (2:1, v/v) for 5 min at 
-20ºC.  Digoxigenin-nucleotide residues were added to 3’-OH ends of double- or 
single-stranded DNA by the terminal deoxynucleotidyl transferase.  Reactions 
were performed according to manufacturer’s recommendations (Serological Corp., 
Norcross, GA, USA).  Finally, cell viability was also analyzed by the metabolism 
of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium (MTT) bromide (Sigma 
Chemical Co.), and by trypan blue dye exclusion. 
 
Transfections with expression plasmids 
Transfections were performed using two expression constructs, pCMVp53 and 
pCMVp53(143Ala).  Overexpression plasmids were generated by cloning either 
wild type p53 (pCMVp53) or mutant p53 (pCMVp53(143Ala)), both under CMV 
enhancer/promoter control (Qin et al. 1992).  Neuroblastoma cells at 40% 
confluence were transfected with 4 μg of expression plasmids using 
LipofectamineTM 2000 (Invitrogen Corp.).  To assess transfection efficiency, 
hepatocytes were cotransfected with the luciferase reporter construct, PGL3-
Control vector (Promega Corp., Madison, WI).  Based on this control, transfection 
efficiencies were approximately 70% and did not differ between wild-type and 
dominant negative plasmids.  Twelve hours prior to transfection with expression 
plasmids, cells were treated with either vehicle or 100 μM of TUDCA.  At 36 h 
post-transfection, cells were fixed for morphologic detection of apoptosis.  In 
parallel experiments, wortmannin (Calbiochem, San Diego, CA, USA), an inhibitor 
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of phosphatidylinositide 3’-OH kinase (PI3K) phosphorylation, was added to cells 
1 h prior to TUDCA at a final concentration of 200 nM. 
 
Caspase activity assays 
Caspase activity was determined in cytosolic protein extracts after harvesting and 
homogenization of cells in isolation buffer, containing 10 mM Tris-HCl buffer, pH 
7.6, 5 mM magnesium chloride, 1.5 mM potassium acetate, 2 mM dithiothreitol, 
and protease inhibitor cocktail tablets (CompleteTM; Roche Applied Science, 
Mannheim, Germany).  General caspase-2, -3, -6 and -8-like activities were 
determined by enzymatic cleavage of chromophore p-nitroanilide (pNA) from the 
substrates VDVAD-pNA, DEVD-pNA, VEID-pNA and IEPD-pNA (Sigma 
Chemical Co.), respectively.  The proteolytic reaction was carried out in isolation 
buffer containing 50 µg cytosolic protein and 50 µM substrate.  The reaction 
mixtures were incubated at 37°C for 1 h, and the formation of pNA was measured 
at 405 nm using a 96-well plate reader. 
 
Immunoblot analysis 
Steady-state levels of TNF-R1, Fas/CD95, p53, Bcl-2 and Bax proteins were 
determined by Western blot analysis.  Briefly, 100 μg of total protein extracts were 
separated on 12% sodium dodecyl sulfate-polyacrylamide electrophoresis gels.  
Following electrophoretic transfer onto nitrocellulose membranes, immunoblots 
were incubated with 15% H2O2 for 15 min at room temperature.  After blocking 
with 5% milk solution, the blots were incubated overnight at 4ºC with primary 
mouse monoclonal antibodies reactive to TNF-R1, Fas/CD95, p53, Bax and Bcl-2 
(Santa Cruz Biotechnology, Santa Cruz, CA, USA); and finally with secondary 
antibody conjugated with horseradish peroxidase (Bio-Rad Laboratories, Hercules, 
CA, USA) for 3 h at room temperature.  The membranes were processed for 
protein detection using Super SignalTM substrate (Pierce, Rockford, IL, USA).  β-
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actin was used as a loading control.  Protein concentrations were determined using 
the Bio-Rad protein assay kit according to the manufacturer’s specifications. 
 
Densitometry and statistical analysis 
The relative intensities of protein bands were analyzed using the ImageMaster 1D 
Elite v4.00 densitometric analysis program (Amersham Biosciences, Piscataway, 
NJ, USA).  All data were expressed as mean ± SEM from at least three separate 
experiments done on different days.  Statistical analysis was performed using 
GraphPad InStat version 3.00 (GraphPad Software, San Diego, CA, USA) for the 
Student’s t test.  Values of p < 0.05 were considered significant. 
 
Results 
 
TUDCA reduces FAD-induced apoptosis 
We investigated the role of apoptosis in FAD mutation-induced cytotoxicity and 
the protective effects of TUDCA, using cells expressing APPwt, APPswe or 
APPswe/∆E9.  In each case, they exhibited Aβ production and aggregation as well 
as cytotoxic cellular signaling pathways (Thinakaran et al. 1996; Xu et al. 1997; 
Luo et al. 2002).  Cell viability was comparable between parental N2a cells and 
APPwt, APPswe and APPswe/∆E9 cell lines prior to transgene induction (data not 
shown).  Transgene expression resulted in at least 6-fold increased Aβ production 
in cells expressing FAD mutations as determined by control immunoprecipitation 
assays using the culture medium (data not shown).  In addition, cell viability 
decreased by ~ 10% in APPswe and 30% in APPswe/∆E9 compared with APPwt 
cells (p < 0.05 and p < 0.01, respectively) (Fig. 1A).  Pre-incubation with TUDCA 
and z-VAD.fmk pan-caspase inhibitor for 12 h and 1 h, respectively, reduced cell 
death by > 50% (p < 0.05) suggesting that caspase-dependent apoptosis may play a 
role in FAD mutation-induced cytotoxicity.  In fact, nuclear fragmentation 
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characteristic of apoptosis was increased in APPswe and APPswe/ΔE9 cells by ~ 
15 and 20%, respectively (p < 0.01) (Fig. 1B).  As expected, apoptosis was further 
increased to 30% after additional oxidative stress by H2O2 (data not shown).  
TUDCA prevented morphologic changes of apoptosis in both APPswe and 
APPswe/ΔE9 overexpression (p < 0.01).  These results were also confirmed using 
the TUNEL assay, where TUDCA was similarly protective (Fig. 1C).  Finally, pre-
incubation of cells with TUDCA for 1 h prior to transgene induction reduced cell 
death by only 6%. 
In agreement with the above findings, caspase-2 and -8 activities increased to 
40% in APPswe and 60% in APPswe/ΔE9 compared with APPwt cells (p < 0.01) 
(Fig. 2).  Executioner caspase-6 activity was also increased in APPswe and 
APPswe/ΔE9 cells by 35 and 65%, respectively (p < 0.01).  TUDCA significantly 
reduced caspase-2 and -6, but not caspase-8, activities.  Surprisingly, caspase-3 
was only marginally activated in neuroblastoma cells after transgene induction 
suggesting the involvement of potentially alternative pathways. 
 
TUDCA modulates FAD-induced mitochondrial-dependent apoptosis 
To provide a possible link between endogenous Aβ production, FAD mutation-
induced cytotoxicity and activation of specific apoptotic pathways, we investigated 
expression of the death receptors TNF-R1 and Fas in neuroblastoma cells 
expressing APPswe or APPswe/ΔE9.  FAD mutations resulted in significant up-
regulation of TNF-R1 and Fas production (p < 0.05) (Fig. 3).  However, co-
incubation with TUDCA failed to modulate death receptor expression in 
neuroblastoma cells. 
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Fig. 1. TUDCA inhibits apoptosis in 
mutant APPswe and APPswe/ΔE9 
neuroblastoma cells.  Cells were treated with 
either no addition (control), 100 μM TUDCA 
for 12 h, or 50 µM z-VAD.fmk for 1 h prior 
to transgene induction.  Cell viability was 
assessed by the MTT metabolism assay 12 h 
after initiating transgene expression.  In 
addition, cells were fixed and stained for 
morphological assessment of apoptosis.  A: 
MTT assay in cells after transgene induction 
± TUDCA or z-VAD.fmk.  B: Fluorescence 
microscopy of Hoechst staining (top) in 
APPwt (a), APPswe/ΔE9 (b), APPwt + 
TUDCA (c) and APPswe/ΔE9 + TUDCA (d), 
and percentage of apoptosis (bottom).  
Apoptotic nuclei were identified by 
condensed chromatin as well as nuclear 
fragmentation (arrows).  C: TUNEL staining 
in APPwt (a), APPswe/ΔE9 (b), APPwt + 
TUDCA (c) and APPswe/ΔE9 + TUDCA (d) 
treated cells.  Apoptotic cells were identified 
by condensed nucleus with brownish staining 
(arrows); normal cells were counterstained 
with methyl green.  The results are expressed 
as mean ± SEM of at least 3 different 
experiments.  *p < 0.01 and §p < 0.05 from 
APPwt; ‡p < 0.01 and †p < 0.05 from cells 
without TUDCA or z-VAD.fmk. 
 
102 
 
 
 
 
 
 
TUDCA modulation of apoptosis in FAD 
_________________________________________________________________________ 
 
 
 
Fig. 2. TUDCA reduces caspase activity in mutant APPswe and APPswe/ΔE9 
neuroblastoma cells.  Cells were treated with either no addition (control) or 100 μM 
TUDCA for 12 h before transgene induction.  Cytosolic proteins were extracted for 
caspase-2, -3, -6 and -8 activity assays 12 h after transgene expression.  The results are 
expressed as mean ± SEM of at least 3 different experiments. *p < 0.01 from APPwt; ‡p < 
0.01 and †p < 0.05 from cells without TUDCA. 
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Fig. 3. Death receptor expression in mutant APPswe and APPswe/ΔE9 neuroblastoma 
cells.  Cells were treated with either no addition (control) or 100 μM TUDCA for 12 h prior 
to transgene induction.  Total proteins were extracted and subjected to Western blot 
analysis 12 h after transgene expression.  Representative immunoblots of TNF-R1 and Fas, 
and corresponding histograms.  The blots were normalized to endogenous β-actin protein 
levels.  Results are expressed as mean ± SEM arbitrary units of at least 4 different 
experiments.  §p < 0.05 from APPwt. 
 
 
The transcription factor p53 is also a key modulator of cellular stress 
responses, and activation of p53 can trigger apoptosis in many cell types, including 
 
104 
 
 
 
 
 
 
TUDCA modulation of apoptosis in FAD 
_________________________________________________________________________ 
 
neurons.  Evidence for a pivotal function of p53 in neuronal death in many 
neurodegenerative diseases, including AD, is provided by data from both in vitro 
and in vivo models of increased p53 cell levels (Morrison et al. 2003).  In fact, our 
own studies with neuronal PC12 cells indicated that exogenous Aβ markedly 
induced E2F-1 activity, which then resulted in Mdm-2 degradation, p53 
stabilization and apoptosis (Ramalho et al. 2004).  In the present study we 
evaluated the levels of p53 in cells expressing FAD mutations.  Interestingly, p53 
expression increased ~ 20% in APPswe and 50% in APPswe/ΔE9 cells (p < 0.05) 
(Fig. 4).  Coincident with p53 up-regulation, anti-apoptotic Bcl-2 protein 
expression decreased 25-50% in APPswe and APPswe/ΔE9 cells (p < 0.01) (Fig. 
4).  Transgene expression also led to increased pro-apoptotic Bax levels in both 
APPswe and APPswe/ΔE9 cells (p < 0.05).  In contrast, coincubation with TUDCA 
reduced p53 protein expression to control levels and modulated Bcl-2 and Bax 
protein changes.  These results suggested that TUDCA prevents neuronal apoptosis 
associated with FAD mutations by interfering with mitochondrial-mediated cell 
death, perhaps through modulation of p53 and its downstream targets. 
To further characterize the mechanism by which TUDCA modulates p53-
regulated mitochondrial apoptosis, we investigated its specific effects on p53-
induced cell death.  Neuroblastoma cells were transfected with plasmids to 
overexpress either wild-type or mutant p53.  In the absence of transgene 
expression, neuroblastoma cells transfected with wild-type p53 showed 
morphologic signs of apoptosis after Hoechst staining in 15-20% of cells, 
compared with only 3-5% in cells transfected with the mutant plasmid (p < 0.01) 
(Fig. 5). 
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Fig. 4. Modulation of p53 and Bcl-
2 family members in mutant APPswe 
and APPswe/ΔE9 neuroblastoma 
cells.  Cells were treated with either 
no addition (control) or 100 μM 
TUDCA for 12 h before transgene 
induction.  Total proteins were 
extracted and subjected to Western 
blot analysis 12 h after transgene 
expression.  Representative 
immunoblots of p53, Bcl-2 and Bax, 
and corresponding histograms are 
shown.  The blots were normalized 
to endogenous β-actin protein levels.  
Results are expressed as mean ± 
SEM arbitrary units of at least 4 
different experiments.  *p < 0.01 and 
§p < 0.05 from APPwt; †p < 0.05 
from cells without TUDCA. 
 
 
 
106 
 
 
 
 
 
 
TUDCA modulation of apoptosis in FAD 
_________________________________________________________________________ 
 
 
 
Fig. 5. Modulation of p53 and Bcl-2 family members in mutant APPswe and 
APPswe/ΔE9 neuroblastoma cells.  Cells were treated with either no addition (control) or 
100 μM TUDCA for 12 h before transgene induction.  Total proteins were extracted and 
subjected to Western blot analysis 12 h after transgene expression.  Representative 
immunoblots of p53, Bcl-2 and Bax, and corresponding histograms are shown.  The blots 
were normalized to endogenous β-actin protein levels.  Results are expressed as mean ± 
SEM arbitrary units of at least 4 different experiments.  *p < 0.01 and §p < 0.05 from 
APPwt; †p < 0.05 from cells without TUDCA. 
 
 
Interestingly, TUDCA markedly reduced apoptosis after transfection with 
wild-type p53 to almost control levels (p < 0.05).  In addition, we have recently 
shown that TUDCA can activate a PI3K survival pathway in neurons (Solá et al. 
2003a).  Wortmannin, a specific inhibitor of the PI3K pathway, blocked 
serine/threonine protein kinase Akt activation, reducing the protective effect of 
TUDCA against Aβ-induced cell death in neurons.  Wortmannin alone was not 
significantly cytototoxic in APPwt cells (data not shown).  Notably, the PI3K 
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inhibitor reduced TUDCA protection in APPwt cells transfected with wild-type 
p53 by almost 100% (p < 0.01).  These results suggest that TUDCA interferes with 
the activation of p53-related apoptotic events in a PI3K-dependent manner. 
 
 
Discussion 
 
The role of Aβ in the pathogenesis and progression of AD-associated 
neurodegeneration has not been firmly established.  Aβ-induced toxicity is a 
multifactorial process that is thought to involve the generation of reactive oxygen 
species, alteration of intracellular calcium homeostasis, mitochondrial perturbation, 
and caspase activation (Selkoe 2001).  Recent studies corroborated the 
involvement of apoptosis by showing that Aβ alters expression of the Bcl-2 family 
of apoptosis-related genes (Yao et al. 2005), and that survival signaling pathways 
are required for protection of Aβ-mediated neuronal apoptosis (Watson and Fan 
2005).  In addition, we have previously reported that TUDCA prevents Aβ-induced 
apoptosis by inhibiting the mitochondrial pathway of cell death and regulating cell 
cycle-related proteins (Ramalho et al. 2004; Solá et al. 2003a).  The present study 
shows that TUDCA inhibits p53-induced toxicity in cells expressing FAD 
mutations.  In stably transfected neuroblastoma cells, the endogenous non-toxic 
bile acid modulates p53 up-regulation, expression of Bcl-2 family members, and 
caspase activation.  These results indicate that attenuation of p53-mediated 
apoptosis may underlie the protective effects of TUDCA, possibly via a PI3K-
dependent manner. 
A major hallmark of AD is the progressive neuronal loss associated with 
reduced memory function.  Results from histopathological studies using post 
mortem brain tissue of AD patients, as well as a variety of in vitro studies suggest 
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that Aβ induces apoptosis and that cell death plays a relevant role in AD 
pathogenesis (Loo et al. 2003; Su et al. 1994).  In the present study, apoptosis 
increased in mutant APPswe and APPswe/ΔE9 overexpressing cells.  Moreover, 
TUDCA inhibited apoptosis, confirming the importance of this bile acid in the 
modulation of FAD mutation-induced cell death. 
Apoptosis induction is an essential function of the transcription factor p53.  
This protein is highly expressed in cells after accumulation of Aβ and in the brains 
of AD patients.  Furthermore, p53 inhibitors can prevent neuronal cell death 
induced by Aβ (Culmsee et al. 2001).  Our results indicate that FAD mutations, 
particularly the expression of the APPswe/ΔE9 transgene, resulted in p53 up-
regulation.  Moreover, overexpression of p53 in neuroblastoma cells induced 
apoptosis, suggesting that it may have an important role in FAD mutation-induced 
cell death.  Interestingly, TUDCA prevented p53-induced apoptosis suggesting a 
specific modulation of p53 expression and/or pathways in which p53 is involved.  
Moreover, co-incubations with wortmannin resulted in inhibition of TUDCA 
protection, suggesting an involvement of the PI3K pathway. 
Studies in three different neuronal cell types showed that Aβ-induced cell 
death requires the activation of caspase-2 (Troy et al. 2000).  Caspase-2, an 
initiator caspase that triggers apoptosis via activation of the mitochondrial 
pathway, can be a target of the c-Jun N-terminal kinases signaling pathway, which 
is known to be involved in Aβ-induced citotoxicity (Troy et al. 2000).  In addition, 
p53 is also known to activate caspase-2, via the PIDDosome (Tinel and Tschopp 
2004).  Our results showed that caspase-2 activity was increased in APPswe and 
APPswe/∆E9 cells, and this was coincident with p53 up-regulation.  Curiously, 
TUDCA prevented caspase-2 activation; it remains to be determined as to whether 
the effect was direct or indirect. 
p53 has additional recognized apoptotic targets, including death receptors 
located at the plasma membrane, such as Fas (Kannan et al. 2001).  Fas and TNF-
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R1 expression was increased in both APPswe and APPswe/ΔE9, compared with 
APPwt cells.  Moreover, caspase-8 was readily activated.  TUDCA, however, did 
not prevent these modifications, suggesting that the bile acid does not modulate 
FAD mutation-induced apoptosis by the extrinsic pathway.  Bcl-2 family members 
represent other well-known targets of p53 (Miyashita et al. 1994).  In addition, Aβ 
has been shown to either up-regulate pro-apoptotic Bax expression or require Bax 
to mediate neurotoxicity (Paradis et al. 1996; Selznick et al. 2000).  Our results 
demonstrated that expression of FAD mutations, Aβ production, and subsequent 
p53 stabilization, resulted in up-regulation of pro-apoptotic Bax and decreased 
expression of anti-apoptotic Bcl-2.  Interestingly, TUDCA significantly tempered 
the observed changes in Bcl-2 and Bax protein levels, confirming our previous 
results in primary neurons (Solá et al. 2003a) and in PC12 neuronal cells (Ramalho 
et al. 2004). 
Effector caspase-3 was only slightly activated in cells expressing FAD 
mutations.  The precise role of caspase-3 in AD is not fully understood.  There are 
several evidences that caspase-3 might be involved in the neuronal death of 
neurodegenerative diseases, including AD (Shimohama et al. 1999; Mashiah et al. 
1998).  Other results, however, suggest that caspase-3 activation is only slightly 
up-regulated in AD patients, and therefore can not justify the massive loss of 
neurons in this pathology.  A study in human neurons showed that microinjection 
with recombinant active caspase-3 did not induce cell death (Zhang et al. 2002).  In 
contrast, caspase-6 induced a protracted TUNEL-positive cell death.  Another 
study failed to detect the active fragment of caspase-3 in post mortem tissue from 
AD patients but could confirm the presence of caspase-6 active protein (LeBlanc et 
al. 1999).  In contrast with caspase-3, caspase-6 was significantly up-regulated in 
APPswe and APPswe/∆E9 cells, confirming the importance of caspase-6 in AD.  
Caspase-6 can cleave the nuclear envelope protein lamin A, several transcription 
factors, poly (ADP-ribose) polymerase, and APP generating potentially 
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amyloidogenic fragments (Galande et al. 2001; Fernandes-Alnemri et al. 1995).  
Nevertheless, the precise role of caspase-6 in the pathogenesis of AD remains to be 
determined.  In addition, although caspase-3 has been implicated, it is not clearly 
known how caspase-6 is activated.  Curiously, a recent study identified caspase-6 
as a downstream target of p53 in the apoptotic process (MacLachlan and El-Deiry 
2002).  This may explain the marginal activation of caspase-3 but a robust 
activation of caspase-6 in APPswe and APPswe/∆E9 cells, which in turn was 
prevented by TUDCA. 
Collectively, our studies further expand the neuroprotective effects of 
TUDCA.  The results demonstrate that TUDCA modulates p53 stabilization and 
Bcl-2 family expression, reduces caspase-2 and -6 activation, and inhibits nuclear 
fragmentation.  Thus, modulation of apoptosis by TUDCA in APPswe and 
APPswe/∆E9 cells appears to result from its specific effects at preventing p53 
activation.  Finally, identification and validation of more cellular targets are likely 
to provide new therapeutic interventions for modulation of neuronal 
apoptotic.death in Alzheimer’s disease. 
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Abstract 
  
The rTg4510 mouse is a tauopathy model, characterized by massive 
neurodegeneration in Alzheimer’s disease (AD)-relevant cortical and limbic 
structures, deficits in spatial reference memory, and progression of neurofibrillary 
tangles.  In this study, we examined the role of apoptosis in neuronal loss and 
associated tau pathology.  The results showed that DNA fragmentation and 
caspase-3 activation are common in the hippocampus and frontal cortex of young 
rTg4510 mice.  These changes were associated with cleavage of tau into smaller 
intermediate fragments, which persist with age.  Interestingly, active caspase-3 was 
often co-localized with cleaved tau.  In vitro, fibrillar Aβ1-42 resulted in nuclear 
fragmentation, caspase activation, and caspase-3-induced cleavage of tau.  
Notably, incubation with the antiapoptotic molecule tauroursodeoxycholic acid 
abrogated apoptosis-mediated cleavage of tau in rat cortical neurons.  In 
conclusion, caspase-3-cleaved intermediate tau species precede cell loss in 
rTg54510 brains and Aβ-exposed cultured neurons.  These results underscore the 
potential role of apoptosis in neurodegeneration. 
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Introduction 
 
Alzheimer’s disease (AD) is a progressive neurodegenerative disease 
characterized by accelerated neuronal death leading to dementia.  Hallmark 
pathologic features include extracellular plaques of amyloid β (Aβ) and 
intracellular aggregations of tau protein (Selkoe 2001).  Tau is a microtubule-
associated protein, abundant in the central nervous system, and predominantly 
expressed in axons (Binder et al. 1985).  It plays fundamental roles in both 
stabilizing neuronal microtubules, and establishing cellular polarity and 
intracellular transport (Drewes et al. 1998).  Under physiological conditions, tau is 
a highly soluble, hydrophobic and unfolded protein, tightly regulated by 
phosphorylation at specific serine and threonine residues (Johnson and Stoothoff 
2004).  In AD and other tauopathies, tau looses its capacity to bind microtubules, 
migrates to the cell body, and aggregates into neurofibrillary tangles (NFT) 
(Mandelkow and Mandelkow 1998).  Post-translational conformational changes of 
tau, such as abnormal hyperphosphorylation and proteolysis increase its ability to 
aggregate (Alonso et al. 2001, Gamblin et al. 2003a).  Curiously, NFT accumulate 
with well defined spatial and temporal progression (Santacruz et al. 2005). 
The role of apoptosis in AD and other tauopathies is still controversial.  
Indeed, synaptic loss and electrophysiological abnormalities typically precede cell 
loss.  Nevertheless, apoptosis is increased (Su et al. 1994) and caspase-3 is 
activated (Selznick et al. 1999) in the brain of AD patients.  Interestingly, tau can 
be cleaved by caspase-3 at Asp421 in its C-terminal region, resulting in a N-
terminal product that can be detected in cultured neurons, in AD brains (Rissman et 
al. 2004), and in other tauopathies (Newman et al. 2005).  Truncated tau plays a 
role in nucleation-dependent filament formation of tau and induces neuronal death.  
Moreover, caspase-3-cleaved tau is often colocalized with Aβ peptide deposition.  
Caspase-3 activation is a well established event in Aβ-induced neuronal apoptosis, 
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suggesting a link between amyloid plaques and NFT formation (Gamblin et al. 
2003b). 
The rTg4510 mouse model expresses human tau containing the P301L 
mutation associated with frontotemporal dementia with parkinsonism linked to 
chromosome 17 (FTDP-17).  It is thought to represent a robust model of tauopathy 
(Santacruz et al. 2005, Ramsden et al. 2005, Spires et al. 2006).  In fact, transgenic 
mice showed massive neurodegeneration in specific cortical and limbic structures, 
leading to forebrain atrophy and brain weight loss.  In addition, the progression of 
NFT pathology and neuronal loss was also correlated with deficits in spatial 
reference memory.  Nonetheless, the onset of memory deficits at 2.5-4 months 
preceded NFT pathology and neuronal loss at 5.5 months.  The suppression of 
transgene expression, after initial NFT formation, prevented further loss of neurons 
and enabled partial recovery of cognitive functions, but did not inhibit the 
progression of NFT.  These findings suggest that NFT formation is not directly 
responsible for neurodegeneration and memory loss in rTg4510.  Instead, toxic 
intermediate tau species may trigger further neurodegeneration. 
Ursodeoxycholic acid (UDCA) and its taurine-conjugated derivative, 
tauroursodeoxycholic acid (TUDCA), are endogenous bile acids that increase the 
apoptotic threshold in several cell types (Rodrigues et al. 2000, Rodrigues et al. 
1998).  We have previously shown that TUDCA stabilizes mitochondrial function 
and prevents Aβ-induced apoptosis in primary rat neurons and in neuronal cell 
lines (Solá et al. 2003, Ramalho et al. 2006, Ramalho et al. 2004).  Furthermore, 
TUDCA was neuroprotective in a transgenic mouse model of Huntington’s disease 
(Keene et al. 2002), reduced lesion volumes in rat models of ischemic and 
hemorrhagic stroke (Rodrigues et al. 2002, Rodrigues et al. 2003), improved the 
survival and function of nigral transplants in a rat model of Parkinson’s disease 
(Duan et al. 2002) and partially rescued a Parkinson’s disease model of 
Caernohabditis elegans from mitochondrial dysfunction (Ved et al. 2005). 
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Using rTg4510 mice, we investigated the role of apoptosis in neuronal loss and 
tau associated pathology.  Our results suggest that apoptosis is an early event 
associated with tau cleavage in the hippocampus and the frontal cortex.  Cleaved 
tau, in turn, appears to represent a toxic form of tau.  In cultured cortical neurons, 
apoptosis and caspase-3 cleavage of tau induced by fibrillar Aβ1-42 were 
significantly inhibited by TUDCA.  Thus, caspase-3-cleaved intermediate tau 
species are responsible, in part, for cell loss in rTg4510 brains and Aβ-exposed 
cultured neurons.  These results underscore the potential role of apoptosis in 
neurodegeneration. 
 
Material and methods 
 
Generation of transgenic mice 
The rTg4510 is a recently developed mouse model of tauopathy in which 
expression of human tau, containing the frontotempotal dementia-associated 
P301L mutation can be suppressed with doxycycline administration (Santacruz et 
al. 2005).  Briefly, the method for generating rTg4510 mice utilized a system of 
responder and activator transgenes.  Mice expressing the activator transgene, 
consisting of a four-repeat human tau with the P301L mutation placed downstream 
of a tetracycline operon responsive element were successively backcrossed at least 
five times onto a 129S6 background strain.  Responder mice, consisting of a tet-off 
open reading frame placed downstream of Ca2+-calmodulin kinase II promoter 
elements were maintained in the FVB/N strain.  From this, double transgenic mice 
were generated in which expression of the P301L tau expression was restricted to 
the forebrain structures.  Mice were screened by PCR using the primer pairs 5’-
GAT TAA CAG CGC ATT AGA GCT G-3’ and 5´-GCA TAT GAT CAA TTC 
AAG GCC GAT AAG-3’ for activator transgenes, and 5’-TGA ACC AGG ATG 
GCT GAG CC-3’ and 5’-TTG TCA TCG CTT CCA GTC CCC G-3’ for responder 
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transgenes.  Tau-expressing mice and littermate control mice (lacking either the tau 
responder transgene or the activator transgene) between 2.5 and 8.5 months were 
used.  Animals were sacrificed with an overdose of ketamine xylazine cocktail via 
an intraperitoneal cavity injection.  The chest cavity was then opened by cutting 
through the diaphragm and rib cage laterally.  The right atrium was cut to drain 
blood; and the left ventricle punctured for cannula placement.  PBS was flushed 
through the circulatory system using a pressure of 60 mmHg for 3-4 min or until 
the right atrium was cleared.  The brain was removed and rapidly frozen in dry ice.  
Cryostat brain sections of 10 µm were prepared for analysis of transgenic and 
control mice.  In addition, different areas of the brain were isolated, including the 
olfactory bulb, frontal cortex, sensorimotor cortex, medial septal nucleus, 
hippocampus, and entorhinal cortex. 
All animals were housed and tested accordingly to standards established by the 
American Association for the Accreditation of Laboratory Animal Care and 
Institutional Animal Care and Use Committee guidelines, with every effort made to 
minimize the number of animals used. 
 
Isolation and culture of rat cortical neurons 
Primary cultures of rat cortical neurons were prepared from 17- to 18-day-old 
fetuses of Wistar rats as previously described (Brewer et al. 1993) with minor 
modifications.  In short, pregnant rats were ether-anesthetized and decapitated.  
The fetuses were collected in Hank’s balanced salt solution (HBSS-1; Invitrogen, 
Grand Island, NY, USA) and rapidly decapitated.  After removal of meninges and 
white matter, the brain cortex was collected in Hank’s balanced salt solution 
without Ca2+ and Mg2+ (HBSS-2).  The cortex was then mechanically fragmented, 
transferred to a 0.025% trypsin in HBSS-2 solution, and incubated for 15 min at 
37ºC.  Following trypsinization, cells were washed twice in HBSS-2 containing 
10% fetal calf serum (FBS) and re-suspended in Neurobasal medium (Invitrogen), 
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supplemented with 0.5 mM L-glutamine, 25 µM L-glutamic acid, 2% B-27 
supplement (Invitrogen), and 12 mg/mL gentamicin.  Neurons were then plated on 
tissue culture plates, precoated with poly-D-lysine at 1 x 106 cells/mL, and 
maintained at 37ºC in a humidified atmosphere of 5% CO2.  All experiments were 
performed on cells cultured for 4 days in fresh medium without glutamic acid and 
B-27 supplement.  Cells were characterized by phase contrast microscopy and 
indirect immunocytochemistry for neurofilaments and glial fibrillary acidic 
protein.  Neuronal cultures were >95% pure.  After 4 days in culture, isolated rat 
neurons were incubated with 20 µM Aβ1-42 (Bachem AG, Budendorf, Switzerland) 
that had been induced to form fibrils by preincubation in culture medium.  In short, 
0.45 mg of Aβ1-42 peptide was dissolved in 20 µl of DMSO and diluted to a 100-
µM stock solution in medium, which was then incubated with gentle shaking at 
room temperature for 4 days.  Fibrillar Aβ1-42 was then diluted to 20 µM and 
applied to neuron cultures; 0.2% DMSO was added to control cultures.  Cortical 
neurons were incubated with fibrillar Aβ1-42 for 24 h, with or without 100 μM 
TUDCA (Sigma Chemical, St. Louis, MO, USA), or no addition.  In co-incubation 
experiments, TUDCA was added to neurons 12 h prior to incubation with Aβ1-42. 
 
Evaluation of apoptosis and caspase-3 activity 
DNA fragmentation in brain sections of both transgenic and control mice was 
detected using an ApopTag® peroxidase in situ apoptosis detection kit 
(Serologicals Corp., Norcross, GA) for transferase mediated dUTP-digoxigenin 
nick-end labelling (TUNEL) staining.  In brief, tissue sections were fixed in 4% 
paraformaldehyde in PBS, pH 7.4, for 10 min at room temperature, post-fixed in 
precooled ethanol:acetic acid (2:1, v/v) for 5 min at -20ºC, and treated with 3% 
hydrogen peroxide to quench endogenous peroxidase activity.  After adding the 
equilibration buffer, sections were treated with terminal 
deoxynucleotidyltransferase (TdT) and digoxigenin-dNTPs for 60 min at 37ºC.  
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Specimens were then treated with anti-digoxigenin-peroxidase for 30 min at 37ºC, 
colorized with 3,3’-diaminobenzidine (DAB) substrate, and counterstained with 
0.5% methyl green.  Finally, slides were rinsed, dehydrated, and mounted.  A 
negative control was prepared by omitting the TdT enzyme to control for non-
specific incorporation of nucleotides or binding of enzyme-conjugate.  The 
specimens were examined using a bright-field microscope (Zeiss Axioskop; Carl 
Zeiss GmbH, Jena, Germany) and the data expressed as the number of TUNEL-
positive cells/high-power field (x400). 
Cell viability of cortical neurons was assessed using trypan blue dye exclusion 
and confirmed by lactate dehydrogenase viability assays (Sigma-Aldrich).  In 
addition, Hoechst labeling of cells was used to detect apoptotic nuclei.  Briefly, the 
medium was gently removed to prevent detachment of cells.  Attached neurons 
were fixed with 4% paraformaldehyde in phosphate-buffered saline (PBS), pH 7.4, 
for 10 min at room temperature, incubated with Hoechst dye 33258 (Sigma-
Aldrich) at 5 μg/ml in PBS for 5 min, washed with PBS and mounted using 
PBS:glycerol (3:1, v/v).  Fluorescent nuclei were scored blindly and categorized 
according to the condensation and staining characteristics of chromatin.  Normal 
nuclei showed non-condensed chromatin dispersed over the entire nucleus.  
Apoptotic nuclei were identified by condensed chromatin, contiguous to the 
nuclear membrane, as well as nuclear fragmentation of condensed chromatin.  
Three random microscopic fields per sample of ~ 250 nuclei were counted and 
mean values expressed as the percentage of apoptotic nuclei. 
Finally, caspase activity was determined in cytosolic protein extracts from 
brain tissue and cell cultures.  Samples were homogenized in isolation buffer, 
containing 10 mM Tris-HCl buffer, pH 7.6, 5 mM MgCl2, 1.5 mM KAc, 2 mM 
DTT, and protease inhibitor cocktail tablets (CompleteTM; Roche Applied Science, 
Mannheim, Germany).  General caspase-3-like activity was determined by 
enzymatic cleavage of chromophore p-nitroanilide (pNA) from the substrate N-
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acetyl-Asp-Glu-Val-Asp-pNA (DEVD-pNA; Sigma Chemical Co.).  The 
proteolytic reaction was carried out in isolation buffer containing 50 µg cytosolic 
protein and 50 µM DEVD-pNA.  The reaction mixtures were incubated at 37°C for 
1 h, and the formation of pNA was measured at 405 nm using a 96-well plate 
reader. 
 
Immunoblotting 
Steady-state levels of total tau and caspase-3-cleaved tau proteins were determined 
by Western blot analysis.  Briefly, 50 μg of total protein extracts were separated on 
12% SDS-polyacrylamide electrophoresis minigels.  Following electrophoretic 
transfer onto nitrocellulose membranes, immunoblots were incubated with 15% 
H2O2 for 15 min at room temperature.  After blocking with 5% nonfat milk 
solution, the blots were incubated overnight at 4ºC with primary mouse 
monoclonal antibodies reactive to total tau (Zymed Laboratories Inc., San 
Francisco, CA, USA) and to caspase-3-cleaved tau (Chemicon, Millipore, 
Billerica, MA, USA) and finally with a secondary antibody conjugated with 
horseradish peroxidase (Bio-Rad Laboratories, Hercules, CA, USA) for 3 h at 
room temperature.  The membranes were processed for protein detection using 
Super SignalTM substrate (Pierce, Rockford, IL, USA).  β-actin was used as a 
loading control.  Protein concentrations were determined using the Bio-Rad protein 
assay kit according to the manufacturer’s specifications. 
 
Immunohistochemistry  
Light-level immunohistochemistry was performed in fixed brain sections to detect 
caspase-3-cleaved tau.  Briefly, slides were soaked in 3% hydrogen peroxide, 10% 
methanol for 10 min, washed, and incubated in serum blocking solution (Santa 
Cruz Biotechnology, Santa Cruz, CA) with 0.3% Triton X-100 for 1 h.  Specimens 
were then incubated with primary antibody overnight at 4ºC.  After rinsing, 
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specimens were incubated with biotinylated secondary antibody and a horseradish 
peroxidase-streptavidin complex, for 1 h each.  Tissue samples were then colorized 
with DAB substrate, counterstained, mounted and visualized in a bright-field 
microscope (Zeiss Axioscope). 
Immunofluorescence was performed to investigate the co-localization of 
caspase-3-cleaved tau and active caspase-3 in brain tissue and cultured cells.  Fixed 
brain sections were soaked in 0.3% hydrogen peroxide for 5 min, washed and 
blocked (0.3% Triton X-100, 10% donkey serum, 1% FBS) for 1 h.  In addition, 
cortical neurons were washed with PBS, incubated for 30 sec in microtubule 
stabilization buffer, and fixed for 10 min in 4% paraformaldehyde at room 
temperature.  Fixed cultured cells were incubated with 1% nonfat milk in PBS 
containing 1% bovine serum albumin and 1.5% Triton X-100 for 1 h at room 
temperature.  Specimens were then incubated with both monoclonal caspase-3-
cleaved tau and polyclonal caspase-3 (Santa Cruz Biotechnology) antibodies 
overnight at 4ºC.  After rinsing, specimens were then incubated with either 
fluorescently labeled anti-mouse or anti-rabbit (CyTM2 and CyTM5, respectively; 
Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA) for 2 h at 
room temperature. Samples were then mounted and visualized in a MRC1000 
confocal microscope (Bio-Rad, Hercules, CA, USA).  Finally, the percentage of 
caspase-3-cleaved tau and active caspase-3-positive cortical neurons with apoptotic 
nuclei was determined by staining with Hoechst 33258. 
 
Densitometry and statistical analysis 
The relative intensities of protein bands were analysed using the ImageMaster 1D 
Elite v4.00 densitometric analysis program (Amersham Biosciences, Piscataway, 
NJ, USA).  All data were expressed as mean ± SEM from at least three separate 
experiments.  Statistical analysis was performed using GraphPad InStat version 
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3.00 for Windows 95 (GraphPad Software, San Diego, CA, USA) for the Student’s 
t test.  Values of p < 0.05 were considered significant. 
 
Results 
 
TUNEL-positive cells and caspase activity in the frontal cortex and 
hippocampus of young rTg4510 animals 
AD is a progressive neurodegenerative disease with well-defined spatial and 
temporal lesions that correlate with neuronal loss.  The entorhinal cortex and 
hippocampus are particularly vulnerable (Braak and Braak 1991), while other 
cortical and subcortical areas are influenced as the disease progresses.  In 
frontotemporal dementias, however, the most affected areas are the frontal and 
temporal cortex (Mirra and Hyman 2002).  Previous studies using rTg4510 mice 
showed marked brain atrophy with massive neuronal loss, especially in the 
hippocampus (Santacruz et al. 2005).  The dental gyrus showed the earliest onset 
of neuronal loss at 2.5 months of age (85% of total neuronal loss), followed by 
CA1 and CA2/3 regions at 5.5 months (69-82%), and cortex at 8.5 months (52%) 
(Spires et al. 2006).  However, the role of apoptosis in neurodegeneration of 
rTg4510 mice remained unclear. 
In this study, levels of apoptosis in brain slices of control and rTg4510 mice at 
2.5, 5.5, and 8.5 months were evaluated using the TUNEL assay.  At 2.5 months, 
transgenic animals showed significant levels of TUNEL-positive cells in specific 
regions of the brain, including the frontal cortex (FC) (p < 0.05), and the medial 
septal nucleus (MSN) (p < 0.01), subgranular zone (SGZ) (p < 0.01) and 
subventricular zone (SVZ) (p < 0.05) of the hippocampus (Fig. 1A, upper 
histogram).  In addition, rTg4510 animals at 5.5 months showed increased 
apoptosis only in the MSN (p < 0.05) and SGZ (p < 0.01) (Fig. 1A, middle 
histogram).  Finally, the number of apoptotic cells in transgenic animals at 8.5 
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months was similar to controls, except in the sensorimotor cortex (SMC) and MSN 
(p < 0.05) (Fig. 1A, lower histogram). 
 
 
 
Fíg. 1.  DNA fragmentation and caspase-3 activity occur early in the frontal cortex and 
hippocampus of rTg4510 mice.  Brain slices were analyzed from both control (white bars) 
and transgenic animals (black bars) at 2.5, 5.5 and 8.5 months.  DNA fragmentation was 
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assessed by the TUNEL assay, and the number of positive cells was counted in the 
olfactory bulb (OB), frontal cortex (FC), sensorimotor cortex (SMC), medial septal 
nucleus, subgranular zone (SGZ), subventricular zone (SVZ), CA1 and entorhinal cortex 
(EC).  Cytosolic proteins were extracted for caspase-3-like activity assays from OB, FC, 
SMC, MSN, hippocampus (H) and EC of both control and transgenic animals at 2.5, 5.5 
and 8.5 months.  A: TUNEL staining in control FC (a); transgenic FC (b); control H (c); 
and transgenic H (d) (top) and number of apoptotic cells (bottom).  Apoptotic nuclei were 
identified by a condensed nucleus with brown staining.  B: DEVD-specific caspase 
activity.  The results are expressed as mean ± SEM of at least 3 different experiments.  *p < 
0.01 and §p < 0.05 from control animals.  Scale bar: 100 µm. 
 
 
As a hallmark of apoptosis, caspase-3 activation was investigated in both 
control and transgenic animals.  Consistent with TUNEL data, caspase-3-like 
activity was increased in FC (p < 0.05) and hippocampus (p < 0.01) at 2.5 months 
(Fig. 1B, upper histogram).  At 5.5 months, despite the increase of TUNEL-
positive cells, caspase-3 activity was not significantly altered in the hippocampus 
(Fig. 1B, middle histogram).  Finally, no significant changes were detected at 8.5 
months (Fig. 1B, lower histogram).  Taken together, these findings indicate that 
DNA fragmentation and caspase-3 activation are early events in the frontal cortex 
and hippocampus of rTg4510, which precede massive neuronal loss (Santacruz et 
al. 2005). 
 
Caspase-3 activation is associated with tau cleavage in rTg4510 animals 
Tau protein is functionally and structurally altered in AD and other tauopathies.  In 
fact, posttranslational changes such as abnormal phosphorylation and cleavage 
result in altered solubility and conformation, as well as aggregation (Alonso et al. 
2001, Gamblin et al. 2003a).  Next, we focused our study in the frontal cortex and 
hippocampus of rTg4510, which showed increased apoptosis, and investigated 
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patterns of tau expression with aging.  Using the antibody T14 to detect total 
human tau, a fragment of ~ 50 kDa was evident in animals of all ages, although to 
a less extent in the hippocampus at 2.5 months (Fig. 2).  This fragment corresponds 
to soluble and physiologic tau, which remains stable throughout the life of 
transgenic animals (Ramsden et al. 2005).  A fragment of 64 kDa was only present 
in older animals, at 5.5 and 8.5 months, corresponding to the insoluble and 
pathological form of tau.  Finally, small fragments of ~ 30 and 25 kDa were only 
present in the frontal cortex and hippocampus of younger animals.  Cleaved 
fragments may represent pathological forms of tau and are associated with 
increased apoptosis.  In fact, cleavage of tau at Asp421 of the C-terminal region by 
caspase-3 has been detected both in neurons and AD brains (Rissman et al. 2004). 
 
 
 
 
 
 
 
 
 
 
Fig. 2.  Expression analysis of tau shows varying patterns with age of rTg4510 mice.  
Total proteins of frontal cortex and hippocampus in both control and transgenic animals at 
2.5, 5.5 and 8.5 months were extracted and subjected to Western blot analysis.  A 
representative immunoblot of total human tau is shown. 
 
 
To determine if caspase-3 was responsible for cleavage of tau, we performed 
immunohistochemistry assays using a specific antibody against Asp421-cleaved 
 
131 
 
 
 
 
 
 
Chapter 4 
_________________________________________________________________________ 
tau.  At 2.5 months, the number of caspase-3-cleaved tau cells was significantly 
higher in FC and SGZ (p < 0.01) (Fig. 3A).  The number of positive cells was also 
significantly higher in the olfactory bulb (p < 0.01), SMC (p < 0.05), and 
entorhinal cortex (p < 0.01) in transgenic animals.  Consistently, western blot 
analysis showed that caspase-3-cleaved tau was already detected at 2.5 months 
(Fig. 3B).  The ~ 50 kDa fragment was also evident in older animals, suggesting 
that tau persists during tangle maturation and neurodegeneration in older animals 
(Rissman et al. 2004, Santacruz et al. 2005, Spires et al. 2006). 
 
 
 
Fig. 3.  Tau cleavage is an early event modulated by caspase-3 activation in rTg4510 mice.  
Brain slices were analyzed from both control (white bars) and transgenic animals (black 
bars) at 2.5 months.  Caspase-3-cleaved tau cells were identified by immunohistochemistry 
and the number of positive cells was counted in the olfactory bulb (OB), frontal cortex 
(FC), sensorimotor cortex (SMC), medial septal nucleus, subgranular zone (SGZ), 
subventricular zone (SVZ), CA1 and entorhinal cortex (EC).  Total proteins of frontal 
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cortex and hippocampus of both control and transgenic animals at 2.5, 5.5 and 8.5 months 
were extracted and analyzed by Western blot.  A: Immunohistochemical staining in control 
FC (a); transgenic FC (b); control H (c); and transgenic H (d) (top) and number of caspase-
3-cleaved tau positive cells (bottom).  Positive cells were identified by brown staining.  B: 
Representative immunoblots of caspase-3-cleaved tau.  The results are expressed as mean ± 
SEM of at least 3 different experiments.  *p < 0.01 and §p < 0.05 from control animals.  
Scale bar: 100 µm. 
 
 
Finally, we performed co-immunohistochemistry analysis of brain slices to 
determine if cleaved tau co-localized with active caspase-3 in the frontal cortex and 
hippocampus.  By confocal microscopy, the labeled cleaved tau was readily 
detectable (Fig. 4).  Active caspase-3, however, was less obvious and showed more 
of a diffuse pattern.  Nevertheless, cleaved tau was often co-localized with active 
caspase-3 in the frontal cortex and hippocampus of transgenic animals at 2.5 
months.  This suggests that active caspase-3 may be responsible for cleavage of tau 
in younger rTg4510 animals, specifically in the frontal cortex and hippocampus.  
Cleaved tau persists with age, possibly with a significant role in NFT formation. 
 
 
 
Fig. 4.  Active caspase-3 is co-localized with cleaved tau in the frontal cortex and 
hippocampus of transgenic animals at 2.5 months.  Brain slices were analyzed from both 
control and transgenic animals at 2.5 months.  Co-localization of active caspase-3 and 
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caspase-3-cleaved tau was evaluated in the frontal cortex and hippocampus by fluorescent 
immunohistochemistry and confocal microscopy.  Scale bar: 20 µm. 
 
 
Modulation of Αβ-induced toxicity and cleavage of tau in cortical neurons 
Amyloid plaques and NFT have been largely categorized as independent 
neuropathologic phenomena.  In tauopathies, mutations in tau are thought to be 
sufficient to induce its aggregation in NFT and the consequent neuronal 
dysfunction, without the presence or aggregation of Aβ.  However, in AD, there 
are no described mutations in tau and studies have suggested that tau is necessary 
for Aβ-induced cognitive dysfunction (Gotz et al. 2001).  In fact, only a direct or 
indirect interaction between Aβ and tau could explain the mechanistic development 
of AD.  A possible link would be Aβ-induced caspase-3 activation, followed by 
cleavage and subsequent aggregation of tau (Gamblin et al. 2003b).  Thus, we 
examined this correlation in primary rat cortical neurons incubated with fibrillar 
Aβ1-42 and investigated the potential modulation by incubation with the 
antiapoptotic bile acid, TUDCA.  General cell death increased after fibrillar Aβ1-42 
incubation as evaluated by trypan blue dye exclusion and lactate dehydrogenase 
viability assays (data not shown).  Nuclear fragmentation characteristic of 
apoptosis increased to ~ 30% (p < 0.01) in cells exposed to fibrillar Aβ1-42 (Fig. 
5A).  In contrast, TUDCA abrogated nuclear condensation and fragmentation (p < 
0.01).  Similar results were obtained in caspase-3 activity assays (p < 0.05) (Fig. 
5B).   
Next, we investigated if Aβ1-42-induced caspase activity was responsible for 
cleavage of tau.  Immunofluorescence assays showed that nuclear fragmentation 
and active caspase-3 were often colocalized with Asp421 cleaved-tau in cortical 
neurons undergoing apoptosis (Fig. 6A).  Interestingly, cleaved-tau was 
abnormally distributed within the neurons and detected in cell bodies.  In addition, 
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immunoblotting revealed that cleaved-tau was upregulated by almost 10-fold after 
incubation with Aβ1-42 (p < 0.05) (Fig. 6B).  Notably, TUDCA reduced caspase-3-
cleaved tau to control values (p < 0.05); and this was further confirmed by 
immunofluorescence.  These results showed that fibrillar Aβ1-42 decreased cell 
viability, and induced apoptosis with subsequent cleavage of tau, which may 
precede tau aggregation in NFT. 
 
Fig. 5.  TUDCA inhibits apoptosis and 
caspase-3 activity in primary cortical 
neurons incubated with fibrillar Aβ1-42.  
Cells were incubated with 20 µM fibrillar 
Aβ1-42, or no addition (control), ± 100 µM 
TUDCA for 24 h.  In coincubation 
experiments, TUDCA was added 12 h 
prior to incubation with Aβ1-42.  Cells 
were fixed and stained for microscopy 
assessment of apoptosis.  Cytosolic 
proteins were extracted for caspase-3-like 
activity assays.  A: Fluorescence 
microscopy of Hoechst staining in 
controls (a); and in cells exposed to Aβ1-42 
(b) (top) and percentage of apoptosis 
(bottom).  Apoptotic nuclei were 
identified by condensed chromatin as well 
as nuclear fragmentation.  B: DEVD-
specific caspase activity.  The results are 
expressed as mean ± SEM of at least 3 
different experiments.  *p < 0.01 and §p < 
0.05 from control; ‡p < 0.01 and †p < 
0.05 from Aβ.  Scale bar: 15 µm.     
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Fig. 6.  TUDCA modulates cleavage of tau by caspase-3 in primary cortical neurons 
incubated with fibrillar Aβ1-42.  Cells were incubated with 20 µM fibrillar Aβ1-42, or no 
addition (control), ± 100 µM TUDCA for 24 h.  In coincubation experiments, TUDCA was 
added 12 h prior to incubation with Aβ1-42.  Colocalization of active caspase-3 and cleaved 
tau was evaluated by confocal immunofluorescence microscopy.  Apoptotic nuclei were 
visualized with Hoechst staining.  Total proteins were extracted and subjected to Western 
blot analysis.  A: Confocal microscopy and colocalization of apoptotic nuclei, active 
caspase-3, and cleaved tau in cells exposed to Aβ1-42.  B: Confocal microscopy and 
colocalization of apoptotic nuclei and cleaved tau in cells exposed to Aβ (a) and Aβ + 
TUDCA (b) (top); representative immunoblot of caspase-3 cleaved tau in cells after 
treatment with Aβ ± TUDCA (bottom).  The blot was normalized to endogenous β-actin 
protein levels.  Scale bar: 20 µm. 
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Discussion 
 
The precise molecular mechanisms involved in AD-related neuronal death and 
cognitive decline are not entirely understood.  Aggregation of tau into insoluble 
NFT and formation of extracellular plaques by Aβ are the most characterized 
pathological features in AD.  Nevertheless, the correlation between these abnormal 
entities and their role in neuronal death is still unclear.  Implication of apoptosis as 
a general mechanism in many neurodegenerative disorders including AD has been 
supported by several studies (Fadeel and Orrenius 2005).  In addition, we have 
previously reported that antiapoptotic treatment with TUDCA prevents Aβ-induced 
degeneration in neuronal cells (Solá et al. 2003, Ramalho et al. 2006, Ramalho et 
al. 2004).  In the present study, we provide evidence that apoptosis is an early 
event in the frontal cortex and hippocampus of rTg4510 mice.  Moreover, caspase-
3 activation is associated with cleavage of tau in its C-terminal region, which 
precedes NFT formation.  Cleaved tau represents potentially intermediate 
neurotoxic species that are correlated with initial neuronal dysfunction.  Finally, 
antiapoptotic TUDCA prevents cleavage of tau from Aβ-induced apoptosis in 
cultured neurons, underscoring the role of modulation of apoptosis in tau cleavage. 
Previous studies have shown that the rTg4510 mouse is a remarkable model of 
tauopathy.  Tau expression induces age-dependent memory impairment, NFT 
formation and memory loss (Ramsden et al. 2005, Santacruz et al. 2005, Spires et 
al. 2006).  Transgenic aged mice undergo massive neuronal loss, but the 
mechanisms by which neurons die are still not clear.  In addition, although 
expressed in all forebrain structures, the transgene tau with the P301L mutation 
affects only specific brain regions.  Neuronal loss is > 80% in hippocampal area 
CA1 and dentate gyrus, and ~ 50% in cortex by 8.5 months (Spires et al. 2006).  
These results are consistent with the regional specificity observed in tauopathies, 
including AD (Braak and Braak 1991). 
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Here, we investigated whether apoptosis is primarily involved in neuronal loss 
of rTg4510 mice.  DNA fragmentation and caspase activation were evident in 
transgenic animals at 2.5 months.  In fact, TUNEL-positive cells were easily 
detected in the frontal cortex, subgranular zone of the dentate gyrus, and 
subventricular zone.  Interestingly, the subgranular zone gives rise to neural stem 
cells that ultimately differentiate into granule cell neurons.  Therefore, apoptosis 
seen in the subgranular zone may account for the loss of granule cells.  Levels of 
apoptosis were still slightly elevated in the subgranular zone at 5.5 months, but 
showed no changes at 8.5 months.  Activation of caspase-3 was no longer evident 
at 5.5 and 8.5 months.  Interestingly, apoptosis was increased in the medial septal 
nucleus at all ages, and in the sensorimotor cortex in older animals.  We were also 
unable to detect significant levels of apoptosis in hippocampal CA1 of rTg4510 
mice.  Thus, caspase-dependent and -independent cell death is confined to specific 
areas, possibly signaling other brain regions. 
Evidence of apoptosis in AD has been largely supported by tissue culture 
studies (Fadeel and Orrenius 2005).  Contradictory results came from observations 
of human post-mortem brain tissue, where clear detection of apoptotic cells is 
difficult (Migheli et al. 1994).  This may be explained by the fact that cell death in 
AD occurs over decades, while apoptosis is executed within a few hours.  Thus, 
synchronous detection of a substantial number of apoptotic cells at any given time 
would be very difficult.  In addition, there is strong evidence to suggest that 
apoptotic mechanisms may play an important role in disease pathogenesis, even in 
the absence of overt apoptosis (Dickson 2004).  Our results suggest that apoptosis, 
rather than being responsible for extensive neuronal loss in older animals, triggers 
toxic events that ultimately contribute to cognitive deficits.  In fact, activation of 
caspase-3 in the frontal cortex and hippocampus resulted in cleavage of tau in 
rTg4510 mice at 2.5 months.  Neurons with active caspase-3 often showed 
Asp421-cleaved tau.  Caspase-3-cleavage of tau is thought to induce abnormal 
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conformations by removing part of the C-terminal region, which is essential to 
inhibit tau aggregation in vitro (Abraha et al. 2000, Berry et al. 2003).  Although 
early apoptosis may also represent a developmental-related phenomenon (Ramsden 
et al. 2005), it is clear that the cleavage of tau is a toxic process with potentially 
important neurodegenerative repercussions. 
Importantly, the formation of NFT appears to be dissociated from neuronal loss 
in rTg4510 mice.  It has been shown that, at 4 months of age, ~ 50% of neurons in 
the dentate gyrus were lost before any early conformational changes in tau were 
detectable (Spires et al. 2006).  In addition, after transgene suppression, neuronal 
loss was prevented and memory decline reverted, but NFT continued to accumulate 
(Spires et al. 2006, Santacruz et al. 2005).  Interestingly, rT4510 mice developed 
the first signs of cognitive decline at 2.5 months, coincident with cleavage of tau.  
Thus, it is possible that deficits in neurons occur in the early stages of disease, 
resulting from aberrant forms of tau, prior to massive neuronal loss and NFT 
formation.  In this scenario, apoptosis and subsequent cleavage of tau are strong 
candidates to trigger the primary deleterious effects on neuronal function. 
The identification of two forms of tau multimers with 140 and 170 kDa have 
recently been described in rTg4510 mice (Berger et al. 2007).  The molecular 
weights suggest an oligomeric aggregate of the soluble and insoluble forms of tau, 
respectively.  The aggregates accumulate early in the pathogenesis and appear to 
be associated with the development of functional deficits.  Thus, it is tempting to 
speculate that cleavage of tau occurs prior to formation of the first oligomers, 
promoting their aggregation.  Further, the fact that cleaved tau was found in older 
animals suggests that although cleavage may occur early in NFT formation, the 
resultant fragment persists throughout NFT evolution.  It is possible that apoptosis 
continues beyond 2.5 months, and that other proteases such as calpains are also 
involved in tau cleavage (Park and Ferreira 2005).  In this scenario, apoptosis may 
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represent the triggering event for the formation and aggregation of intermediate 
species of tau, which ultimately result in massive non-apoptotic neuronal death. 
The efficacy of the rTg4510 mouse model relies on the capacity of mutated tau 
to induce neuronal modifications.  Mutations of tau reduce its ability to interact 
with microtubules and are associated with tauopathies (Goedert et al. 1998).  These 
disorders are distinct from AD because there is no evidence for Aβ, amyloid 
precursor protein (APP) or presenilin involvement.  In AD, however, Aβ plays an 
important role in neuronal toxicity and cell death, and its involvement in tau 
pathology cannot be neglected.  Indeed, both mutations of APP with Aβ deposition 
and intracranial injection of Aβ increased NFT formation in transgenic mice 
expressing an FTDP-17-causing mutant (Gotz et al. 2001, Lewis et al. 2001).  
Several evidences suggest that the link between Aβ and tau is predominantly, if not 
exclusively, unidirectional.  In fact, tau has no effect on the onset and progression 
of Aβ accumulation (Oddo et al. 2007).  Rather, tau accumulation occurs after 
amyloid plaques formation, further exacerbating the neurotoxicity induced by Aβ.  
In fact, it has been recently shown that overexpression of tau with the P301L 
mutation induces mitochondria dysfunction, increasing the production of reactive 
oxygen species and the vulnerability to Aβ insults (David et al. 2005).   Moreover, 
reduction of endogenous tau levels proved to inhibit behavioural deficits in 
transgenic expressing human APP, without altering Aβ levels (Roberson et al. 
2007). 
  Recent studies suggest that Aβ accumulation and caspase activation precedes 
and induces cleavage of tau and NFT formation (Gamblin et al. 2003b, Rissman et 
al. 2004).  Our results confirmed that fibrillar Aβ1-42 induces toxicity, nuclear 
fragmentation and caspase-3 activation, which was associated with cleavage of tau.  
Moreover, cleaved tau was often co-localized with active caspase-3 in neurons 
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undergoing nuclear modifications.  Thus, apoptotic events and cleavage of tau 
occur almost simultaneously in neurons exposed to aggregated Aβ. 
TUDCA prevented apoptosis and caspase-3 activation after incubations of 
neurons with fibrillar Aβ1-42, thus reducing caspase-3-cleaved tau.  This suggests 
that TUDCA may inhibit further aggregation of tau in NFT and promote cell 
survival.  It would be interesting to investigate whether administrations of TUDCA 
to newborn or up to 2.5 months rTg4510 mice would prevent cleavage of tau, and 
subsequent massive neuronal loss, memory decline and NFT formation. 
Collectively, the present study provides evidence that apoptosis may represent 
a crucial event in AD.  Either by promoting further cell death or activating toxic 
effectors, apoptosis interferes with the pathogenesis of the disease.  In rTg4510 
mice, apoptosis is an early event in the frontal cortex and hippocampus, that 
preceeds NFT formation and massive neuronal death.  Caspase-3-cleaved 
intermediate tau species were responsible for cell loss in rTg54510 brains and Aβ-
exposed cultured neurons.  These results underscore the importance of 
antiapoptotic agents in treating neurodegeneration associated with AD and other 
tauopathies. 
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The results presented in this thesis underscore the potential relevance of 
apoptosis in the pathogenesis of Alzheimer’s disease (AD)-associated 
neurodegeneration in cell culture and in vivo.  We suggest that apoptosis results in 
characteristic neuronal death and triggers additional neurotoxic mechanisms during 
neurodegeneration.  Moreover, the neuroprotective role of tauroursodeoxycholic 
acid (TUDCA) has been extended to AD, which is considered the major cause of 
dementia.  In fact, we have established that TUDCA inhibits amyloid β (Aβ)-
induced neuronal death by modulating the transcription of genes involved in 
apoptosis and cell cycle.  Aβ resulted in E2F-1 and p53 activation, associated with 
Bcl-2 family regulation, and further activation of effector caspases.  TUDCA was a 
strong modulator of these changes.  In addition, caspase-3 activation was 
responsible for cleavage of tau into a toxic fragment that facilitates aggregation in 
neurofibrillary tangles (NFT).  These effects were also inhibited by TUDCA.  
Thus, our results further elucidate the signaling mechanisms involved in AD-
associated neurodegeneration and neuroprotection by TUDCA.  In this final 
Chapter, we integrate all findings, discuss some questions, and consider future 
perspectives. 
Ursodeoxycholic acid (UDCA) is an endogenous bile acid used in the 
treatment of cholestatic liver diseases.  The therapeutic effects of UDCA and its 
taurine-conjugated form, TUDCA, have been mainly attributed to their unique role 
in modulating the classical mitochondrial pathway of apoptosis (Botla et al. 1995; 
Rodrigues et al. 1998; Rodrigues et al. 1999).  In fact, UDCA was shown to 
modulate mitochondrial membrane perturbation, channel formation, Bax 
translocation, cytochrome c release, caspase activation and subsequent substrate 
cleavage (Rodrigues et al. 1999).  Importantly, UDCA appears to act in many cell 
types and in response to different toxic stimuli.  The protective role of TUDCA has 
therefore been extended to non-hepatic diseases, including neurological disorders, 
such as Huntington’s and Parkinson’s diseases, as well as acute and hemorrhagic 
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stroke (Rodrigues et al. 2004).  However, despite the increased relevance and 
applicability of UDCA and TUDCA, the precise mechanisms by which the bile 
acids initiate and transduce signals to the mitochondria remain a matter of 
discussion. 
AD is a neurodegenerative disorder characterized by the presence of amyloid 
plaques and NFT, increased production of reactive oxygen species, disruption of 
calcium homeostasis, activation of inflammatory cytokines, and neuronal 
dysfunction (Selkoe 2001).  Ultimately, neurons lose their ability to survive and 
undergo cell death in areas of the brain associated with memory and cognitive 
skills.  However, the primary mechanism responsible for neuronal death in AD is 
still not clear.  In the last several years, apoptosis has emerged as a key event in the 
pathogenesis of the disease.  Its occurrence has been confirmed in AD brains 
(Colurso et al. 2003).  Thus, the inhibition of apoptosis opens a new window of 
opportunities for therapeutic intervention in AD. 
Aggregated and/or soluble Aβ are thought to trigger apoptosis in AD.  
Moreover, Aβ can also induce other cellular abnormalities, including cell cycle 
deregulation. In fact, in AD brains, cell cycle-related proteins are often 
upregulated, which may also be associated with increased levels of apoptosis 
(Busser et al. 1998).  Using PC12 neuronal cells incubated with Aβ, we 
demonstrated increased DNA fragmentation, caspase-3 activation, as well as E2F-
1, p53, and Bax expression.  Importantly, TUDCA modulated Aβ-induced 
apoptosis by interfering with the E2F-1/p53/Bax pathway.  These results suggest 
that TUDCA modulates neuronal apoptosis by both promoting mitochondrial 
stability, and regulating transcription of apoptosis- and cell cycle-related proteins 
(Fig. 1).  This transcriptional function of TUDCA has already been demonstrated 
in DNA microarray analysis of bile acid-treated rat hepatocytes (Castro et al. 
2005).  Nevertheless, it remains to be determined how TUDCA regulates the 
transcriptional activity of p53 and E2F-1.  A recent study suggested that nuclear 
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translocation of TUDCA, through a nuclear steroid receptor, transactivation-
independent mechanism, is crucial for its antiapoptotic function in primary rat 
cortical neurons (Solá et al. 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.  Proposed model for the antiapoptotic function of TUDCA in AD.  TUDCA 
prevents Aβ-induced mitochondrial apoptosis by modulating the expression of E2F-1, p53, 
and Bcl-2 family proteins, and subsequent activation of effector caspases.  In addition, 
TUDCA prevents c-Jun N-terminal kinase-mediated caspase-2 activation, further inhibiting 
mitochondrial dysfunction.  Finally, TUDCA promotes neuronal survival by reducing 
caspase-3 activation and subsequent cleavage of tau.  See text for more complete 
description.  JNK, c-Jun N-terminal kinase. 
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The incubation of cells with Aβ, however, is far from the ideal model of AD.  
In fact, the concentrations of Aβ added to culture media are usually much higher 
than those found in AD brains.  Therefore, we pursued our studies using a model of 
familial AD consisting of neuroblastoma cells expressing hereditary mutations in 
the amyloid precursor protein (APP) and in presenilin 1.  These cells exhibited 
endogenous Aβ aggregation, mimicking the natural process of AD.  Similar to 
other studies, including our own, p53 played a pivotal function in neuronal death 
(Morrison et al. 2003).  Indeed, apoptosis was associated with increased levels of 
p53, upregulation of Bax, and downregulation of Bcl-2.  Importantly, TUDCA 
modulated p53 expression and Bcl-2 family changes.  Moreover, we also showed 
that TUDCA modulated Aβ-induced neuronal apoptosis, in part, by activating a 
phosphatidylinositol 3-kinase (PI3K) signaling pathway.  In fact, TUDCA 
interfered with the activation of p53-related apoptotic events in a PI3K-dependent 
manner, underscoring the pleiotropic effect of the bile acid. 
As executioners of the apoptotic process, caspases have a pivotal role in AD-
associated neuronal death.  In fact, active caspase-3 and -6 have been detected in 
AD brains (Su et al. 2001; Guo et al. 2004).  In our studies, caspase-3 was only 
marginally activated in the cell culture model of familial AD, while, caspase-6 was 
highly activated via a p53-dependent mechanism.  These apparently contradictory 
results reflect the complexity of neuronal apoptosis in AD and underscore the 
importance of more accurate models of AD pathology.  Interestingly, a recent 
study suggested that Aβ-induced cell death also requires the activation of caspase-
2 (Troy et al. 200).  Caspase-2 triggers apoptosis via activation of the 
mitochondrial pathway.  It has also been described as a target of the c-Jun N-
terminal kinase signaling pathway (Troy et al. 2000).  Notably, TUDCA prevented 
caspase-2 activation in neuroblastoma cells expressing hereditary mutations 
associated with AD.  Further investigations are warranted to elucidate the 
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mechanism(s) by which TUDCA interferes with this pathway linked to Aβ-induced 
toxicity. 
The role of tau in AD and other tauopathies has recently attracted much 
attention.  Although essential for physiological microtubule stability, tau 
distribution and abundance after posttranslational modifications is well correlated 
with neuronal degeneration and clinical symptoms in AD (Braak and Braak 1991).  
Using a transgenic model of tauopathy, the rTg4510 mice, with age-dependent 
memory impairment, NFT formation and memory loss (Santacruz et al. 2005), we 
further investigated the role of apoptosis in neurodegeneration.  Our results showed 
that apoptosis is not primarily responsible for massive neuronal death.  Rather, 
apoptosis triggers toxic mechanisms that precede NFT formation and memory loss.  
In fact, DNA fragmentation and caspase-3 activation were evident in the frontal 
cortex and hippocampus of young animals, which resulted in cleavage of tau into a 
toxic fragment that enhances NFT formation.  Moreover, we explored a possible 
link between Aβ and tau, since tau is necessary for Aβ-induced cognitive 
dysfunction (Gotz et al. 2001).  In our cell culture study, Aβ treatment of rat 
cortical neurons resulted in caspase-3 activation and subsequent cleavage of tau.  
Importantly, TUDCA markedly reduced levels of cleaved tau, by inhibiting 
apoptosis and, more specifically, caspase-3 activation.  Thus, by interfering with 
apoptotic pathways, TUDCA not only increased the survival of neurons, but also 
prevented downstream conformation changes of tau, which may have positive 
consequences in slowing cognitive decline.  To characterize the role of TUDCA in 
rTg4510 mice, it would be important to determine whether administration of the 
bile acid to newborn or young rTg4510 mice prevents apoptosis and cleavage of 
tau.  In this regard, the effects of TUDCA on neuronal death, memory, and NFT 
formation warrant further experiments. 
In vivo models are valuable tools to investigate the pathogenic mechanisms of 
a specific disease.  However, a model that recapitulates all relevant aspects of AD 
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is not yet available.  In an ideal model, Aβ and tau aggregation would mimic the 
neuronal abnormalities that are characteristic of AD.  In this regard, a triple-
transgenic model that expresses mutated forms of APP, presenilin 1, and tau has 
already been developed (Oddo et al. 2003).  This may represent an efficient tool for 
understanding the pathology of AD and, more importantly, for developing effective 
therapeutic approaches. 
As a final note, it is important to underscore the antiapoptotic properties of 
TUDCA.  In this thesis, we showed that in addition to its direct effect at the 
mitochondria, TUDCA also appears to act upstream of mitochondria regulating 
apoptosis induced by Aβ at the level of transcription.  Moreover, by modulating 
neuronal cell death, TUDCA may also interfere with subsequent downstream 
production of toxic factors responsible for AD-associated neuronal pathology.  The 
ultimate challenge will be to characterize and integrate all the separate pathways in 
an orchestrated mechanism of TUDCA antiapoptic function, focusing on its 
potential clinical application in AD. 
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